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Summary
Prostate cancer is the most common cancer amongst the male population in most devel-
oped countries. It is the most common cancer amongst the male population in France
(73.609 cases in 2014) and in Colombia (9564 cases in 2014). It is also the third most
common cause of cancer deaths in males in both countries (9.3% and 7.1% in France and
in Colombia in 2014, respectively). One of the standard treatment methods is external
radiotherapy, which involves delivering ionizing radiation to a clinical target, namely the
prostate and seminal vesicles. Due to the uncertain location of organs during treatment,
which involves around forty (40) radiation fractions delivering a total dose ranging from
70 to 80Gy, safety margins are defined around the tumor target upon treatment plan-
ning. The radiation units are expressed in Grays, abbreviated as Gy, which represents
1 Jule/Kg. This leads to portions of healthy organs neighboring the prostate or organs
at risk — the bladder and rectum — to be included in the target volume, potentially
resulting in adverse events affecting patients' urinary (hematuria and cystitis, among
others) or rectal (rectal bleeding, fecal incontinence, etc.) functions. Several studies
have shown that increasing dose delivery to the prostate leads to improved local cancer
control, up to approximately 80Gy. However, such dose increases are limited by their
associated risks of treatment-related toxicity involving the organs at risk.
The bladder is notorious for presenting the largest inter-fraction shape variations
during treatment, caused by continuous changes in volume. These variations in shape
introduce geometric uncertainties that render assessment of the actual dose delivered to
the bladder during treatment difficult, thereby leading to dose uncertainties that limit
the possibility of modeling dose-volume response for late genitourinary (GU) toxicity.
The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) project
has stated that a similar dose-response to that of late gastrointestinal (GI) toxicity is
far from being established. The dosimetric variables obtained from the planning CT
prove to be very poor surrogates for the real delivered dose. As a result, it appears
crucial to quantify uncertainties produced by inter-fraction bladder variations in order
to determine dosimetric factors that affect late GU complications.
The aim of this thesis was thus to characterize and predict uncertainties produced
by geometric variations of the bladder between fractions, using solely the planning CT
as input information. In clinical practice, a single CT scan is only available for a typi-
cal patient during the treatment planning while on-treatment CTs/CBCTs are seldom
available. In this thesis, we thereby used a population approach to obtain enough
data to learn the most important directions of bladder motion and deformation using
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principal components analysis (PCA). As in groundwork, these directions were then
used to develop population-based models in order to predict and quantify geometri-
cal uncertainties of the bladder. However, we use a longitudinal analysis in order to
properly characterize both patient-specific variance and modes from the population.
We proposed to use mixed-effects (ME) models and hierarchical PCA to separate intra
and inter-patient variability to control confounding cohort effects. Other than using
PCA, bladder shapes were represented by using spherical harmonics (SPHARM) which
additionally enables data compression without losing information. Subsequently, we
presented PCA models as a tool to quantify dose uncertainties produced by bladder
motion and deformation between fractions. We then estimated mean and variance of
the dose delivered to the bladder using PCA-based models via Monte Carlo simulation
and dose integration; and subsequently, we compared the estimated accumulated doses
with the accumulated dose derived from non-rigid registration and patient’s available
images. We also calculated average voxel doses, local dose variability and dose-volume
histogram uncertainties.
Résumé
Le cancer de la prostate est le cancer le plus fréquent chez les hommes dans la plupart
des pays développés. C’est le cancer le plus fréquent chez les hommes en France (73.609
cas en 2014) et en Colombie (9564 cas en 2014). En outre, c’est la troisième cause
de décès par cancer chez les hommes dans les deux pays (9,3 % en France et 7,1 %
en Colombie en 2014). Il existe de nombreuses techniques différentes pour soignier le
cancer de la prostate, comme la chirurgie, la chimiothérapie, la radiothérapie externe
et la curiethérapie, entre autres. La radiothérapie externe (EBRT) est une technique
principalement utilisée pour le cancer localisé qui consiste à délivrer un rayonnement
ionisant pour détruire les cellules tumorales. Cependant, les tissus sains qui entourent
recevront également une dose de rayonnement, ce qui peut altérer le fonctionnement
normal. L’EBRT est donc un compromis entre permettre une dose élevée à la tumeur
et épargner des organes sains qui sont voisins. Ces tissus sains entourant la tumeur
sont appelés les organes à risque (OARs). Le terme radiothérapie désignera dorénavant
l’EBRT.
Dans la radiothérapie du cancer de la prostate, la prostate et les vésicules séminales
définissent la cible principale à irradier tandis que les OARs sont la vessie et le rectum.
Quand un patient, qui a la maladie du cancer de la prostate, est soigné avec radio-
thérapie, une tomodensitométrie (TDM) est prise de la zone pelvienne et les organes
du patient sont délimités (à savoir la prostate, les vésicules séminales, la vessie et le
rectum). Depuis le plan de délivrance de la dose est optimisé afin de respecter les con-
traintes de dose maximale sur les organes à risque et de dose prescrite sur la prostate.
Ensuite, le traitement est délivré au patient sur plusieurs fractions sur plusieurs jours,
où une petite quantité de la dose est donnée pour chaque fraction. Par exemple, si une
dose de 80 Gy est prescrite à la prostate, des fractions de 2 Gy administrées pendant 5
jours en huit semaines sont le planning du traitement classique. Le fractionnement de
dose est effectué pour augmenter le rapport thérapeutique, c’est-à-dire qu’il permet aux
tissus sains de se réparer entre les fractions et d’augmenter les dommages aux cellules
de la tumeur par réoxygénation et redistribution.
Cependant, les organes pelviens se déplacent et se déforment entre les fractions
en introduisant des incertitudes géométriques aléatoires qui rendent difficile la cor-
recte livraison de la dose à la tumeur et les OARs. Ces changements de taille et de
forme dans les organes conduisent à des géométries qui ne sont pas exactement à celles
délimités lors de la planification. Par exemple, ces variations peuvent inclure des con-
tractions/dilatations du rectum, remplissage et vidange quotidiens de la vessie, des
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contractions musculaires involontaires, etc. Ces variations d’organe peuvent donc ex-
poser le patient à une sous-dose de rayonnement dans la zone de la tumeur ou à une
surdose concernant OAR. Ainsi, des marges de sécurité sont introduites autour de la
tumeur sur le plan de délivrance afin d’élargir la zone irradiée. Néanmoins, cela im-
plique également que des portions des OARs seront fortement irradiées, ce qui peut
entraîner des événements indésirables qui affectent les fonctions organiques du patient
(hématurie, cystite, hémorragie rectale, incontinence fécale, entre autres). Bien que
les nouvelles technologies - comme la radiothérapie guidée par image (IGRT), les mar-
queurs et la radiothérapie à intensité modulée (IMRT)- nous permettent de distribuer
des doses complexes et de réduire les incertitudes sur la position et la forme réelles des
organes, l’intégration en ligne de tous ces technologies lors de la thérapie n’est pas en-
core pratique ou trop coûteuse (par exemple, l’imagerie en ligne de la zone pelvienne et
le calcul de la dose pendant une fraction quotidienne en temps réel). En conséquence,
les incertitudes géométriques aléatoires ont encore un impact au cours du traitement,
en réduisant sa qualité.
La vessie présente les plus grandes variations de forme entre fractions de traitement,
provoquées par des changements continus de volume. Ces variations de forme intro-
duisent des incertitudes géométriques qui rendent difficile l’évaluation de la dose qui est
réellement délivrée à la vessie pendant le traitement. Ces incertitudes limitent la pos-
sibilité de modéliser une relation dose-volume pour la toxicité génito-urinaire tardive
(GU). Le projet QUANTEC (Quantitative Analysis of Normal Tissue Effects in the
Clinic) a déclaré qu’une dose-réponse similaire à celle de la toxicité gastro-intestinale
tardive (GI) était loin d’être établie. Les variables dosimétriques obtenues à partir
de la tomodensitométrie de planification peuvent être faiblement représentative de la
dose effectivement délivré. En conséquence, il est crucial de quantifier les incertitudes
produites par les variations inter-fraction de la vessie afin de déterminer les facteurs
dosimétriques qui affectent les complications GU tardives.
Le but de cette thèse était donc de caractériser et de prédire les incertitudes pro-
duites par les variations géométriques de la vessie entre les fractions de traitement, en
utilisant uniquement la tomodensitométrie de planification comme information d’entrée.
En pratique clinique, une seule tomodensitométrie est disponible lors de la planification
du traitement d’un patient typique, alors que des images supplémentaires peuvent être
acquises en cours de traitement. Dans cette thèse, une approche basée population a
été utilisée pour obtenir suffisamment de données pour apprendre les directions les plus
importantes du mouvement et de la déformation de la vessie en utilisant l’analyse en
composante principales (PCA). Comme dans les travaux de référence, ces directions
ont ensuite été utilisées pour développer des modèles basés population pour prédire
et quantifier les incertitudes géométriques de la vessie. Cependant, nous avons utilisé
une analyse longitudinale afin de caractériser correctement la variance du patient et ses
modes spécifiques à partir de la population. Nous avons proposé d’utiliser un modèle à
effets mixtes (ME) et une PCA hiérarchique pour séparer la variabilité intra et inter-
patients afin de contrôler les effets de cohorte confondus. Outre l’PCA, la forme de la
vessie a été représentée par l’utilisation d’harmoniques sphériques (SPHARM), ce qui
a permis la compression des données sans perte d’information. Finalement, nous avons
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présenté des modèles sur l’PCA comme un outil pour quantifier des incertitudes de la
dose produit par le mouvement et déformation de la vessie entre fractions. Également,
en utilisant seulement l’information de planification, les objectifs spécifiques de la thèse
sont: i) de caractériser et prédire le mouvement et la déformation de la vessie entre les
fractions ; ii) de quantifier les incertitudes de dose et de DVH produites par les varia-
tions géométriques de la vessie entre les fractions ; iii) proposer une méthodologie pour
modéliser le mouvement et la déformation OAR entre les fractions qui aide à déter-
miner la dose de planification optimale et les modifications du traitement en intégrant
contraintes du traitement (taille de fraction et événements de toxicité), le mouvement
OAR et les contraintes de déformation et de traitement.
La première étape de cette thèse consistait en apprendre les directions les plus im-
portantes (modes dominants) du mouvement et de la déformation de la vessie à partir
d’une base de données de population à l’aide de l’analyse des composantes principales
(PCA). Nous avons utilisé ces modes dominants pour caractériser les formes de la vessie
et les régions de déformation/mouvement. Cette thèse a aussi proposé une méthode
de normalisation pour aligner anatomiquement les structures pelviennes (prostate et
vessie) pour tous les patients dans le même référentiel spatial. Cette méthode était
un enregistrement rigide qui permettait de quantifier le mouvement et les déformations
de la vessie par rapport au barycentre de la prostate d’un patient modèle. La deux-
ième étape était une première étape de réduction de la dimensionnalité en utilisant des
harmoniques sphériques (SPHARM). Cette étape nous a permis de réduire le nombre
de paramètres requis pour représenter la surface de la vessie, de plus encodés avec les
modes dominants dérivés par PCA. La troisième étape consistait à introduire une anal-
yse longitudinale pour développer des modèles basés sur la population, au lieu d’utiliser
l’analyse transversale comme dans les travaux précédents. Avec cela, .
Deuxièmement, nous avons caractérisé la variance du patient de la population sur
chaque mode. En plus, nous avons proposé d’utiliser un modèle à effets mixtes (ME) et
une PCA hiérarchique pour séparer la variabilité intra et inter-patients afin de contrôler
les effets de cohorte confondu. La troisième étape était de quantifier les incertitudes
de la dose et DVHs qui sont produites par le mouvement de la vessie et la déformation
entre les fractions. Nous avons formé des modèles individuels de PCA à partir des
échantillons de vessie disponibles sur les images CT/CBCT en cours de traitement de
trois patients. Sur la base des modèles ci-dessus, des sommes pondérées de ces modes
ont été utilisées pour estimer les vessies avec leur probabilité d’occurrence. Nous avons
ensuite estimé la moyenne et la variance de la dose délivrée à la vessie en utilisant des
modèles basés sur la PCA par la méthode de simulation de Monte-Carlo et l’intégrale
de la dose; et par la suite, nous avons comparé les doses cumulées estimées avec la dose
accumulée obtenue en utilisant un recalage d’image non-rigide et les images du patient.
Également, nous avons calculé la moyenne de la dose par voxel, la variabilité de la dose
locale et des incertitudes d’histogramme de volume de dose.
Finalement, les contributions de cette thèse ont été sur trois sujets de recherche prin-
cipaux : i) la caractérisation des formes et des régions de mouvement/déformation de la
vessie pour une base de données de patients utilisant PCA; ii) l’approche longitudinale
utilisé pour prédire le mouvement et la déformation de la vessie spécifiques du patient en
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apprenant à partir d’une base de données d’entraînement longitudinale; iii) l’utilisation
des modèles PCA comme outil virtuel pour évaluer les incertitudes dosimétriques pro-
duites par le mouvement de la vessie et la déformation entre les fractions. Concernant
au premier sujet, la méthode de normalisation utilisée pour aligner anatomiquement
les structures pelviennes nous a permis de quantifier le mouvement et les déformations
de la vessie par rapport à un point référentiel spatial. Egalement, la réduction de la
dimensionnalité en utilisant SPHARM nous a permis de réduire le temps de calcul,
les erreurs numériques produit par des opérations arithmétiques finies et le stockage
de données. Concernant au deuxième sujet, l’approche longitudinale nous a permis de
caractériser des formes et des régions de mouvement/déformation de la vessie; et par la
suite, de visualiser et d’identifier la variabilité hétérogène observée dans base de données
de la vessie. Concernant au troisième sujet, cette thèse a déterminé le nombre de modes
nécessaires pour déterminer les régions de mouvement/déformation, ainsi que pour es-
timer la dose cumulée de la vessie. Nous avons montré que seul le premier mode avait
un impact significatif sur l’estimation de dose cumulée car il décrit les changements les
plus significatifs en volume en dehors des faisceaux.
Resumen
El cáncer de próstata es el cáncer más común entre la población masculina en muchos
de los países desarrollados. Especificamente, es el cáncer más común de la población
masculina tanto en Francia (73.609 casos en 2014) como en Colombia (9564 casos en
2014); y además, es también la tercera causa de muerte por cancer en los hombres para
ambos países (9.3% y 7.1% en Francia y en Colombia en 2014, respectivamente). Uno
de los métodos de tratamiento más común es la radioterapia externa, el cual consiste
en enviar una radiación ionizante a un objetivo clínico, en este caso la próstata y las
vesículas seminales. Debido a incertidumbres producidas por variaciones anatómicas de
los órganos durante el tratamiento, el cual consiste en 40 fracciones para un total de
dosis entre 70 y 80 Gy, márgenes de seguridad son definidos alrededor del tumor durante
la planeación del tratamiento. Lo anterior, conlleva a que partes de los órganos sanos,
también llamados órganos en riesgo, que son cercanos a la próstata y vesículas seminales
-como la vejiga y el recto- también sean irradiados, potencialmente resultando en eventos
adversos que afectan las funciones urinarias (hematuria e infección urinaria) o rectal
(sangrado rectal, incontinencia fecal) del paciente. Algunos estudios han demostrado
que el incrementando la dosis a la próstata permite un mejor control local del cáncer
(por encima de los 80Gy aproximadamente). Sin embargo, tales incrementos de dosis
son limitados por sus riesgos asociados de toxicidad para los órganos en riesgo.
La vejiga es particular por presentar las variaciones de forma más grandes entre
las fracciones del tratamiento, las cuales son causadas por continuos cambios de vol-
umen. Estas variaciones de forma de la vejiga introducen incertidumbres geométricas
que hacen difícil la determinacion de la verdadera dosis entregada a la vejiga durante
el tratamiento. Estas incertidumbres limitan la posibilidad de modelar una relación
dosis-volumen para la toxicidad Genitourinario tardia (GU). El proyecto Quantitative
Analysis of Normal Tissue Effects in the Clinic (QUANTEC) ha establecido que una
respuesta dosis-volumen similar a la que se tiene para la toxicidad Gastrointestinal tar-
dia (GI) está lejos de ser establecida. Las variables dosimétricas que se obtienen de
la tomografía computarizada de planeación pueden ser débilmente represenativas de la
verdadera dosis suministrada. Por lo tanto, es crucial identificar las incertidumbres
producidas por el movimiento y deformación entre fracciones de la vejiga con el fin de
determinar los factores dosimétricos que afectan las complicaciones GU tardías.
El propósito de esta tesis fue entonces caracterizar y predecir las incertidumbres
geométricas producidas por las variaciones geométricas de la vejiga entre fracciones,
usando solamente el CT de planeación como información de entrada. En la práctica
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clínica, un sola tomografía computarizada esta disponible en la fase de planeación del
tratamiento para un paciente típico, mientras que imágenes suplementarias durante
el tratamiento estan raramente disponibles. Por lo tanto, en esta tesis fue usado un
enfoque poblacional para obtener suficientes datos para aprender las direcciones más
importantes de movimiento y deformación de la vejiga usando análisis de componentes
principales (ACP). Tal como en trabajos anteriores, estas direcciones fueron también us-
adas para desarrollar modelos poblacionales para predecir y cuantificar incertidumbres
geométricas de la vejiga. Sin embargo, en esta tesis se propuso un análisis longitu-
dinal con el fin de adecuadamente caracterizar la varianza y los modos del paciente
de la población. Básicamente, se propuso usar modelos de efectos-mixtos (ME) y ACP
jerárquico para separar la variabilidad intra e inter-paciente para controlar efectos confu-
sos de la población. Adicional a ACP, la superficie de la vejiga también fue representada
usando esféricos harmónicos (SPHARM), lo cual nos permitio adicionalmente comprimir
los datos sin perder información. Finalmente, se presentan los modelos basado en ACP
como una herramienta para cuantificar las incertidumbres de la dosis producidas por el
movimiento y deformación de la vejiga entre fracciones. El promedio y la varianza de
la dosis entregada a la vejiga fueron estimadas utilizando modelos ACP via simulación
de Monte Carlo e integración de la dosis; y posteriormente, se comparo las dosis acu-
muladas estimadas con la dosis acumulada obtenida a partir de registro no-rigido y las
imagenes disponibles del paciente. Igualmente, se calcularon los valores promedio de la
dosis por voxel, la variabilidad local de la dosis y las incertidumbres de los histogramas
dosis-volumen.
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Introduction: clinical context and
treatment uncertainties in prostate
cancer radiotherapy
This chapter introduces the clinical context of prostate cancer treated with EBRT. It
also introduces the research problem and objectives of this thesis, and the workflow
methodology used in this thesis. We firstly introduce a description of the prostate
anatomy and nearby organs in the pelvic zone. Subsequently, we briefly describe the
diagnosis and curative methods, and the main concepts of EBRT. We finally introduce
a review of approaches developed to model inter-fraction motion and deformation of
pelvic organs.
1.1 Prostate cancer
The prostate is a gland that plays an important role in the male reproductive system.
Some of its functions are to produce part of the alkaline fluid that makes up semen and
enables ejaculation by contracting its muscles. The prostate is located in the pelvic
cavity, below the bladder and in front of the rectum. The seminal vesicles, two glands
that make most of semen, connect behind the prostate, see Fig. 1.1.
The prostate changes size over time, growing mostly during puberty, due to a rise of
male hormones. In adults, it usually remains stable in the same size or grows slowly, so
the average prostate weight is approximately 20𝑔. However, the prostate sometimes gets
bigger as men get older, leading to an enlarged prostate. This is called benign prostatic
hyperplasia (BPH) or benign enlargement of the prostate (BPE). Prostate enlargement
is usually benign, but men can have an enlarged prostate and prostate cancer at the
same time.
The prostate cancer is the most common cancer amongst the men population in
most developed countries. According to the World Health Organization (WHO), it was
the second most common cancer among men with 1.112 million of diagnosed cases in










Figure 1.1: Visualization of the male pelvic zone anatomy. Source wikimedia
in 2014) and in Colombia (9564 cases in 2014). Meanwhile, it is the third most common
cause of cancer deaths in males in both countries (9.3% and 7.1% in France and in
Colombia in 2014, respectively) [2–4]. It develops mainly in men over the age of 50,
and it usually grows slowly without causing any symptoms or problems over a men'
lifetime. However, some men may have cancer that grows quickly, likely resulting in
health problems. About 42% in fifty-year-old men have developed histological evidence
of cancerous cells in the prostate; 9.5% of these will develop an aggressive form of cancer,
and 2.9% will die from prostate cancer [5, 6]. Medical treatments are thus needed
to prevent or delay the tumor from spreading outside the prostate. For a complete
review on prostate cancer diagnosis, staging and treatments (with curative intent), see
guidelines of the European Association of Urology [7, 8].
1.1.1 Diagnosis and staging of prostate cancer
The biopsy is the only procedure that can fully confirm the diagnosis of prostate cancer
[9,10]. It consists of introducing a needle — through the rectum wall into the prostate
— in order to remove small prostate tissues. Biopsy samples are then sent to a lab to
be examined under a microscope to determine whether they have cancer cells or not. A
grade called grade score (GS) is subsequently assigned based on how much cancer looks
like normal prostate tissue, according to the Gleason system [11, 12]. Grade 1 means
that the cancerous tissue looks very much like normal prostate tissue, i.e the glands are
1.1. Prostate cancer 25
small, well-formed, and closely packed. Meanwhile, Grade 5 means that the cancerous
tissue does not have any or only a few recognizable glands, and grades between 2 and
4 mean that tissue has features in between both extremes. Since prostate cancers may
have areas with different grades, the pathologist assigns a primary grade to the dominant
pattern of tumor (greater than 50% of the total pattern), and a secondary grade to the
next-most frequent pattern ( less than 50%, but at least 5% of the pattern). The GS
is then obtained by summing the primary and secondary grade. For example, if the
primary grade was 3 and the secondary tumor grade was 4, the Gleason score would be
3 + 4 = 7.
In addition to the biopsy, there are two methods used to suspect the presence of
cancer: the prostate-specific antigen (PSA) test and the digital rectal exam (DRE)
[13,14]. The PSA test measures the level of prostate-specific antigen which is a protein
produced by prostate cells. Meanwhile, DRE test consists of inserting a gloved and
lubricated finger into the rectum to feel any bumps or hard areas on the prostate, and
it can help to determine whether tumor is only in one or both sides of the prostate.
Most healthy men have PSA levels under 4 ng/ml of blood, and it usually goes above
4 when prostate cancer develops. However, PSA can also be raised in a man that has
other medical conditions like BPH, prostate infection, exercise, or sex. The PSA and
DRE test are not thus 100% accurate, and they can have abnormal results in a man
that does not have cancer (i.e false-negative), or normal results in a man that does have
cancer (i.e false-positive). For example, about 15% of men with a PSA below 4 will
have prostate cancer on a biopsy. As a result, other tests can be undergone to avoid
false-positives, such as those based on medical image (MRI, bone scan or CT), medical
history or tests ( TRUS, PIA or ASAP) [15,16].
The stage or extent of a cancer is one of the most important factors in choosing
treatment options and predict prognosis [8, 17, 18]. The objective is to determine how
far cancer has spread. The most widely used staging system for prostate cancer is the
TNM classification system, which is an international standard that can be adapted to
each type of cancer. The TNM system assesses the tumor (T category), lymph nodes
(N category) and secondary cancer (metastases- M category). The stage is determined
based on the prostate biopsy results (including the Gleason score (GS)), PSA level, and
any other exams that are done. The general outline for the T stages is given as follows:
 T: size or extent of the primary tumor
- T1: tumor present, but not detectable with imaging or clinically:
T1a: tumor is less than 5% of prostate tissue resected during a transurethral
resection of the prostate (TURP) for BPH.
T1b: tumor is more than 5% of prostate tissue resected in a TURP.
T1c: tumor is found in a biopsy performed due to a high level PSA.
- T2: tumor can be felt in a DRE or seen with imaging clinically, but it still
appears to be confined to the prostate.
T2a: tumor is in half or less of one (left or right) of the prostate lobes.
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T2b: tumor is in more or half one (left or right) of the prostate lobes,
but not both.
T2c: tumor is in both sides of the prostate lobes but still in the prostate
capsule.
- T3: tumor has spread outside the prostate and may have spread to the
seminal vesicles.
T3a: tumor has spread outside the prostate but not to the seminal
vesicles.
T3b: tumor has spread to the seminal vesicles.








Figure 1.2: Diagram showing the T1-3 stages of prostate cancer. Source Cancer Research
UK/Wikimedia
Fig. 2.1 illustrates a diagram showing the T stages of prostate cancer. Once the
TNM categories are defined, this information is combined with the results of the prostate
biopsy, the Gleason score, the PSA level, and any other exams done to determine an
overall staging, which is divided into four stages, as follows:
 Stage I (low risk and confined): T1 to T2a, GS≤ 6, PSA≤ 10𝑛𝑔/𝑚𝐿.
 Stage IIA (intermediate risk and confined): T2b or GS= 7 or 10𝑛𝑔/𝑚𝐿 ≤PSA≤
20𝑛𝑔/𝑚𝐿.
 Stage IIB (high risk and confined): T2c or GS≥ 8 or PSA≥ 20𝑛𝑔/𝑚𝐿.
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 Stage III (high risk and non-confined): T3, any GS, any PSA.
 Stage IV (metastasis): any GS, any PSA, T4.
Once the staging procedure is carried out, treatment options are considered and the
prognosis is predicted.
1.1.2 Curative treatments for localized prostate cancer
There are several treatment options for localized prostate cancer with comparable out-
comes but different side effects [8]. Table 1.1 illustrates a classification of treatment
options according to the risk grade given during staging phase [18]. A short description
of these treatment options is given as follows:
 Surgery. Men in good health whose tumor is still confined in the prostate may be
treated with surgery to remove the tumor. Radical prostatectomy is the main type
of surgery, which consists of removing the entire prostate gland plus surrounding
tissue and the seminal vesicles. However, erectile dysfunction following radical
prostatectomy is a common complication due to nerve damage after the procedure
[19].
 Watchful waiting or active surveillance. Because prostate cancer is often slow-
growing, these options are usually recommended for some older men without seri-
ous health problems. Both treatment options seek to monitor tumor growth and
avoid having unnecessary treatment. However, key differences rely on the type of
follow-up and medical tests used to monitor prostate cancer. For example, active
surveillance implies more regular doctor visits, hospital tests such as PSA tests,
DRE exams, biopsies, or MRI scans about every six (6) months.
 Hormone therapy. Prostate cancer grows when male hormones like testosterone
and dihydrotestosterone (DHT) stimulated the tumor. Hormone therapy thus
seeks to stop male hormones from reaching prostate cancer cells. However, its
purpose is not to cure cancer but rather to keep it under control slowing down its
growth.
 Radiotherapy. This option uses high-energy x-rays or other types of radiation to
kill cancer cells. The main two types of radiotherapy are EBRT and brachyther-
apy. Brachytherapy consists of inserting a source of radiation inside or next to
the tumor, while EBRT uses X-ray beams to irradiate prostate gland from outside
the body.
1.2 External beam radiotherapy in prostate cancer
More than two thirds of patients diagnosed with prostate cancer will be treated with
EBRT, which is mostly used if prostate cancer is between stage TI and T3. EBRT uses
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Figure 1.3: Patient lying on a table of a linear particle accelerator (right ) and multileaf
collimator (left, manufactured by Varian, 120 leafs).
X-ray beams to irradiate prostate gland and seminal vesicles in order to kill cancerous
cells (tumor control) while sparing neighboring healthy organs classified as OARs. The
radiation dose is delivered in several sessions in order to allow healthy tissue to recover
and increase tumor damage by reoxygenation. A small dose called fraction is thus de-
livered in each session. For example, if a dose of 80 Gy is prescribed to the prostate,
fractions of 2 Gy delivered over five (5) days in eight weeks are the conventional treat-
ment schedule. The radiation units are expressed in Grays, abbreviated as Gy, which
represents 1 Jule/Kg [18]. Dose fractionation is used to increase the therapeutic ra-
tio, i.e. it enables both normal tissues to repair between fractions and increase tumor
damage by reoxygenation and redistribution.
Before treatment starts, the radiotherapy team will carefully plan the proper radi-
ation dose, fractionation scheme and correct angles of the beams. This session, known
as treatment planning, starts by acquiring a computed tomography (CT) scan on the
zone being irradiated. This scan shows the patient’s organs which are delineated by an
expert (e.g. prostate, seminal vesicles, bladder, femoral heads, and rectum). This infor-
mation is then exported to a TPS, which is a software used to generate the prescribed
dose, known as the planning dose. The prescribed dose is a three-dimensional map that
relates every point within patient with a level of dose. The following step is then to
set up the linear accelerator to deliver the planning dose using the selected fraction-
ation scheme, whereby each treatment fraction lasts only a few minutes. The patient
is fitted with a plastic mold on a table that is below the linear particle accelerator for
each fraction during treatment. The aim is to keep the patient in the same position as
that of the planning CT, see Fig. 1.3. Markers can be implanted on the patient's skin
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Treatment Low risk Intermediate risk High risk
(T1-T2a, GS ≤ 6) (T2b, GS= 7 (T2c-T4, GS≥ 8




EBRT X X X
Watchful waiting X X X
Hormone therapy X
Table 1.1: Treatment options for localized prostate cancer.
or prostate to align him at each irradiation session. It is worth mentioning that a few
days or weeks may have passed between the planning and start of the treatment itself.
During this time, physicists and clinician decide the areas to be irradiated or spared
using a TPS. Fig. 1.4 depicts the treatment planning workflow in radiotherapy.
1.2.1 Irradiation techniques
There are two types of irradiation techniques: 3D conformal radiotherapy (3D-CRT)
and intensity modulated radiotherapy (IMRT). In both techniques, the fluence (radia-
tion energy per unit area) of the radiation beams are modulated to match the prostate
shape as closely as possible and optimally avoid dose being delivered to the surround-
ing healthy tissues. In 3D-CRT, between five to nine convergent beams are used to
conform the target volume via the modulation of a multileaf collimator located at the
linear accelerator output (see Fig. 1.3). The multileaf collimator is made up of metal
bars called leaves that block part of the radiation beam. These leaves are arranged in
opposing pairs, and they are positioned under computer control in order to conform
the target shape. IMRT also uses multileaf collimator to modulate the fluence, but
it can provide non-uniform dose distribution and control independently the beam in-
tensity in different regions [18]. IMRT appeared with the arrival of inverse-planning
software that enables us to obtain concave iso-doses, a property desired mainly at the
prostate-rectum junction. IMRT has become the standard irradiation technique in 30%
of French treatment centers [2], including at the Centre Eugène Marquis (from 2003
onwards) that provided the medical support and background to this thesis. Fig. 1.5
shows the work-flow of the Direct Machine Parameter Optimization with RayMachine
using the Pinnacle TPS manufactured by Phillips. As is illustrated, IMRT dose is de-
rived by an inverse-planning software that starts from the end-product (i.e. desired
dose ) and ends with the input (i.e. fluence profile). The desired dose is represented
as a mathematical cost function 𝑓 to be optimized with some constraints. The input
parameters of this function include leaf positions, some weights (w), and the fluence
matrix (deposition matrix). Fig. 1.6 depicts a planning dose to treat prostate cancer
with IMRT, and demonstrates the concave shape of the iso-doses.
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Figure 1.4: Treatment planning workflow for external beam radiotherapy of the prostate.
1.2.2 Image guided radiotherapy
Image-guided radiotherapy (IGRT) is defined as frequent imaging in the treatment room
that allows treatment decisions to be solved [21]. IGRT then uses different imaging tech-
niques, ranging from planar to fluoroscopy to X-ray images, to check that the actual
treatment delivered matches with that which was planned [18, 22]. IGRT has played
an important role in the evolution of radiotherapy by achieving important accomplish-
ments such as reducing the uncertainty of the exact position of tumor and OARs, and
improving the precision of the delivered dose. IGRT has also enabled the development
of adaptive radiotherapy based on the assessment of information obtained from daily
images.
The most important problem to be solved in IGRT is organ motion during treat-
ment [22]. In prostate cancer radiotherapy, organ motion and deformation mostly arise
from geometric variations in the prostate, bladder, and rectum. These anatomical vari-
ations can lead to an under-radiation of the target volume, or an over-radiation to
OARs, decreasing the local control in the former and increasing the risk of toxicity in
the latter. Localizing the tumor and OARs is thus a requirement that has resulted in
the development of new image modalities (with new devices integrated to linear acceler-
ators), such as kilovolts (kV), megavolts (MV), ultrasound or electromagnetic detection.
The most common modalities in radiotherapy are: cone beam computed tomography
(CBCT), computed tomography (CT), magnetic resonance imaging (MRI), MR-linac,





Figure 1.5: Workflow of the Direct Machine Parameter Optimization with RayMachine
using Pinnacle® TPS manufactured by Phillips. (image modified from [20])
and positron emission tomography (PET). CT enables a 3D image of the internal struc-
ture of an object to be obtained without cutting from many X-ray images taken from
different angles. CT provides detailed cross-sectional anatomy of organs and 3D tumor
information (see Fig. 1.6) [18, 22]. CBCT is also an X-ray CT, but the X-rays taken
with this modality are divergent, forming a cone. The voxel value of the CBCT thus de-
pends on the position in the image volume, rather than its tissue density. Nevertheless,
CBCT has become an important tool in IGRT to position patients, whose reconstructed
3D image is compared to the planning CT scan.
1.3 Current practices and treatment plan evaluation in
prostate cancer radiotherapy
According to the International Commission on Radiation Units and Measurements
(ICRU) [23], there are five target volumes defined in radiotherapy: gross tumor vol-
ume (GTV), clinical target volume (CTV), planning tumor volume (PTV), and treated
and irradiated volume. The CTV represents the main target volume to be irradiated in
radiotherapy, receiving all the prescribed dose. The CTV contains the primary tumor
(called GTV) and/or sub-clinical malignant disease that has to be eradicated in order
to control the tumor. Fig. 1.7 shows the target volumes set by ICRU in order to define
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Figure 1.6: Above: Planning CT scan and the main structures delineated (prostate,
bladder and rectum). Below: IMRT planning dose distribution.
a common international language to delineate tumors. 3D safety margins around the
CTV define the planning target volume (PTV). This target volume is set in order to en-
sure that the prescribed dose is actually delivered to the CTV, even if it does experience
geometric variations in organs during a fraction or between fractions. In prostate can-
cer radiotherapy, it is not possible to accurately define the GTV with current imaging
techniques [18]. As a result, it is standard practice to define a CTV that includes the
whole prostate and any possible extension of the seminal vesicles. The target volume
then includes the prostate and base of seminal vesicles in the low risk group, while the
prostate and entire seminal vesicles in the other risk groups [18]. The PTV is defined
by an isotropic margin of 1𝑐𝑚 around the CTV, but the posterior the PTV region is







Figure 1.7: Diagram representation of ICRU target volumes. This diagram was made
following the same idea of target volume definitions from ICRU (1993) Prescribing, Recording
and Reporting Photon Beam Therapy. ICRU report 50.
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Planned dose distributions are usually evaluated by means of a two-dimensional
graph that relates the percentage of the organ volume that receives a dose equal to,
or lower than, a certain value. This graph is called a dose volume histogram (DVH).
The ideal scenario is then to have 100% of the CTV receiving the total prescribed dose,





Figure 1.8: Example of dose distribution used to treat prostate cancer. The figure on
the left shows a sagittal view of the planning CT with the main delineated organs, target
volumes and dose in colorwash. Meanwhile, the figure on the right shows the DVH of
the CTV, PTV, bladder and rectum compared with ideal CTV and OAR DVH.
Table 1.2 shows dose-volume constraints recommended by Groupe d’ètude des tumeurs
uro-gènitales (GETUG) for target volumes and OARs in prostate cancer radiotherapy.
1.4 Random geometric uncertainties in prostate cancer
radiotherapy
In radiotherapy geometric uncertainties may be systematic or random. Systematic un-
certainties may result from organ delineation errors in the planning CT (either due
to the limited CT resolution or different human interpretations), misalignments in the
patient repositioning with respect to the planning phase [24], or inaccurate placing of
devices, among others [18]. Meanwhile, random uncertainties mostly arise from unpre-
dictable and involuntary anatomical changes in patient's organs during the delivering of
a dose fraction or between fractions [18,25]. For example, in prostate cancer radiother-
apy, the prostate can be displaced or compressed by filling and emptying the bladder
and/or rectum; SV volume can also vary during treatment, between 30% and 50% [26].
These anatomical changes in organs thus introduce random geometric uncertainties that
make their positions and shapes unknown within and between fractions, reducing the
treatment quality.
IMRT has enabled us to deliver complex dose distributions with higher doses and
sharp concave iso-doses that conform target volumes well. However, IMRT dose distri-
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Table 1.2: GETUG dose-volume constraint recommendations for target volumes and




Minimum dose to PTV must be higher
than 90% of the prescribed dose.
𝑉95% > 90%
The volume receiving at least 95% of
the prescribed dose must be higher
than 90% of the total volume.
Bladder wall (7mm)
𝐷𝑚𝑎𝑥 < 80𝐺𝑦
The average dose to 1.8 cm3 must be
always lower than 80Gy.
𝑉70 < 50%
The volume receiving at least 70 Gy
must be lower than 50%.
Rectal wall (7mm)
𝐷𝑚𝑎𝑥 < 76𝐺𝑦
The average dose to 1.8 cm3 must al-
ways be lower than 76 Gy.
𝑉72 < 25%
The volume receiving at least 72 Gy
must be lower than 25%.
Femoral heads 𝑉55 < 5%
For each femoral head, the volume re-
ceiving at least 55 Gy must be lower
than 5%.
butions are only made using the planning CT scan, where organ structures observed
on this image does not hold during treatment, either caused by systematic and/or ran-
dom geometric uncertainties [26,28–32]. For example, Fig. 1.9 depicts the planned and
accumulated DVHs for a patient treated for prostate cancer, showing an overdose on
the bladder caused by its changes in volume during treatment. These geometric uncer-
tainties can thereby make the beams miss the target volume and hit the healthy organs
increasing the probability of developing side-effects.
There are some efforts made to overcome these geometrical uncertainties. For ex-
ample, systematic uncertainties can significantly be reduced by means of body cast,
skin tattoos, or fiducial markers, whose position can be determined in three dimensions
using IGRT. Translational errors can thus be reduced to 1𝑚𝑚 and rotational errors to
1∘ [18]. Safety margins are also introduced around the CTV upon treatment planning,
in order to enlarge irradiated area [23]. Nevertheless, this also means including portions
of OARs that may be highly irradiated, potentially resulting in adverse events affecting
patient's organ functions (hematuria, cystitis rectal bleeding, fecal incontinence, among
others). Although new technologies — such as image guided radiotherapy (IGRT),
fiducial markers and intensity-modulated radiation therapy (IMRT) — have enabled
us to determine organ location and deliver higher doses with sharp iso-doses, random
geometric uncertainties still have an impact during treatment. In the case of IGRT,
on-line adaptive imaging has arisen as a promising solution, but integration in real time
of on-line imaging and dose adaptation while fraction are performed is task that is not









* Easy to interpret.
* Systematic and random un-
certainties assumed to be nor-
mally distributed.
* Population-based approach.
* Organ deformation is not
considered.
* High number of CT scans
per patient.
* Scalar variables like vol-
ume, translation or rotation




* Organ changes in size and
shape are considered.
* Population-based approach.
* Probability distributions of




* The database should repre-
sent the patient population.









* Limited by the required
number of CT scans per pa-
tient.
* Organ motion and defor-










* Slow convergence of the esti-
mated non-parametric distri-
bution.
* Limited by the requited
number of CT scans per pa-
tient.
Table 1.3: Methods developed in order to quantify geometrical uncertainties.
feasible or too expensive. As a result, the dosimetric variables obtained from the plan-
ning CT are very poor surrogates for the actual-delivered dose [33–35], and random
geometrical uncertainties still have an impact during treatment, reducing its quality.
Several approaches have been developed in order to quantify geometrical uncertain-
ties produced by organ variations between fractions, including: serial imaging measure-
ment of the organ during treatment course [26,36], fiducial markers [28,37], margins of




Bladder at the  
planning CT
Figure 1.9: Impact of random geometric uncertainties on the delivered dose on a bladder.
The figure on the left shows the CTV, bladder and rectum delineated at the planning CT
with the planning dose. It also shows the bladder delineated at two CT scans obtained
during treatment. The figure on the right shows the bladder DVH obtained with the
planning dose (planned DVH), and the bladder DVH obtained by dose accumulation
during treatment (accumulated DVH).
organ shape [27,44,45], as well as biomechanical [46,47] and statistical models [48–56].
Table 1.3 provides a short description of advantages and disadvantages of the developed
approaches to quantify random geometric uncertainties.
From statistical models, a method based on weighted scenarios of the fundamen-
tal directions of geometric variability has been introduced [54, 57]. These directions
of variability, called motion/deformation modes, were obtained by applying principal
component analysis (PCA) to a data set of (pre-)treatment organ geometries, usually
parameterized by a set of corresponding surface points. This approach known as a
point-distribution model (PDM) has also been applied in statistical shape models and
organ segmentation [58–60]. The idea of PCA-based models is to represent any organ
structure 𝑥 as a linear combination of 𝑞 dominant directions called modes:




where ?̄? is the mean shape vector, 𝜙𝑘 is the k-th mode, 𝑧𝑘 = (𝑥 − ?̄?)𝑇𝜙𝑘 is the
projection of 𝑥 along mode 𝜙𝑘. The scalar 𝑧𝑘 may be interpreted as a “measure" of
geometric variability around the mean shape. These modes were derived by diagonal-
ization of a data matrix, called the covariance matrix, whose columns were made of
patient’s motion/deformation vectors (i.e. vectors that describe the observed geometric
variation of the organ at the on-treatment CTs/cone-beam CTs (CBCTs) relative to the
mean shape). Denoting the observed organ structure at the i-th CT as 𝑥𝑘, the empirical
covariance matrix C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙 is defined as follows:






(𝑥𝑖 − ?̄?)(𝑥𝑖 − ?̄?)𝑇 = UDU𝑇 (1.2)
where U is a matrix composed of eigenvectors 𝜙𝑘 of C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙, and D is the diago-
nal matrix constructed from its corresponding eigenvalues 𝜆𝑘, i.e. C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙𝜙𝑘 = 𝜆𝑘𝜙𝑘.
New organ geometries can then be generated by adding a weighted sum of a few dominat-
ing modes to the mean organ shape, where each weight obeyed a Gaussian distribution
with mean of zero and the corresponding eigenvalue as variance. PCA-based models
thus have the following advantages: i) organ motion and deformation are parameterized
by few dominating directions; ii) the number of model parameters is defined according
to a pre-fixed error; iii) geometric uncertainties can be quantified; iv) PCA enables
the reduction of dimensionality of high-dimensional data (repeated CTs/CBCTs) while
preserving the most important information. Table 1.4 provides a short description of
developed methodologies for statistical models of organ motion and deformation based
on PCA.
PCA-based motion/deformation models were initially used by Söhn et al. [57] for
modeling individual geometric variations between fractions of the rectum, bladder, and
prostate. The main goal was to estimate the patient's variance along each mode of
geometric variability. These modes were derived by diagonalization of a data matrix,
called the covariance matrix, whose columns were made of patient’s motion/deformation
vectors (i.e., vectors that describe the observed geometric variation of the organ at the
on-treatment CTs/cone-beam CTs (CBCTs) relative to the mean shape). New organ
geometries were then generated by adding a weighted sum of a few dominating modes
to the mean organ shape, where each weight obeyed a Gaussian distribution with mean
of zero and the corresponding eigenvalue as variance. PCA has also been applied to
generate individual 4D statistical models for organs undergoing respiratory motion like
the lung, liver, and heart [52,53,63]. The same method was in turn applied to describe
the geometric variations of organs like prostate, seminal vesicles, and pelvic lymph
nodes [51].
However, this individual-based methodology was limited by the required number of
CT scans per patient for training the model. In clinical practice, only one CT scan is
available at the planning treatment for a typical patient, and on-treatment CTs/CBCTs
are seldom available during treatment. Budiarto et al. [54] thus proposed a population-
based method that learned the geometric variations from a population database seeking
to infer the possible organ variations for a typical patient despite his small number of
CTs/CBCTs. Budiarto et al. [54] applied his method to describe clinical target volume
(CTV) motion and deformation between fractions in prostate cancer using a longitu-
dinal database. It is worth mentioning that longitudinal data set consists of repeated
observations of a set of homologous objects or variables at several time points [64, 65].
In our context, it corresponds to repeated observations of the organ at different frac-







tion of organ motion and de-
formation.
* Limited by the required
number of CT scans per pa-
tient.
* Organ parametrization via a
set of surface points.
* A mesh relaxation process is





* Few number of CT scans
per patient.
* Voxel-wise implementation
without using a mesh relax-
ation process [56].
* Not suitable to longitudinal
data: modes are biased to the
most observed directions in
the population.
It is based on a cross-sectional
analysis, where the inherent
correlation of intra-individual







* Organ shapes represented
with less variables.
* A mesh relaxation process is
not needed.
* Intra-patient variance is
characterized from the total
variance.
* Patient-specific eigenmodes
are characterized from the
population modes
* Problems to properly repre-
senting non-convex organs.
* The bladder at the planned
CT may not be a proper esti-
mation of the mean bladder
shape.
* Orthogonal eigenmodes
may not properly describe the
latent structure of the data.
Table 1.4: Methodologies developed for statistical models of organ motion and defor-
mation based on PCA.
and deformation of the CTVs and bladder in rectal and prostate cancer radiotherapy,
respectively [55, 56]. In addition, Hu et al. [66] proposed a population-PCA model to
describe prostate deformation in magnetic resonance (MR)-tumor-targeted biopsies us-
ing a longitudinal database of prostates obtained from MR images and biomechanical
models. Similarly, several researchers have introduced so-called 4D population-based
or cross-population models for organs undergoing respiratory motion [63, 67, 68]. In
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population-based models, modes were derived from the population covariance matrix
made by the patients' motion/deformation vectors, i.e., all the rigid and non-rigid or-
gan displacements observed for each patient around his mean bladder were stacked as
columns. For a given patient, new organ samples were also generated by a weighted
sum of the dominating modes to the mean shape, whereby each weight also obeyed a
Gaussian distribution with mean of zero and the corresponding eigenvalue as variance
(i.e., the total population variance). However, this may lead to a suboptimal estimation
of individual-specific variability as it is considered that the mode variance is shared
by all the individuals. In addition, the dominating modes used to generate new organ
samples were the most observed directions of geometric variability in the population.
As a result, patients with dominating modes different from the population modes may
not properly be described. Therefore, as the patients may exhibit heterogeneous organ
variability, it is not necessarily verified that all the patients share the same dominant
modes as well as the same mode variance.
1.5 Research problem
In prostate cancer radiotherapy the bladder is notorious for presenting the largest inter-
fraction shape variations during treatment, caused by continuous changes in volume [26,
31]. These variations in shape introduce geometric uncertainties that render assessment
of the actual dose delivered to the bladder during treatment difficult, thereby leading
to dose uncertainties that limit the possibility of modeling the dose-volume response for
late genitourinary (GU) toxicity [35, 69]. The Quantitative Analysis of Normal Tissue
Effects in the Clinic (QUANTEC) project has stated that a similar dose-response to
that of late gastrointestinal (GI) toxicity is far from being established. The dosimetric
variables obtained from the planning CT are very poor surrogates for the real-delivered
dose [33, 34]. As a result, it is crucial to quantify uncertainties produced by inter-
fraction bladder variations in order to determine dosimetric factors that affect late GU
complications.
The aim of this thesis was thus to characterize and predict uncertainties produced
by geometric variations of the bladder between fractions, using solely the planning CT
as input information. In clinical practice, a single CT scan is only available for a typical
patient at the treatment planning while on-treatment CTs/CBCTs are seldom avail-
able during treatment. In this thesis we thereby used a population approach to obtain
enough data to obtain the most important directions of bladder motion and deforma-
tion using principal components analysis (PCA). As in groundwork, these directions
were then used to develop population-based models to predict and quantify bladder ge-
ometrical uncertainties. However, we used a longitudinal analysis in order to properly
characterize both patient-variance and patient-specific modes from the population. We
proposed to use a mixed-effects (ME) model and hierarchical PCA to separate intra-
and inter-patient variability to control confounding cohort effects. Other than using
PCA, bladder shapes were also represented by using spherical harmonics (SPHARM)
which additionally enable data compression without resulting in a loss of information.
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We lastly presented PCA models as a simulation tool to quantify dose uncertainties
produced by bladder motion and deformation between fractions.
Fig. 1.10 provides a workflow of the methodology used in this thesis. The first step
was to learn the most important directions (dominant modes) of bladder motion and de-
formation from a population database using principal components analysis (PCA). We
used these dominant modes to characterize bladder shapes and deformation/motion re-
gions. The second step was an early step of dimensionality reduction using spherical har-
monics (SPHARM). This step enabled us to reduce the number of parameters required
to represent the bladder surface, further encoded with the dominant modes derived by
PCA. The third step was to introduce longitudinal analysis to develop population-based
models, instead of using cross-sectional analysis as in previous works. With this, we
firstly sought to properly characterize patient-specific variance from the population vari-
ance along each mode. We proposed the use of mixed-effects (ME) models to separate
intra- and inter-patient variability in order to control confounding; secondly, we sought
to properly characterize the patient-specific modes from the population modes by using
hierarchical PCA-based models. Table 1.5 provides a list of divergence and convergence
points between the developed methodologies to describe organ motion and deformation
based on PCA. Finally, we quantified dose and DVH uncertainties produced by bladder
motion and deformation between fractions. From on-treatment CT/CBCTs of three
patients, we trained individual PCA models using the bladder samples available from
the images. Based on the above models, weighted sums of these eigenmodes were used
to estimate bladders with their probability of occurrence. We then estimated mean and
variance of the dose delivered to the bladder using PCA-based models; subsequently,
we compared the estimated accumulated dose with the accumulated dose derived using
non-rigid image registration and the on-treatment CT/CBCTs available for the patient.
1.6 Objectives
The main objective of this thesis is to develop a methodology to predict and quantify
geometrical uncertainties produced by bladder motion and deformation between dose
fractions using planning and on-treatment CT/CBCTs scans of population databases
Also, using only planning information, specific objectives of the thesis are:
 To characterize and predict bladder motion and deformation between fractions.
 To quantify dose and DVH uncertainties produced by geometric variations of the
bladder between fractions.
 To propose a methodology to model OAR motion and deformation between frac-
tions that helps to determine optimal planning dose and treatment modifications
by integrating treatment constraint (fraction size and toxicity events), OAR mo-
tion and deformation and treatment constraints (PTV: 𝐷min > 90%, 𝑉76 > 90%;
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Table 1.5: List of divergence and convergence points between the developed method-
ologies to describe organ motion and deformation based on PCA.
1.7 Chapter by chapter overview
This thesis comprises of six chapters. A brief description of each chapter is presented,
as follows:
 Chapter 2 presents the clinical context of prostate cancer treated with radiother-
apy. It thereby introduces a brief description of the prostate anatomy, statistics
related to prostate cancer, and the different options available to treat this cancer.
It also presents the main aspects of radiotherapy, and a survey of methods to
model organ motion and deformation between fractions.
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 Chapter 3 describes the training database used in this study. It also presents the
characterization of bladder shapes and motion/deformation regions by means of
the limited number of directions of geometric variability called modes, and goes
on to describe the validation method performed to assess whether the modes can
be used to describe bladder motion and deformation for a typical patient.
 Chapter 4 and 5 describe the longitudinal approach proposed to develop popula-
tion PCA-based models. Chapter 4 firstly describes the additional database used
in this study and the early step of dimensionality reduction used to represent
bladder surface with a lesser number of variables. It subsequently addresses the
characterization of the patient-specific variance from the population using mixed-
effects models. This chapter also describes the validation process used to assess
the performance prediction in population-based models. Meanwhile, chapter 5
presents the characterization of the patient-specific variance from the population
using hierarchical PCA.
 Chapter 6 presents PCA models as a versatile tool to quantify dose uncertain-
ties produced by bladder motion and deformation. Individual PCA models were
trained using the bladder samples available from the on-treatment CT/CBCTs of
three patients; and subsequently based on the above models, cumulated doses,
local dose variability and dose-volume histogram uncertainties were estimated.
The main contributions of this thesis were:
 A methodology to characterize shapes, and motion/deformation patterns (modes)
and regions of the bladder.
 The reduction of the number of variables required to represent bladder surface in
a factor of 10 using spherical harmonics (SPHARM).
 A methodology based on longitudinal analysis to develop population-based models
that predict motion/deformation regions using solely the planned CT.











Data, spatial normalization and
organ parametrization
This chapter describes the two population databases used in this study. It also describes
the rigid-spatial normalization that was proposed in order to anatomically align the
pelvic structures (prostate and bladder). Subsequently, this chapter describes the early
step of dimensionality reduction followed to represent all the bladder contours by means
of spherical harmonic coefficients (SPHARM). The figures in this chapter, as well those
of subsequent chapters, were made by using Matlab R2014, Inkscape, Paraview, and
VV image viewer.
2.1 Data
In this study we included two population databases of patients treated for prostate
cancer with external beam radiotherapy (RT). These databases were longitudinal data
sets, which consisted of repeated observations of the prostate and bladder at different
fractions for a patient population. Both databases are named and described below.
2.1.1 Training database
This study included a cohort of 20 patients treated for prostate cancer with external
beam radiotherapy with an average age of 70 years. Patients approximately had one
additional CT scans per week under identical conditions on a Scanner Philips Big Bore
16. Each patient had a planning CT and several on-treatment CTs (5-8), bringing a
total number of 156 images. The resolution of the CT scans were 512× 512× 80, with
a voxel size of 1𝑚𝑚× 1 𝑚𝑚× 3 𝑚𝑚.
Patients were positioned in supine position, arms folded over the chest, pillow under
the head and a hold under the knees. Three points had been tattooed on the skin of the
patients to allow their positioning under the treatment device. Three fiducial markers
were placed on these three points to make them appear in the image before acquiring
each CT scans. The contours of the bladder, rectum, prostate and seminal vesicles
47
48 Data, spatial normalization and organ parametrization
(SV) were manually delineated following the same observer (an expert radiotherapy
physician). A full bladder protocol was followed, where the patients were asked to hold
the volume of his bladder 1 hour before each CT scan and radiotherapy session. None
daily-temporal schedule was followed in order to acquire the planning and on-treatment
CT scans of the patients. Besides, there were not specific procedures that would have
affected the bladder shapes (TURBT/TURP) of the patients.
The prescribed dose was computed in the Philips Pinnacle Treatment Planning
System (TPS) Version 9.4. Organ delineation was set to meet GETUG group rec-
ommendations [70]. The bladder walls were derived from a 7𝑚𝑚 negative expansion
from the manually delineated contours. Two CTVs were delineated, CTV1 including
the prostate and seminal vesicles while CTV2 including only the prostate. PTVs were
generated from the CTVs by adding a 1𝑐𝑚 margin in all the directions, except for the
posterior direction, where 5𝑚𝑚 were added. The total dose was 46𝐺𝑦 in PTV1, fol-
lowed by a boost of 34𝐺𝑦 to deliver 80𝐺𝑦 in PTV2, at 2𝐺𝑦 per fraction. Five 18 MV
photon beams were used. GETUG dose-volume constraints were respected through-
out: 𝑉 70𝐺𝑦 ≤ 50% and 𝐷𝑚𝑎𝑥 ≤ 80% for the bladder wall, and 𝑉 50𝐺𝑦 ≤ 50%,
𝑉 72𝐺𝑦 ≤ 25%, and 𝐷𝑚𝑎𝑥 ≤ 76𝐺𝑦 for the rectum wall.
2.1.2 Validation database
This study included a cohort of 28 patients treated for prostate cancer with external
beam radiotherapy with an mean age of 70 years. 25 patients had a planning CT and
several on-treatment CTs (6-9) (approximately one CT scans per week were obtained
under identical conditions using a Scanner Philips Big Bore 16). Three patients had
a planning CT and daily on-treatment CBCTs (35-39). CBCT images were acquired
during the 8 weeks of treatment. The total number of bladder contours were 195. The
resolution of the CT scans were 512×512×80, with a voxel size of 1𝑚𝑚×1 𝑚𝑚×3 𝑚𝑚.
Patients were positioned in supine position, arms folded over the chest, pillow under
the head and a hold under the knees. Three points had been tattooed on the skin of the
patients to allow their positioning under the treatment device. Three fiducial markers
were placed on these three points to make them appear in the image before acquiring
each CT scans. The contours of the bladder, rectum, prostate and seminal vesicles
(SV) were manually delineated following the same observer (an expert radiotherapy
physician). A full bladder protocol was followed, where the patients were asked to hold
the volume of his bladder 1 hour before each CT scan and radiotherapy session. None
daily-temporal schedule was followed in order to acquire the planning and on-treatment
CT scans of the patients. Besides, there were not specific procedures that would have
affected the bladder shapes (TURBT/TURP) of the patients.
The prescribed dose was computed in the Philips Pinnacle Treatment Planning
System (TPS) Version 9.4. Organ delineation was set to meet GETUG group rec-
ommendations [70]. The bladder walls were derived from a 7𝑚𝑚 negative expansion
from the manually delineated contours. Two CTVs were delineated, CTV1 including
the prostate and seminal vesicles while CTV2 including only the prostate. PTVs were



































































Figure 2.1: Average values for the bladder and prostate volume in both databases.
posterior direction, where 5𝑚𝑚 were added. The total dose was 46𝐺𝑦 in PTV1, fol-
lowed by a boost of 34𝐺𝑦 to deliver 80𝐺𝑦 in PTV2, at 2𝐺𝑦 per fraction. Five 18 MV
photon beams were used. GETUG dose-volume constraints were respected through-
out: 𝑉 70𝐺𝑦 ≤ 50% and 𝐷𝑚𝑎𝑥 ≤ 80% for the bladder wall, and 𝑉 50𝐺𝑦 ≤ 50%,
𝑉 72𝐺𝑦 ≤ 25%, and 𝐷𝑚𝑎𝑥 ≤ 76𝐺𝑦 for the rectum wall.
2.1.3 Descriptive information
Table 2.1 provides the population avarage of some parameters that describe the bladder
and prostate contours in both databases. Besides, Fig. 2.1 shows the distribution of
the average volume of the bladder and prostate during treatment in both databases.


















Figure 2.2: Overlay of a typical individual bladder registered to the template.
Table 2.1: Population average of parameters describing bladder and prostate volumes
in both databases.
Training database Validation database
Prostate Bladder Prostate Bladder
Mean volume [𝑐𝑚3] 42.65 145.48 57.40 136.10
std volume [𝑐𝑚3] 17.43 102.18 25.17 80.1
Max. volume [𝑐𝑚3] 113.47 645.24 121.30 531.70
Min. volume [𝑐𝑚3] 12.46 25.20 17.85 30.17
2.2 Prostate-based rigid registration
This was served to spatially align all the bladders in the same spatial referential. After
defining the prostate barycenter of a patient as common coordinate system, henceforth
called the template, all the patient structures were thus registered by semi-automatically
aligning the prostate barycenters, which provided a transformation T. The template
was a patient from the training database whose prostate exhibited the lowest volume
variation and the most similar mean volume to the population mean. The individual
bladders were then propagated to the common template using the obtained 𝑇 . This
transformation was derived from the difference in physical positions between the two
barycentres of the prostates. Non rotation or affine transformation were made as the
bladder does not present rotations as the prostate does, neither volume changes in the
prostate are correlated with volume changes in the bladder. This spatial normalization
thus enabled bladder motion and deformations to be quantified with respect to the
template prostate barycenter. Fig. 2.2 depicts an example of the performed rigid
registration/propagation step.
In addition, all the binary images representing the bladder contours were cropped to
the resolution of 135× 215× 55 voxels as each delineated bladder in the database only
occupied a region in the whole image. This dimension was chosen seeking the minimum
image size that covered all the bladder contours in the database. The binary images
were thus cropped as follows: firstly, the binary image representing the bladder contour
at the planning CT of the template patient was defined as the reference image; secondly,
we manually cropped the reference image to the resolution of 135 × 215 × 55 by using
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the VV image viewer; thirdly, the binary images representing the bladder contours were
semi-automatically cropped based on cropped reference image.
2.3 Bladder shape parametrization
An essential objective in shape modeling has been the reduction of parameters needed to
describe a shape instance. As a first step towards this goal, PDM method was proposed
to parameterize 3D shapes by means of a set of boundary points [58, 71]. However,
this approach required thousands of points to properly describe shape surfaces and a
one-to-one correspondence between these boundary points [46,54,55,57,71]. SPHARM,
the extension of 2D Fourier techniques to three dimensions, was proposed to obtain
smooth, accurate and fine parametrization of 3D shapes with spherical topology with a
fewer number of parameters [72–75]. This method consisted in expressing a surface as a
linear combinations of a reduced number of spherical harmonics basis functions, where
different levels of approximation errors can be obtained by truncating the spherical
harmonic series.
As opposed to other methods like PDM, it offers the advantage of delivering a
shape parametrization with an implicit correspondence between shapes on the boundary.
Besides, the spherical harmonics define an orthogonal basis functions whose spanned
space has a reduced dimension that enables us to describe and quantify shape variations.
This implies that the number of parameters (i.e. SPHARM coefficients) needed to
describe a shape instance is lower than other shape modeling methods like PDM.
In medical imaging, SPHARM has played a crucial role in 3D-shape representation
and modeling of anatomic structures in several applications, including computer as-
sisted diagnosis [76–80], rigid registration [79,81] and organ segmentation [73–75,82,83],
among others. In most of these applications, statistical shape models were developed by
applying PCA to a training population of organ surfaces parameterized with SPHARM
coefficients, where eigenmodes of maximum variation around the mean shape were cal-
culated. In these applications, the surfaces of these binary organs were initially param-
eterized by surface boundary points, and these boundary points-based parametrization
were subsequently expanded into series of spherical harmonics.
In our study, SPHARM was used to parameterize the surface of each delineated
bladder into a vector of SPHARM coordinates. As a result, we initially defined a
reference point for each bladder contour, which was its distance map point. An uniform
3D sphere contour with 64442 evenly distributed vertices was then created and centered
on the defined reference point, using a sampling of 1 degree for each spherical angle.
The sampling was an arbitrary number aiming to obtain a re-sampling lines in radial
directions that were dense enough to fully capture the feature points of bladder surface.
Following mesh parameterization, each bladder was represented by a sphere surface
function 𝑓 = (𝑥(𝜃, 𝜑), 𝑦(𝜃, 𝜑), 𝑧(𝜃, 𝜑)) ∈ ℛ3, and we subsequently encoded this function
𝑓 in a reduced number of spherical harmonic functions, as follows:















𝑙 (𝜃, 𝜑), 0 < 𝐿 <∞ (2.1)
where 𝜃 and 𝜑 denoted the spherical coordinates, and with









defining a spherical harmonic function of degree 𝑙 and order 𝑚, where 𝑃𝑚𝑙 was an
associated Legendre polynomial; 𝐿 was the number of spherical harmonic functions
used to approximate 𝑓 ; and coefficients 𝑐𝑚𝑙 corresponded to the coordinates in the
space spanned by the spherical harmonic basis. The 𝑐𝑚𝑙 coefficients were obtained as
the projection of the mesh function 𝑓 onto the spherical harmonic basis, i.e, 𝑐𝑚𝑙 =<
𝑓(𝜃, 𝜑), 𝑌 𝑚𝑙 (𝜃, 𝜑) >. By fixing a harmonic degree to 𝐿, the bladder surface at the j-th
CT scan of the i-th patient, denoted by 𝑥𝑖 ,𝑗 ∈ R𝑑1×𝑑2×𝑑3 , was uniquely represented in
spherical harmonic coordinates as follows:
𝑐𝑖𝑗 =
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𝑐𝑖𝑗 ∈ R𝑝 ∧ 𝑝 = 2
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(𝐿+ 1)2 − (𝐿+ 1)
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2
]︂
<< 𝑑 = 𝑑1 × 𝑑2 × 𝑑3 (2.4)
Observe that we have taken only the SPHARM coefficients that were different to
0. The value of 𝐿 was optimally chosen by analyzing its impact on the approximation
error in the training cohort. The approximation error was assessed as a function of 𝐿
in terms of dice score (DS) and the Hausdorff distance (HD).
In the study, an 𝐿 of 15 spherical harmonics was selected to approximate bladder
surfaces in the population database. With 𝐿 = 15 in Eq. 2.1, the average DS and HD
values in the training database were 0.954 ± 0.0522 and 6.112 ± 4.997𝑚𝑚, respectively.
Conversely, validation database equivalents were 0.97± 0.0099 and 4.32± 2.27𝑚𝑚, re-
spectively. Any bladder in the databases can thus be represented by 𝑝 = 272 coefficients
instead of 𝑑 = 1596375 voxel variables. The SPHARM surface parameterization was
implemented in C+/C using ITK libraries.
2.4 Discussion
We have hereby described the population databases used in this study. We have also
proposed a prostate-based rigid registration process to map all the bladders in the same
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spatial referential. After defining the prostate barycenter of the template patient as
common coordinate system, all the patient structures were thus registered by semi-
automatically aligning the prostate barycenters. This rigid-registration was derived
from the difference in physical positions between the two barycentres of the prostates.
We have also proposed to parameterize the bladder surface using spherical harmonic
expansion. A number of 15 spherical harmonic basis functions were used, since accept-
able reconstruction errors were obtained in the population databases in terms of DS
and HD.
In this study we have used two databases that consisted of repeated observations of
the bladder at different fractions for a patient population. Each patient in the data set
had more than one observation at different time-points. As a result, the analysis of such
data sets should lead to the characterization of the most common geometric variations
of the bladder that patients shared between them (i.e. inter-patient variability), and
also those geometric variations that make them different (i.e. intra-patient variability).
We therefore followed a longitudinal analysis instead a cross-sectional in order to take
into account the inherent correlation of repeated measurements of the same patient.
As opposed to previous works, our aim was then to separate intra- and inter-patient
variability in order to tailor organ motion and deformation models to a typical patient
using population databases. It is important to highlight that we consider that our
databases were representative of the population due to the prostate and bladder volume
distributions were similar to the volume distributions of previous studies [26, 32]. For
example, in the study of [26], the population volume of the prostate and bladder were
55.46 ± 21.16𝑐𝑚3 and 187.21 ± 71.05𝑐𝑚3, respectively. Meanwhile, in the study of
[32], the population bladder volume was approximately 151.63 ± 95.07𝑐𝑚3, and the
maximum and minimum volume were 686𝑐𝑚3 and 46𝑐𝑚3, respectively. In our study,
the bladder volume was 145.48± 102.18𝑐𝑚3 and 136.10± 80.10𝑐𝑚3 in the training and
validation databases, respectively. Meanwhile, the maximum and minimum volume
were 645.24𝑐𝑚3 and 25.2𝑐𝑚3 in the training database, and 531.70𝑐𝑚3 and 30.17𝑐𝑚3 in
the validation database.
Previous studies have matched CT scans for modeling geometric variations of the
pelvic organs based on body anatomy, soft-tissue registration, or fiducial markers.
For example, Söhn et al. [57] used bone anatomy to match for each patient the re-
peat CT scans to the planning CT in order to obtain an intra-patient model for the
prostate/bladder/rectum. Thörnqvist et al. [51] used fiducial markers to model individ-
ual geometric variations of the prostate. In contrast, Hu et al. [66] proposed anatomical
apex and base points of the prostate. Meanwhile, Budiarto et al. [54] defined the
prostate barycenter as the origin for each CT scan in order to derive a population-based
model of the CTV for prostate cancer. However, we believe that using the barycenter as
a reference point is not feasible for all pelvic organs to obtain population-based models.
For this reason, Bondar et al. [55] used a setup based on bone anatomy for each patient,
to calculate intra-patient motion-deformation vectors and develop a population model
of CTVs for rectum cancer, as did [54]. Nevertheless, this method may not be the most
suitable setup for analyzing in the same framework all the different sizes and shapes
that an organ can manifest in patients [56]. In our study, we did not use bone anatomy
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as it can significantly differ from one patient to another, affecting the rigid registration
and distribution of the pelvic organs. On the other hand, the bladder is attached to
the prostate across the urethra, and the surface in contact with the prostate is gener-
ally stable, or is at least considered the least mobile part, while the top and anterior
part can expand. We thereby sought to align this fixed bladder section in order to
model both bladder motion and deformation. We believe that the ideal setup could be
to match CTs using the boundary between the bladder and prostate, yet that type of
rigid-registration is not possible. For intra-patient analysis, we think that the prostate
barycenter offers a better means to perform this alignment due to the prostate volume
being near constant during treatment, despite its rigid displacements [26, 30] (see Fig.
1 in appendix A).
For inter-patient analysis, we consider that differences in prostate size and shape in
the population can be reduced by defining the template as a patient presenting a prostate
with the lowest volume variation and the most similar mean volume to the population
mean (see Fig. 6.5 in appendix A). In our training database, this patient prostate
volume was 42.14 ± 3.33𝑐𝑚3, whereas the population volume was 42.65 ± 17.43𝑐𝑚3.
For example, Fig. A.1b shows 3D sagittal views of some segmented patient prostates
that were plotted as outside the first and third quartiles of the boxplot of the average
prostate volumes. In Fig. A.1a, it can be observed that the size and shape differences
were not significant for patients 17, 7, and 20, particularly in the upper anterior part
of the prostate (the surface in contact with the bladder). The highest dissimilarity
was obtained for Patient 8, an outlier like Patient 17. We thus consider that size and
shape differences among prostates in the population are not sufficiently greater than
those observed in bladders to introduce disturbances, at least in the first eigenmodes.
For example, it can be observed in Fig. 3.3 that the first three modes did not reveal
geometric variations in the lower posterior bladder section, i.e., the region that presented
the geometric variations in the bladder produced by the barycenter alignment (see Figs.
4.5, 6.5 and A.1). Also, Fig. 6.5 demostrates that for intra-patient analysis, the first
mode was also dominated by the bladder volume, meaning that volume changes in the
prostate do not affect at least the most important mode in the bladder. It is worth
mentioning that we did not introduce any rotation, nor conduct affine transformation,
as the bladder does not present rotations as the prostate does, nor do volume changes in
the prostate correlate with volume changes in the bladder. Besides, if all the bladders
in the population are transformed using affine or non-rigid registration, inter-patient
geometric variability can disappear, which is the main advantage of using ME models,
where individual effects are separated from the mean. We therefore considered that
the prostate barycenter also provided a suitable reference point in the pelvic zone to
model bladder motion and deformation for inter-patient analysis, despite the potential
variations of prostate in size and shape across the population.
Similar to other SPHARM-based shape models, our study was significantly aided by
encoding the information of the bladder shape into vectors of SPHARM coefficients with
orders of 102, instead of vectors of boundary points with orders of 103 obtained from
a meshing process, as used in [54, 57]. The SPHARM parameterization thus enabled
us to reduce not only computation time but also numerical errors, by affording finite
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arithmetic operations, and data storage while preserving shape information. However,
it is important to highlight that not all the bladder shapes were properly parameter-
ized using the radial sampling in spherical coordinates. In our training database, some
bladders with non-convex dilations in the inferior-ventral region resulted in higher re-
construction errors. Future work should thus be dedicated to improve bladder-shape
modeling. One way would be to extend the SPHARM methodology to model a much
larger class of simply-connected closed shapes using an area-preserving, distortion min-
imizing spherical mapping, as expressed in [73, 80]. Alternatively, a second possibility
is to use a different computational technique called isogeometric analysis, which gener-
alizes and improves on the standard finite element method [84,85]. In population data,
this technique offers the advantage of obtaining a surface parameterization with corre-
sponding points in all organ instances without requiring a mesh relaxation procedure.
This methodology defines a transformation to a canonical domain, where parametriza-
tion is carried out and extrapolated to any organ instance.
2.5 Conclusion
We have described the population databases used in this study in order to propose
a methodology to predict and quantify geometrical uncertainties produced by bladder
motion and deformation between fractions. We have also proposed a prostate-based
rigid registration that enable us to align all the bladders in the same spatial referential.
Besides, we have proposed an early step of dimensionality reduction using SPHARM in
order to reduce the number of variables required to represent the bladder contours in a
factor of 10.
56 Data, spatial normalization and organ parametrization
Chapter 3
Characterization and
dimensionality reduction of bladder
motion and deformation in prostate
cancer radiotherapy
This chapter is dedicated to characterize shapes and motion/deformation regions of the
bladder using PCA for patients treated for prostate cancer with radiotherapy. This
study included the cohort of 20 patients, where for each patient a planning CT scan
and several (ranging from 5 to 8) on-treatment CT scans were available. As in Budiarto
et al (2011), we obtained a limited number of directions of geometric variability that
enabled us to characterize bladder shapes and motion/deformation regions, but using a
voxel representation rather than a set of corresponding surface points. These directions
of geometric variability called modes were then used to characterize bladder shapes
and motion/deformation regions in the latent space. These modes were validated using
a reconstruction error and leave-one-cross validation on the training database. A di-
mensionality reduction was obtained by representing any bladder in term of 104 scores
instead of 1596375 voxel variables. 28 modes were considered as population directions
to model bladder geometric variations.
The methodology proposed in this chapter was accepted for publication in the In-
ternational Journal of Innovation and Research in BioMedical engineering (IRBM) [56].
The chapter is organized as follows. Section 3.1 describes the database used in this
study, and it provides a description of the proposed model together with the validation
framework. Section 3.2 presents the results while section 3.3 provides a discussion of
the experimental findings. Lastly, section 3.4 summarizes the main conclusions.
3.1 Data
We used the training database previously described in Chapter 2.
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3.2 Methods
Our proposed model is based on the assumptions stated in the methodology developed
by Budiarto et al. [54]: firstly, that the bladder moves and deforms in a limited number
of directions, constrained by the body’s anatomy; secondly, that the inter-fraction geo-
metric organ variations are randomly distributed along the set of variability directions;
thirdly, that despite the potential variations in organ size and shape across the pop-
ulation, principal directions of geometric variation prove to be similar in all patients;
fourthly, that geometric variations between fractions are independent random variables,
where the time sequence of the observations does not matter. Hence, each bladder
within the population can be characterized by its variation along each direction.
The paper is organized as follows. Section 1 describes the two databases (training
and testing) included in this study. Section 2 provides a detailed description of the
proposed method together with the validation framework. Section 3 presents the results
and comparison to groundwork methods. Lastly, Section 4 discusses the experimental
findings, with a conclusion given in Section 5 in addition to final considerations and
future perspectives.
Fig. 3.1 shows the steps followed to train the population-based PCA model. Firstly,
rigid-spatial normalization was performed in order to align all the bladders in the same
spatial referential; secondly, a step of dimensionality reduction was conducted using
PCA, thereby yielding a limited set of directions of maximum geometric variability.
These directions, or modes, were validated by leave-one-out cross validation, seeking to



























number of  
modes
Figure 3.1: Workflow of the method used to train the population-based model. 0)
Prostate-based registration, 1) principal component analysis (PCA) reduction, 2) leave-
one-out cross-validation.
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3.2.1 Principal component analysis
PCA is a powerful tool used for dimensionality reduction of high-dimensional data while
preserving the most important information. In this study the modes of bladder motion
and deformation were obtained using PCA, where each bladder instance was considered
as an observation and each voxel as a variable.
Let 𝑥 ∈ R𝑑 be an anatomical structure after stacking the image into a vector, where
𝑑 denoted the number of voxels. The aim was then to approximate 𝑥 as a weighted
combination of a limited number of the modes 𝜓𝑖, as follows:




where 𝑧𝑖 = 𝑥𝑇𝜓𝑖 was the projection of 𝑥 along the mode 𝜓𝑖, which may be interpreted
like a “measure" of geometric variability. Modes 𝜓𝑖 were obtained by applying SVD to
a data matrix denoted as 𝒳 whose columns were the bladders stacked as vectors (see
Eq. 3.2). The objective was to have a sample that described all the possible bladder
shapes and sizes, i.e a snapshot matrix of the “bladder space". Denoting the observed
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]︀
= UΣV𝑇 (3.2)
where 𝑗𝑖 was the number of images available for the i-th patient and 𝑛 was the
number of patients. Σ was the singular value matrix, and U and V were the left
and right singular vectors, respectively. Each right singular vector defined a mode.
Meanwhile, the singular values defined an significance ranking for the data variability
described by each mode, attesting 𝑣𝑎𝑟(𝜓1) = 𝜎21 ≥ 𝑣𝑎𝑟(𝜓2) = 𝜎22 ≥ · · · ≥ 𝑣𝑎𝑟(𝜓𝑟) = 𝜎2𝑟 ,
where 𝑟 was the rank of the data matrix 𝒳 (given by the number of available images).
The variance of the original variables was thus dominated by the first 𝑞 modes. The





, 𝑞 = 1, . . . , 𝑟 (3.3)
The dimensionality reduction was thereby obtained by projecting each anatomical
structure 𝑥 on the subspace spanned by the first 𝑞 modes, called “latent space”; then
each structure 𝑥 was represented by the scores 𝑧1, . . . , 𝑧𝑞 with 𝑞 < 𝑟 << 𝑑.
3.2.2 Validation
In order to test whether the modes described common directions of bladder motion and
deformation among all patients, we performed a leave-one out cross validation on the
training database. The modes were evaluated by using a reconstruction error metric in
both data sets. Given a bladder 𝑥 and its approximation ?̂? in Eq. 3.1, the reconstruction
error 𝑒 was defined as follows:
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Figure 3.2: Accumulated mode variance 𝑃𝑞 obtained by PCA. 90% of accumulated







where 𝑣𝑗 and 𝑣𝑗 were the intensity at the j-th voxel of the image 𝑥 and its approx-
imation ?̂?, respectively. If the reconstruction of 𝑥 was exact, then 𝑒 was equal to 1;
otherwise, the value of 𝑒 was between 0 and 1. The mean of the reconstruction error 𝑒
in all the bladders was also calculated, i.e.,ℳ = (1/𝑁) ·
∑︀𝑁
𝑖=1 𝑒𝑖, where 𝑒𝑖 denoted the
approximation error of the i-th image 𝑥𝑖 and 𝑁 the number of available images, either
in the training or validation data set.
3.3 Results
The analysis was carried out in MATLAB (R2014a). The eigenvectors and were obtained
using the function eigs. Fig. 3.2 shows the spectrum of the singular values of all 20
combinations of cutting the training database from the leave-one-out cross validation.
The size of the data matrix 𝒳 was 1596375 × 𝑛, where 𝑑 = 135 × 215 × 55 = 1596375
voxels and 𝑛 varied between 151 and 154 (i.e. the available images after removing the
left-out patient’s images). The first mode contributed the largest variance ( 11.4% of
the variability); similarly, the second and third modes contributed, on average, 5.05%
and 3.18%, respectively. Fig. 3.2 shows also that 90% of the accumulated variability
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Third mode
First mode Second mode
90-th mode
Figure 3.3: Sagittal view of the first three and 90-th mode. Each voxel of a given mode






























Figure 3.4: Scatterplot of the patients projected in the space spanned by the first
two modes (Black points). Non-black points correspond to the observations for some
patients in the database.
was contributed approximately by the first 103 modes. Any bladder was therefore
represented as a vector of 𝑞 = 103 scores (𝑞 = 103 << 𝑟 << 𝑑 = 1596375). The


































Figure 3.5: Scatterplot of the observations available for one patient projected in the
space spanned by the first two modes. The symbol 𝐶𝑖 denotes the observed bladder in
the i-th CT scan.
analysis was carried out in MATLAB (R2014a). The eigenvectors and were obtained
using the function eigs.
Fig. 3.3 presents sagittal views of the first three and 90-th modes. Each voxel of
a given mode has a normalized value that represents its contribution in that direction
of geometric variability. The first mode, the static component of the database, then
represents the non-zero voxels that are the most significant to reconstruct any bladder,
i.e. it is associated with the bladder volume. Similarly, modes with higher indices, like
the second and third, represent those voxels that dilate and shrink regions in the bladder
according to its negative and positive values. For example, if the weight z happens to be
increased in Eq. (3.1), the second mode will shrink the superior-region of the bladder.
However, higher modes, like the 20-th, do not describe directions of geometric variability
observed in patients rather than patient-specific directions (see Fig. 3.6).
Fig. 3.4 depicts the projection of all the bladders on the space generated by the
first two modes. Each point can be interpreted like measure of geometric variation
along each direction. As observed in Fig. 3.4, this reduced space provides some well-
defined regions or clusters of bladder shapes. Flat bladders, for example, are mainly
found in the square region (0, 0.5) × (−1.5, 0.5). It is also observed that each patient
has a motion/deformation region. Fig. 3.5 shows the observations of a patient during
treatment, demonstrating that bladder geometric variations between fractions follow a
random trajectory.
Fig. 3.6 shows that both mean and standard deviation of the approximation error
ℳ decreased as the number of modes was increased in both the PCA model and left-
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Figure 3.6: Mean approximation errorℳ as a function of the number of modes in the
PCA model and left-out patients. There are bands (dotted-lines) that represent the
mean approximation errorℳ (solid-lines) plus and minus one standard deviation of 𝑒𝑖.
out patients. However, mean and standard deviation of the reconstruction errorℳ did
not reach the value of zero in the left-out patients, mean reconstruction error settles
between 0.75 and 0.80 after the 25-th mode.
3.4 Discussion
We have hereby implemented a methodology to describe and quantify uncertainties
produced by inter-fraction geometric variations of the bladder in prostate cancer radio-
therapy via population analysis. We performed leave-one-out cross validation in order
to assess whether the modes described common directions of bladder motion and de-
formation for a typical patient. A reconstruction errors metric was proposed to assess
the modes in both data sets in order to test whether they described common direc-
tions of bladder motion and deformation for a typical patient. Bladder shapes and
motion/deformation regions were then characterized in the latent space spanned by the
first two modes.
As opposed to previous studies, we proposed a population PCA-based model using
a voxel representation rather than surface points [54,57]. We consider that the meshing
approach has the disadvantage of requiring a relaxation process to ensure an one-to-one
correspondence among surface points before applying PCA. Meanwhile, our voxel rep-
resentation has the disadvantage of requiring a higher number of modes to sufficiently
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describe the data variability. For example, 15 modes were required to describe 90%
of CTV motion and deformation for prostate cancer in [54] whereas 104 modes were
sufficient in our study to describe the same percentage of data variability. We consider
that this result can be a consequence of the higher number of parameters being used
to describe the bladder surface, which increases the information to be analyzed. Nev-
ertheless, future studies should be done to confirm or disapprove the number of modes
required to properly describe bladder motion and deformation due to the studied organs
were not the same.
As established in the model assumptions, the modes represent directions of geometric
variability. Unlike the first mode, they do not clearly define affine transformations that
can be initially corrected using rotations along a certain axis or using a uniform dilation.
Each mode dilates and shrinks regions in the bladder, showing that bladder motion and
deformation are not uniform. In addition, we show that it is possible to characterize
bladder shapes and patient’s motion/deformation region in the latent space, which is
an infeasible task in the original space due to its high dimensionality and the intra- and
inter-patient variability. It is also proved that bladder motion and deformation between
fractions follow a random behavior.
As in Budiarto et al. [54], the mean error decreased as the number of modes increased
in both data sets. However, we found that the mean error settled in 0.8 in the left-
out patients, implying that some individual directions were not detected by the modes.
Besides, it can be observed We consider that the first 28 modes can thus be considered
as truly population directions with a mean reconstruction error of 88% and 80% in the
training and validation data, respectively. Nevertheless, comparing Figs. 3.2 and 3.6, a
trade-off between truly population modes and accumulated data variability can be done
to define the suitable order of a population-based PCA model, where we considered that
60 modes were needed in our study.
3.5 Conclusion
We implemented a model to characterize shape and motion/deformation regions of the
bladder in prostate cancer radiotherapy via population analysis. This model was imple-
mented following a voxel representation. This model can be used to quantify uncertain-
ties produced by inter-fraction geometric variations of the bladder in dose delivering.
Future studies should now be conducted to develop a model that predicts deforma-
tion/motion regions for a typical patient using solely the planned CT scan as input
information. Future studies should also be focused to study the relationship among




using a longitudinal approach:
characterization of patient-specific
variance from the population
variance
This chapter presents the longitudinal approach proposed to properly characterize pa-
tient’s variance from the total population variance. This study included two population
databases of patients treated for prostate cancer with external beam radiotherapy (RT).
We trained the model using data from the database of 20 patients, including a planning
CT and several on-treatment CTs (5-8) for each patient. We also used the validation
database of 28 patients described as follows: 25 patients had a planning CT as well as
6-9 on-treatment CTs, and 3 patients with a planning CT as well as 35-39 on-treatment
CBCTs for each. In this chapter, we used mixed-effects (ME) models to separate intra-
and inter-patient variability along each mode in order to control confounding effects.
This step enabled us to reduce the number of parameters required to represent the blad-
der surface, further encoded with the dominant modes derived by PCA. This step also
allowed us to reduce data storage and the processing time, among others aspects. We
evaluated the model by means of leave-one-out cross validation on the training data and
also the validation data. Probability maps (PMs) were thus generated as predicted re-
gions of probable bladder motion and deformation. These PMs were compared with the
observed region using a metric based on mutual information distances. The prediction
was compared with two previous population PCA-based models.
Our main contribution regarding groundwork was to introduce ME models in order
to estimate individual-specific variations between fractions from a reduced-order model
(SPHARM/PCA based model). Using the ME model the following aspects were ad-
dressed for each mode: i) the estimation and separation of individual-specific variance
from that of the population, i.e, the inherent correlation of intra-individual observations;
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ii) the reduction of the observed population variance by grouping repeated observations
per patient by means of a “patient factor”; iii) the characterization of the individual-
specific directions of motion and deformation from the population; iv) the study of
longitudinal observations ordered in time, which may reflect temporal trajectories in
the latent space. This study is also the first one in explicitly addressing the issue of
predicting a region of probable inter-fraction bladder motion/deformation using solely
the planning CT. A quantitative comparison of predicted vs observed probability maps
was proposed using our model and other previous motion/deformation models.
The methodology proposed in this chapter was published in the International Jour-
nal of Medical Image Analysis (MedIA) [62]. The chapter is organized as follows. Section
4.1 describes the two databases (training and testing) included in this study. Section
4.2 provides a detailed description of the proposed method together with the validation
framework. Section 4.3 presents the results and comparison to groundwork methods.
Lastly, section 4.4 discusses the experimental findings, with a conclusion in section 4.5
in addition to final considerations and future work.
4.1 Data
We included the training and validation databases previously described in Chapters 2.
Population-based models were thus trained using the training database. Meanwhile,
the prediction performance of the model was evaluated by following leave-one-out cross
validation in the training database and also using the validation database.
4.2 Methods
The training steps are depicted in Fig. 4.1. Firstly, all the bladders were aligned in the
same spatial referential by performing the same prostate-based rigid registration used in
Chapter 3; secondly, bladder surface parameterization was conducted using SPHARM,
followed by dimensionality reduction using PCA, thereby yielding a limited set of direc-
tions of maximum geometric variability. These directions, or modes, were validated by
leave-one-out cross validation, aiming to determine whether patients exhibited common
directions of bladder motion and deformation; finally, a mixed-effects model was fit to
each direction to model the inter and intra-individual geometric variations obtained.
4.2.1 Principal component analysis
This step was aimed to represent, in a reduced space, all possible rigid and non-rigid
bladder displacements. After obtaining SPHARM coefficients, an empirical covariance
matrix C of local patient motion-deformation vectors was thus defined in order to
calculate the directions of maximum variability by using matrix diagonalization. Here,
a local patient motion-deformation vector defined the difference between the observed
bladder and patient mean bladder. Thus, denoting the observed bladder of the i-th
patient at the j-th CT as 𝑐𝑖𝑗 , the empirical covariance matrix C was defined as follows:
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Figure 4.1: Workflow of the method used to train the population-based model. 0)
Prostate-based registration, 1) spherical harmonics (SPHARM) representation, 2) prin-
























where 𝑑𝑖𝑗 = 𝑐𝑖𝑗−𝑐𝑖, 𝑛 was the number of patients, 𝑗𝑖 was the number of observations
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available for the i-th patient, and 𝑐𝑖 the average shape of the i-th patient. Similarly,
U was a matrix composed of eigenvectors 𝜙𝑘 of C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙, and D was the diagonal
matrix constructed from its corresponding eigenvalues 𝜆𝑘, i.e, C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙𝜙𝑘 = 𝜆𝑘𝜙𝑘.
Eigenvectors 𝜙𝑘 defined the directions of geometric variability of the bladder, called
modes. As a result, each bladder in the spherical harmonic space was expressed as a
linear combination of the modes, as follows:
𝑐𝑖𝑗 = 𝑐𝑖 + 𝑧𝑖𝑗 1 𝜙1 + · · ·+ 𝑧𝑖𝑗 𝑟 𝜙𝑟 (4.2)
where 𝑧𝑖𝑗𝑘 = 𝑑𝑇𝑖𝑗 𝜙𝑘, and 𝑟 was the rank of covariance matrix C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙, and equal
to the number of available images in the population database. Modes {𝜙𝑘}𝑘 defined
a new coordinate system, where each vector 𝑑𝑖𝑗 was represented by new 𝑟 coordinates
𝑧𝑖𝑗 1, . . . , 𝑧𝑖𝑗 𝑟. The eigenvalues of matrix D defined a significance ranking for the data
variability represented by each mode, attesting 𝑣𝑎𝑟(𝜙1) = 𝜆1 ≥ 𝑣𝑎𝑟(𝜙2) = 𝜆2 ≥ · · · ≥
𝑣𝑎𝑟(𝜙𝑟) = 𝜆𝑟, and showing that data variability was dominated by the first 𝑞 modes
with 𝑞 << 𝑟.
In order to test whether the modes described common directions of bladder motion
and deformation among all patients, we performed a leave-one out cross validation on
the training database. Thus, the error assessing the difference between the original and
reconstructed motion-deformation vector was defined as follows:
𝑒𝑖 =
‖ 𝑑𝑖 − 𝑑𝑖 ‖
‖ 𝑑𝑖 ‖
(4.3)
where 𝑑𝑖 and 𝑑𝑖 were the i-th bladder motion-deformation vector and its approx-
imation, respectively. If the reconstruction of 𝑑𝑖 was exact, then 𝑒𝑖 was equal to 0;
otherwise, the value of 𝑒𝑖 was between 0 and 1. The mean of the reconstruction error
𝑒𝑖 in all the motion-deformation vectors was also calculated, i.e.,ℳ = (1/𝑁) ·
∑︀𝑁
𝑖=1 𝑒𝑖,
where 𝑒𝑖 denoted the approximation error of an i-th motion-deformation vector 𝑑 and
𝑁 the number of the available images, either in the PCA model or left-out patients.
4.2.2 Linear mixed-effects model
Several longitudinal studies have been designed to investigate anatomical or functional
changes over time in objects or variables that are observed repeatedly at several time
points [64, 86–89]. For instance, these repeated observations may be brain volume,
response to clinical treatments, disease progression, blood pressure, heart motion or
tumor evolution, among others [90–94]. In these longitudinal studies, observations
may be obtained under changing experimental conditions that are not possible to fully
control, leading to considerable variations among subjects in the number and time points
of the observations. The resulting data sets, which are known as unbalanced data, have
often analyzed using ME models that offer to simultaneously model both the random
effects that differentiate one subject from a population and the inherent correlation of
repeated measurements in the same subject [65, 86–89, 95, 96]. A linear ME model is
then a statistical model that incorporates both “fixed effects”, which are parameters
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related to the entire population or a certain level of classification factor, as well as
“random effects”, which are parameters associated with differences among individual
subjects drawn at random from a population.
The use of basis functions and ME have already proposed in the literature to ac-
count for random effects in longitudinal data. These basis function methods include:
smoothing splines, wavelet basis, polynomial basis, and functional principal compo-
nents [97–100]. In our study, the longitudinal data was encoded in the PCA modes,
where the observed motion-deformation vectors in the training database were projected
over each mode while a linear ME model was fit to each. The score resulting from
each projection could be interpreted as a measure of how much a direction of geometric
variability was presented in a motion-deformation vector. The implemented ME model
thus aimed the characterization of population and individual bladder variations along
each mode by introducing a “patient” factor modeled as a random effect.
Let 𝑧 be the measure of motion/deformation of an organ along a mode. Considering
the patient as the unit of observation state (subject), we used an index 𝑖, ranging from 1
to 𝑛, to differentiate among patients, and an index 𝑗 to differentiate between observation
times in a patient. The encoded longitudinal data was thus defined as follows:
{𝑧11𝑘, . . . , 𝑧1𝑗1𝑘}, {𝑧21𝑘, . . . , 𝑧2𝑗2𝑘}, · · · , {𝑧𝑛1𝑘, . . . , 𝑧𝑛𝑗𝑛𝑘}, 𝑘 = 1, . . . , 𝑞 (4.4)
with the linear mixed-effects model proposed for each mode described as follows:
𝑧𝑖𝑗𝑘 = 𝜇𝑘 + 𝑏𝑖𝑘 + 𝜀𝑖𝑗 𝑘, 𝑖 = 1, . . . , 𝑛, 𝑗 = 1, . . . , 𝑗𝑖, (4.5)
𝑏𝑖𝑘 ∼ 𝒩 (0, 𝜎2𝑏𝑘), 𝜖𝑖𝑗𝑘 ∼ 𝒩 (0, 𝜎2𝑘),
where 𝜇𝑘 was the mean projection along the k-th mode for the whole population,
𝑏𝑖 𝑘 was a random variable representing the deviation of the i-th patient mean from the
population mean, and 𝜀𝑖𝑗, 𝑘 was a random variable representing the deviation for j-th
projection of the i-th patient from the i-th patient mean. In addition, variances 𝜎2𝑏𝑘 and
𝜎2𝑘 denote inter and intra-patient variability, respectively. The population based model
is thus described as follows:















𝑧1 𝑧2 · · · 𝑧𝑞
]︀
where 𝑐𝑖 was the patient mean shape, 𝑧𝑘 ∼ 𝒩 (𝜇𝑘, 𝜎2𝑏𝑘 + 𝜎2𝑘), for 𝑘 = 1, . . . , 𝑞.
4.2.3 Out-of-sample problem
We sought to predict a likely motion-deformation region of the bladder for a new patient
using only his planning CT information. We described regions of motion/deformation
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in terms of 3D probability maps (PM) that express the probability of a voxel being
occupied by the bladder during treatment. As shown in Fig. 4.2, the first step was to
spatially normalize the out-of-sample patient 𝑃𝑙 to match the template patient; secondly,
the SPHARM and PCA representations of his delineated bladder 𝑐𝑙,0 and 𝑧𝑙,0 were
obtained; and thirdly, each ME model was adapted to the new patient by estimating
his patient-specific mean and variance ?̂?𝑙𝑘 and ?̂?𝑙𝑗𝑘.
In ME models, random subject-specific effects are summarized to predict the re-
sponse of a new subject. The predictor is a linear combination of both fixed and
random effects, and it can be interpreted as a shrinkage estimator. Let us suppose that
the l-th patient was included in the data set and we want to estimate the following
linear model:
𝑧 𝑙𝑗𝑘 = 𝜇𝑘 + 𝑏𝑙 𝑘 + 𝜖𝑙𝑗 𝑘 ∼ 𝒩 (?̂?𝑙 𝑘, ?̂?2𝑙 𝑘), 𝑗 = 1, . . . , 𝑗𝑙, 𝑘 = 1, . . . , 𝑞 (4.7)
A shrinkage estimator of ?̂?𝑙 𝑘 = 𝜇𝑘 + 𝑏𝑙 𝑘 is then given by:







, 𝑘 = 1, . . . , 𝑞 (4.8)
where 𝜇𝑙 𝑘 is the mean of the l-th patient at the k-th mode, and 𝑗𝑙 is the number of
patient's observations. Term 𝜁 is known as the credibility factor. Similarly, the variance
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2
𝑏𝑘 (4.9)
In our study, 𝑐𝑙 = 𝑐𝑙,0, 𝜇𝑙 = 𝑊 𝑇 (𝑐𝑙 − 𝑐𝑙,0) = 𝑧𝑙 = 0 and 𝑗𝑙 = 1 due to we only
had the information obtained from the planning CT. In this way, probable structures
of the bladder during treatment were thus inferred after sampling 𝑆 times the Normal
distributed vector 𝑧. We used the function mvnrnd of Matlab to drawn random vec-
tor of 𝑧. Subsequently, each sample of 𝑧 was mapped to a vector 𝑐 in the spherical
harmonic space using matrix 𝑊 . Then, binary images representing probable bladder
configurations were obtained from the parameterized surfaces that were coded in vectors
𝑐. Following this, an estimation of the motion/deformation region was calculated by
the ratio between the number of times that a voxel was occupied by the bladder and
the 𝑆 generated samples.
4.2.4 Evaluation of prediction performance
Two additional population PCA-based models were used to compare the model’s pre-
diction performance. Considering motion-deformation vectors computed between the
observed bladders and population mean bladder, the PCA model implemented by Söhn













Figure 4.2: Workflow to estimate new structures based on the planning CT for a new
patient.


















(𝑐𝑖𝑗 − 𝑐𝑝𝑜𝑝)(𝑐𝑖𝑗 − 𝑐𝑝𝑜𝑝)𝑇 𝜓𝑘 = 𝛼𝑘 𝜓𝑘, (4.10c)
where 𝑁 =
∑︀𝑛
𝑖=1 𝑗𝑖 was the total number of observations in the training database,
𝑐𝑝𝑜𝑝 was the population mean bladder, and vectors 𝜓𝑘 were the eigenvectors of the
empirical covariance matrix centered in terms of the population mean bladder. Observe
that in this model it was thus considered that all the observed bladders in the training
set came from a single individual. The second model proposed was taken from Budiarto
et al. (2011), defined as follows:










C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙 𝜙𝑘 = 𝜆𝑘 𝜙𝑘, (4.11c)
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where 𝑐𝑖 was the mean bladder of the i-th patient, and vectors 𝜙𝑖 were the eigen-
vectors of empirical covariance C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙. Then, given a new patient with planned
delineated bladder 𝑧𝑙, both PCA models were adapted as follows:
Global PCA model : 𝑐 = 𝑐𝑙,0 +
𝑞∑︁
𝑘=1
𝑧𝑘 𝜓𝑘, ∧ 𝑧𝑘 ∼ 𝒩 (𝑧𝑙, 𝛼𝑘) (4.12)
Local PCA model : 𝑐 = 𝑐𝑙,0 +
𝑞∑︁
𝑘=1
𝑧𝑘 𝜙𝑘, ∧ 𝑧𝑘 ∼ 𝒩 (𝑧𝑙, 𝜆𝑘) (4.13)
Both PCA based models used the modes to transform the delineated bladder on the
planning CT and predict new bladder structures. It is worth mentioning that both sets
of modes {𝜓𝑘} and {𝜙𝑘} expressed different directions of organ motion and deformation.
For example, modes {𝜓𝑘} described motion/deformation deltas regarding the population
mean bladder whereas modes {𝜙𝑘} described local patient motion/deformation deltas.
The models’ prediction performance was evaluated by following leave-one-out cross
validation in the training database and also using the independent database. We thus
estimated probability maps with each model and compared with the observed PM in
both databases. Estimated PMs were derived for each model and patient, as follows:
firstly, 40 bladder structures were generated using the bladder observed at the planning
CT (i.e. 𝑆 = 40, see Fig. 4.4); and secondly, a distribution of 15 PMs were derived from
the 40 estimated structures, where each PM was obtained from a sub-set of estimated
bladders (without replacement) whose cardinality was equal to the number of available
CT/CBCTs. The value 𝑆 = 40 and 𝑃𝑀𝑠 = 15 were an arbitrary number aiming to
obtain a enough sampling of probable bladder contours and PMs of the patient during
treatment.
Four PMs were thus calculated for each out-sample patient: one PM estimated by
means of the proposed model, labeled 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴−𝑀𝐸 ; one PM obtained from the
patient's observed available images, labeled 𝑃𝑀𝑜𝑏𝑠; one PM estimated by means of the
global PCA model, labeled 𝑃𝑀𝐺𝑙𝑜𝑏𝑎𝑙 𝑃𝐶𝐴; and one PM estimated by using the local
PCA model, labeled 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴.
4.2.5 Metrics of similarity between PMs
Two metrics were proposed for assessing the similarity between two PMs 𝑋 and 𝑌 .
4.2.5.1 Mutual information-based metric
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Figure 4.3: Relative mode variances obtained from the PCA in the training database
(relative values: sum of all eigenvalues normalized to 100%).
where 𝐼(𝑋,𝑌 ) and 𝐻(𝑋,𝑌 )) denoted mutual information (MI) and joint entropy
between 𝑋 and 𝑌 , respectively. Similarly, 𝑥 and 𝑦 corresponded to intensity values in
the voxels of 𝑋 and 𝑌 , respectively. 𝐻(𝑋) and 𝐻(𝑦) denoted marginal entropies of
each image. MI measures the amount of information that both images share (redundant
information) based on the intensities of corresponding voxels, which is assumed to be
maximal if both images are geometrically aligned. Similarly, joint entropy measures the
uncertainty or dispersion between images. 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 also provided a distance based on
the ratio of dependence and dispersion between two PMs, attesting 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦(𝑋,𝑌 )
= 0 iff 𝑋 = 𝑌 , and 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦(𝑋,𝑌 ) ≤ 1 for all pairs (𝑋,𝑌 ) [101–103]. It offers the
advantage of not making any prior assumptions regarding the functional relationship
between images. Since we were dealing with probability images, each voxel was con-
sidered as a discrete random variable. Joint and marginal entropies were calculated by
normalizing the joint, and marginal histograms, i.e a (joint) probability distribution of
intensity values were estimated by counting the number of times each value occurred in
the images and dividing this value by the total number of voxels.
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Figure 4.4: Mean approximation errorℳ as a function of the number of modes in the
PCA model and left-out patients. There are bands (dotted-lines) that represent the
mean approximation errorℳ (solid-lines) plus and minus one standard deviation of 𝑒𝑖
(see Eq. 4.3).
4.2.5.2 Metric of misestimated voxel
We also proposed an error metric to assess whether a voxel was overestimated or under-
estimated. Denoting 𝑣 as a voxel, let 𝑋𝑏 = {𝑣/𝑋(𝑣) > 0} be the binary image obtained
by those voxels with a probability greater than 0. The proposed metric is defined as
follows:
Accuracy(𝑋,𝑌 ) =
|𝑋𝑝 ∩ 𝑌𝑝|+|𝑋𝑝 ∩ 𝑌 𝑝|
𝑑
(4.15)
where 𝑑 denoted the total number of voxels (see Eq. ??), |·| denoted the cardinality,
and 𝑋𝑝 and 𝑌 𝑝 denoted the complement of 𝑋𝑝 and 𝑌𝑝, respectively. As a result, this
metric provided the proportion of the properly estimated voxels (i.e. both true positives










































Figure 4.5: 3D sagittal views of the first three motion/deformation modes applied on
the population mean bladder (center column). The left and right columns correspond to
geometric variations along the respective mode 𝜙𝑖, defined as population mean bladder ±
2𝜎𝑖𝜙𝑖, where 𝜎2𝑖 is the mode variance. The prostate (red color) and rectum (green color)
of the template patient were also included as spatial reference.
4.3 Results
The analysis was carried out in MATLAB (R2014a). The eigenvectors 𝜙𝑘 and 𝜓𝑘 were
obtained using the function eigs while the ME model of each score 𝑧𝑖𝑗𝑘 was fit using the
function fitlme with restricted maximum likelihood estimation (REML) as estimation
method [65,104].
4.3.1 PCA representation
Fig. 4.3 shows the eigenvalue spectrum of all 20 combinations of cutting the train-
ing database from the leave-one-out cross validation. The number of columns of the
covariance matrix C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙 varied between 151 and 154 (i.e. the available images
after removing the left-out patient). The first mode contributed the largest variance
(approximately 60% of the variability); similarly, the second, third, and fourth modes
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contributed, on average, 9%, 7.8% and 5% of the variability, respectively. The first eight
modes contributed 90% of the cumulative variance, on average. Meanwhile, Fig. 4.4
shows that both mean and standard deviation of the approximation errorℳ decreased
as the number of modes was increased in both the PCA model and left-out patients.
However, mean and standard deviation of the reconstruction errorℳ did not reach the
value of zero in the left-out patients, and they exhibited a lower decreasing rate after the
first eight modes. Considering only the first 60 modes, the mean reconstruction errorℳ
was 10% and 20% in the PCA model and left-out patient, respectively. When truncating
the first 40, it still obtained an average accumulated variability of 98% and an average
reconstruction error of 15% and 23% for the PCA model and left-out patients, respec-
tively. Therefore, after performing two phases of dimensionality reduction, any bladder
was represented as a vector of 𝑞 = 40 scores (𝑞 = 40 << 𝑝 = 272 << 𝑑 = 1596375).
Fig. 4.4 also shows bands (dotted lines) around the mean approximation error ℳ,
which represent the mean plus and minus one standard deviation of 𝑒𝑖 (see Eq. 4.3). It
can be observed that the variance also decreased as the number of modes was increased
in both the PCA model and left-out patients.
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Figure 4.6: Scatterplot of the patients from the training database projected in the
first two modes (black points). Color circles and squares correspond to the vectors of
two individuals. 𝑑6,𝑗 denotes the observed motion/deformation vectors of Patient 6’s
bladder.
Fig. 4.5 presents sagittal views of the first three modes over the mean bladder
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(a) 𝑃𝑀𝑜𝑏𝑠 (b) 𝑃𝑀𝑔𝑙𝑜𝑏𝑎𝑙,𝑃𝐶𝐴
(c) 𝑃𝑀𝑙𝑜𝑐𝑎𝑙,𝑃𝐶𝐴 (d) 𝑃𝑀𝑙𝑜𝑐𝑎𝑙−𝑀𝐸,𝑃𝐶𝐴
Figure 4.7: 3D sagittal views of PMs obtained for one patient in the training database as
an out-of-sample patient. Segmented prostate (blue) and rectum (green) at the planning
CT scan are overlaid. Top left figure also depicts the segmented bladder (cyan) at the
planning CT.
of the training database. The first mode was associated with bladder volume. Simi-
larly, modes with greater indices, like the second and third, represented directions of
dilation and contraction in some regions. For example, the second mode indicated dila-
tion/contraction in the left-dorsal and right-ventral regions of the bladder whereas the
third mode indicated dilation/contraction in the inferior-ventral and dorsal regions.
Fig. 4.6 depicts the projection of the motion/deformation vectors of the training
patients on the space generated by the first two modes, where each point represents
the observed geometric variations along these two modes. This figure also presents
the observed motion/deformation vectors of Patient 6, indicating that the geometric
variation followed a random trajectory. In addition, we can observe that Patient 6
and 17 had variance that differed both between them and from the mode’s population
variance. For example, Patient 6’s bladder exhibited greater changes in volume during
treatment than that of Patient 17, as shown in the PMs of both patients, proving that
Patient 6’s specific-variance along the first mode was greater than that of Patient 17. In
addition, we also observed that Patient 17’s variance of along the second mode was very
slight due to the geometric variations of his bladder being greater in the inferior-medial
and dorsal regions.
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(a) 𝑃𝑀𝑜𝑏𝑠 (b) 𝑃𝑀𝑔𝑙𝑜𝑏𝑎𝑙,𝑃𝐶𝐴
(c) 𝑃𝑀𝑙𝑜𝑐𝑎𝑙,𝑃𝐶𝐴 (d) 𝑃𝑀𝑙𝑜𝑐𝑎𝑙−𝑀𝐸,𝑃𝐶𝐴
Figure 4.8: 3D sagittal views of PMs obtained for one patient in the validation database
as an out-of-sample patient. Segmented prostate (blue) and rectum (green) at the
planning CT scan are overlaid. Top left figure also depicts the segmented bladder
(cyan) at the planning CT.
4.3.2 Evaluation of performance prediction with groundwork models
Fig. 4.7 and 4.8 demonstrates the PMs obtained by all three models and the available
observations of two patients as out-sample patients (one for each database). In both
patients, the Global and Local PCA model overestimated more voxels than our proposed
model. Tables 4.1 and 4.2 present the averages obtained by these metrics for these
patients.
Fig. 4.9 depicts the averages of the metric 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 for patients in both databases.
On average, the global PCA model obtained the highest measures of dissimilarity in
both databases while our proposed model obtained the lowest measures. Similarly, Fig.
4.10 also shows the averages of the metric Accuracy for patients in both databases. On
average, the global PCA model also obtained the lowest accuracy in both databases
while our proposed model obtained the highest. For each patient and metric, a signifi-
cant test was made between the PCA models using the Wilcoxon rank sum test for all
15 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 and Accuracy values. The Table 4.3 shows the number of patients that
had significant difference in both databases. Besides, we also obtained four variance









































































Figure 4.10: Average Accuracy values of observed and estimated PMs for patients in
both databases.
Table 4.1: Averaged values from the metric 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 for two patients between esti-
mated and observed PMs.
𝑃𝑀𝑜𝑏𝑠 𝑃𝑀𝑜𝑏𝑠 𝑃𝑀𝑜𝑏𝑠
vs vs vs
Patient 𝑃𝑀𝐺𝑙𝑜𝑏𝑎𝑙 𝑃𝐶𝐴 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴−𝑀𝐸
Training database 0.691 0.676 0.66
Validation database 0.74 0.66 0.65
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Patient 𝑃𝑀𝐺𝑙𝑜𝑏𝑎𝑙 𝑃𝐶𝐴 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴−𝑀𝐸
Training database 0.968 0.972 0.98
Validation database 0.946 0.97 0.975
both databases. Table 4.4 presents the p-values of the significant tests that were made
between these variance distributions of the PCA models using the Wilcoxon rank sum
test.
Fig. 4.11 also presents the average joint histograms of the voxel intensities of 𝑃𝑀𝑜𝑏𝑠
vs 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴−𝑀𝐸 − 𝑃𝑀𝐺𝑙𝑜𝑏𝑎𝑙 𝑃𝐶𝐴 and 𝑃𝑀𝑜𝑏𝑠 vs 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴−𝑀𝐸 − 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴
in both database. This presents the number of times that a joint intensity value was
repeated between the observed and estimated PMs. For example, Figs. 4.11a and 4.11c
reveal that the global PCA overestimated more voxels than our proposed model in both
databases in probabilities p ranging between 0 and 0.6 instead of the observed value of
𝑝 = 0. Meanwhile, Figs. 4.11b and 4.11d demonstrate that our proposed model was
also more capable of estimating voxels observed with probability 𝑝 = 0.
Table 4.3: Number of patients exhibiting significance difference using the Wilcoxon rank
sum test in both databases.
Local PCA-ME model Local PCA model Local PCA-ME model
vs vs vs
Global PCA model Global PCA model Local PCA model
Database 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦/Accuracy 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦/Accuracy 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦/Accuracy
Training 17/18 17/14 0/0
Validation 20/27 20/26 5/3
4.3. Results 81
Table 4.4: p-values of the Wilcoxon rank sum tests for the variance distributions between
PCA models in both databases.
Local PCA-ME model Local PCA model Local PCA-ME model
vs vs vs
Global PCA model Global PCA model Local PCA model
Database 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦/Accuracy 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦/Accuracy 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦/Accuracy
Training 0.0411/0.0001 0.0720/0.003 0.6/0.32

























































































































































































Figure 4.11: Average joint histograms of observed and estimated PMs for patients in the
training and validation database. Left column shows the average joint histograms be-
tween 𝑃𝑀𝑜𝑏𝑠 vs 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴−𝑀𝐸−𝑃𝑀𝐺𝑙𝑜𝑏𝑎𝑙 𝑃𝐶𝐴 while right column shows the average
joint histograms between 𝑃𝑀𝑜𝑏𝑠 vs 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴−𝑀𝐸 − 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴.
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4.4 Discussion
We have hereby proposed a new methodology for predicting bladder motion and defor-
mation between fractions in prostate cancer radiotherapy via population analysis. We
calculated bladder motion and deformation regions based solely on the planning CT
scan. In order to predict which regions were likely to exhibit motion/deformation, we
first performed a prostate-based rigid-registration alignment, two dimensionality reduc-
tion steps, and fitting regression. The first dimensionality reduction step consisted of
surface parameterization of the bladder in the spherical harmonic space. The second
step of dimensionality reduction was to determine the directions of bladder geometric
variability by means of PCA. These directions, called modes, were validated by leave-
one-out cross validation. Following this, an ME model was fitted along each mode to the
longitudinal data defined by the projections of motion/deformation vectors observed in
the training database. We used leave-one-out cross validation on the training database
and an external database to validate the model. The proposed model was then com-
pared to two additional population PCA based models. Motion/deformation regions
were characterized by means of probability maps (PMs) and metrics were provided in
order to measure similarities between observed and estimated PMs.
When considering population-based models developed for pelvic organs, we found
that 15 modes were required to describe 90% of CTV motion and deformation for
prostate cancer [54]. For rectum cancer, 28 modes were found to be required to de-
scribe 90% of the accumulated variability in CTVs [55]. In contrast, eight modes were
sufficient in our study to describe the same percentage of accumulated variability. On
analysis of the three methods' results, we noted that there were less fundamental direc-
tions of geometric variability in the bladder compared to other pelvic organs, despite
its great volume and shape variations. Nevertheless, we were interested to note that
more directions were observed in the prostate/SV composition, potentially due to the
prostate and seminal vesicle centroids move independently [105], or due to patient-
specific variations and delineation errors. Regarding the rectum, its greater number of
directions may result from its flexible and vertical structure, enabling it to deform in
any direction along its major axis [44], in addition to patient-specific variations and
delineation errors. Future studies using other population databases would be required
to confirm or contradict the number of principal directions of motion and deformation
reported in these organs.
On the other hand, as in [54], the reconstruction error in the PCA model and left-out
patients in our study tended to decrease towards 0 as the number of modes was increased.
However, the error did not completely disappear in the left-out patients, meaning that
not all individual directions were accounted for by the PCA modes. In addition, as
observed in Fig. 4.4, the rate in the left-out patient curve decreased after the first eight
modes, implying that the order of the modes was not preserved in all patients. As a
result, both of these issues may significantly affect the performance of any population
PCA model. For example, the lowest measures of similarity were observed in Patients
6, 12, and 20 in the training database, whose bladders exhibited geometric variations
in the superior-ventral region (see Patient 6's PM in Fig. 4.6). These variations were
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not represented by at least the first four modes (81% of the accumulated variability). It
would therefore be interesting for future studies to first make a classification of bladders
with similar shapes [56], then design the proposed model locally for each subgroup. For
example, [106] introduced a methodology for developing hierarchical PCA models where
each observation is plotted in the latent space to determine the number of sub-PCA
models in the inferior levels.
It is also crucial to emphasize that we applied a quadratic relative error in the
SPHARM space to assess the modes in our study, unlike [54], who used a quadratic
error normalized by the number of points. Nevertheless, we considered it possible to
compare the behavior of both errors. For example, [54] required 37 modes to reduce
the initial error by 62% in the left-out patients, whereas 60 modes were needed in
our study to reduce it by 80%. Both results may indicate there was significant intra-
patient variability that was not sufficiently detected by the first modes obtained from the
population. This also means that intra-patient variability may be higher in the bladder,
potentially due to anatomical differences among patients and delineation errors. In this
way, a trade-off was made between accumulated variability and the reconstruction error
for determining the number of modes (40) in our PCA model, where an additional 20
modes only reduced the reconstruction error by 3%.
As established in the model assumptions, each mode corresponded to a direction of
geometric variability that dilated or contracted certain regions of the bladder. Unlike
the first mode, not all the rest were found to define an affine transformation that
may be initially applied in the setup, such as rotation along an axis or a uniform
dilation/contraction. In addition, we showed that the bladder motion and deformation
between fractions follows random trajectory, as the data projections showed in the latent
space (see Fig. 4.6). It was also possible, in this space, to characterize the geometric
variations of each patient, where some directions were clearly found to be more dominant
than others.
Although several studies have previously addressed the estimation of motion/ de-
formation regions of the pelvic organs by means of the coverage matrix concept [25,38,
41, 107], this is the first, to our knowledge, to introduce a quantitative and qualitative
comparison between estimated and observed regions using metrics of similarity and joint
histograms. As observed in Figs. 4.9, 4.10, and 4.11, our proposed model obtained the
lowest measures of dissimilarity and misestimated voxels. Previous population PCA
models have thus overestimated or underestimated more voxels, primarily those not
occupied by the bladder. As a result, our proposed model reduced uncertainties in
estimations of the probable region of motion and deformation. This was achievable
as the ME models enable us to reduce the observed population variance along each
mode by grouping repeated observations per patient. For example, we obtained more
patients presenting significant differences between the Global PCA model and our pro-
posed model in both databases than the Local PCA model; moreover, we significantly
reduced uncertainties in estimations of motion/deformation region regarding the Global
PCA model (see Table 4). We therefore concluded that the Global, Local, and Local
PCA-ME models provided a progressive decrease in uncertainties for estimating likely
motion/deformation regions, while our proposed model led to the lowest reduction in all
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the patients (see Fig. 4.9 and 4.10). When more CTs/CBCTs scans become available
for a patient during treatment, this information could be used to improve estimation
of the motion/deformation region by personalizing modes, variance, and mean bladder
shape. It is worth mentioning that one limitation to use PCA models for modeling
organ motion and deformation is their strong dependence on the organ’s mean shape,
as planning CT scans may not provide a good estimation. Future studies should be
focused on analyzing the methodology’s robustness for handling outlier patients whose
variance along a mode is almost similar to the population variance. This kind of patient
may lead to a misestimation of the intra-patient variability 𝜎2 affecting the performance
of the ME model (see Patient 6 in the training database in Fig. 4.6). A robust formu-
lation of PCA, the so-called robust PCA, could help overcome the problems associated
with outlier patients.
PCA-based shape models are typically efficient for organs whose shape variations
can be captured by a reasonable number of modes [108]. For instance, two studies have
shown that 15 and 16 modes were required to describe most of the inter- and intra-
patient motion and deformation of CTVs in prostate and rectum cancer, respectively [54,
55]. However, in population databases concerning highly-varying soft-tissue volumes, a
large number of modes may be required to properly capture the complex shape variations
observed in the training database. In our study, for instance, we required 40 modes to
generate an inter-patient PCA model for the bladder. We believe that the large number
of modes may render interpretation of higher modes difficult, as they may not describe
directions of geometric variability observed in the population rather than patient-specific
directions. In addition, the large number of modes may also hinder inference and
analysis of the results for each ME model. However, as in [100], the modes define an
orthogonal basis that enables us to consider each score 𝑧𝑖𝑗𝑘 as an independent random
variable across 𝑘 that can be easily modeled as a response variable [109,110].
We have previously mentioned that the scores can be interpreted as measures of
geometric variability along the modes. Future studies should therefore focus on deter-
mining covariates that may help to describe patient-specific bladder deformation. The
results displayed in Fig. 4.6 and published by [56] appear to indicate that there are
some covariates that may underlie the motion/deformation region in the latent space or
mode’s variance for any arbitrary patient. For example, bladder size or volume could be
considered as fixed parameters that may determine changes in volume and directions of
geometric variations. [56] and [111] reported, in line with Fig. 4.6, that bladders with
large volumes exhibited geometric variations in the superior-ventral region and higher
variance along the first mode. In an adaptive radiotherapy scheme, a time covariate
can also be added, as a random or fixed variable, to describe the daily volume changes
of the bladder.
As previously stated, Hu et al. [66] proposed a population-PCA model to describe
prostate deformation in MR-tumor-targeted biopsies. Concerning this methodology,
we found two shared characteristics: firstly, that the scores were also considered as
parameters that describe intra-subject organ motion; secondly, the added objective of
characterizing subject-specific probability density functions (SSPDFs) of motion and
deformation (parameterized by means of multivariate Gaussian distributions). How-
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ever, [66] proposed a fixed-effects model to describe SSPDF of the scores across the
population, while such a model consists of a multivariate non-linear regression involv-
ing the scores of the reference shapes defined as covariates. [66] also decided to model
the SSPDF parameters instead of the subject-specific scores, as proposed in our study.
Nevertheless, we believe that it could be interesting for future studies to add the scores
of the bladder segmented at the planning CT as fixed variables, as this may help to
correlate the subject-specific variance and directions of geometric variability. For future
works, we wish to underline that both studies have suggested the possibility of includ-
ing other parameters in the learning framework, such as organ size or any temporal
information.
For future developments, it is worth noting that our main goal has been to predict
late GU toxicity based only on planning treatment information, and we thus only used
the planning CT scan to predict bladder motion/deformation regions. Nonetheless, we
have also performed some simulations using two and three observations of the out-of-
sample patient, with the aim of simulating an adaptive radiotherapy treatment, and
the results achieved better estimation of the region. We think that the number of ob-
servations for the out-of-sample patient helps to decrease the variance of the estimate
for the shrinkage predictor. Thus, the more observations we have for the out-of-sample
patient, the more certain we can be about how the patient differs from the popula-
tion mean. In these simulations, it is also worth mentioning that we only used these
observations to improve the estimation of the patient’s average bladder and shrinkage
estimator of each mode, i.e. to improve the model adaptation yet not retrain the model’s
parameters (modes 𝜙𝑘, and inter- intra-patient variances). We considered that more
observations should be available to fit the model’s parameters again, as five CTs/CBCTs
has been established as the minimum number of observations required for intra-patient
models [57].
In this study, we described regions of motion/deformation in terms of 3D probability
maps (PM) that were obtained by sampling the model’s distribution or using patient
images. We have thus considered motion/deformation regions as histograms that can
be compared using the proposed metrics. We believe that the next step should be fo-
cused on estimating the uncertainty of the motion/deformation region using the model’s
joint distribution. However, we considered that the large number of modes may hinder
inference of the associated joint distribution, as the number of combinations of scores
at the boundaries of the confidence intervals will significantly grow when we add modes
to the joint distribution. Nonetheless, we consider that the uncertainty region can also
be estimated using only those modes that have a strong influence on variables, like the
accumulated delivered dose, i.e., that the uncertainty region can be restricted to those
modes that have a strong influence on the mean accumulated dose. Finally, it may also
be interesting to add linear modes that describe geometric variations between the mean
bladders of the patients as the modes obtained from the covariance matrix C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙
only described directions observed on the intra-patient level. These models are known
as multi-level PCA models [112,113].
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4.5 Conclusion
We proposed a population based model to predict bladder motion and deformation
between fractions using solely the planning CT. In comparison with previous studies,
our proposed model was able to decrease uncertainty in the estimation of the region
where the bladder will likely move and deform. We also demonstrated that, by following
a longitudinal study with ME models, it was possible to separate the patient-specific
variance from population variance and thus reduce the total variance. The potential
applications of this model include margin evaluation, delivered dose estimation, toxicity
prediction, and the design of robust treatment plans, among others. Future studies
should now be conducted to validate the proposed model by means of a large cohort of
patients who have undergone prostate cancer radiotherapy. It could also be valuable to
focus on the relationship between inter-fraction bladder motion/deformation, delivered
dose, and late GU toxicity in the prostate cancer radiotherapy context.
Chapter 5
Population PCA-based models
using a longitudinal approach:
characterization of patient-specific
modes from the population modes
This chapter proposes hierarchical PCA to properly characterize patient-specific modes
from the population modes. This study included two population databases of patients
previously described in Chapter 4. As in previous population-PCA models, we use the
data to obtain the dominant eigenmodes that describe bladder geometric variations.
However, PCA-based models have the limitation of not being suitable to properly cap-
ture the latent structure of longitudinal data of organs with highly varying soft-tissue.
We propose hierarchical modes to separate intra- and inter-patient bladder variability.
This model was derived by following a hierarchical visualization algorithm that was
initially proposed in Ref. 106. This algorithm seeks to design a single flexible model by
hierarchically nesting latent variable models, which reveals the internal structure of a
complex data set. The population database of 20 patients was initially used to derive
a top-level PCA model that describe the entire structure of the bladder space. This
space was subsequently divided into subspaces by lower-level PCA models describing
the internal structure of clusters. The model was evaluated using a reconstruction error
and compared with a conventional PCA model following leave-one-out cross validation.
Probability maps (PMs) were also generated, which were compared with the observed
region using a metric based on mutual information.
A similar methodology was also proposed by Foruzan et al. [60] to model shape
variations in a population database of livers. However, two differences were observed:
firstly, that the tree-like structure of the hierarchy was not defined by using a visu-
alization algorithm; and secondly, that the population database of livers used in the
study was not longitudinal. The methodology proposed in this chapter was submitted
in the 12th International Symposium on Medical Information Processing and Analysis
(SIPAIM) in Tandil, Argentina.
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The chapter is organized as follows. Section 5.1 describes the database used in
this study. Section 5.2 subsequently presents a detailed description of the proposed
hierarchical method together with the validation framework. Section 5.3 then presents
the results and validation with the conventional PCA model. Lastly, section 5.4 dis-
cusses the experimental findings, with a conclusion in section 5.5 in addition to final
considerations and future work.
5.1 Data
We included the training and validation databases previously described in Chapters 2.
Population-based models were thus trained using the training database. Meanwhile,
the prediction performance of the model was evaluated by following leave-one-out cross
validation in the training database and also using the validation database.
5.2 Methods
Fig. 5.1 describes the steps followed to train the hierarchical population-based PCA
model. The first and second step were also to spatially normalize all the bladders in
the same spatial referential and to parameterize the bladder surface using SPHARM
coefficients, respectively. The third step was then to perform a dimensionality reduction
using hierarchical eigenmodes, followed by mixed effects models. Finally, the last step
was the validation framework, where we also developed a conventional population-based
PCA model to test the performance of our proposed model.
5.2.1 Hierarchical Principal Component Analysis
This step was sought to determine a hierarchical structure of modes that properly char-
acterized the patient-specific modes from the population. We performed a hierarchical
visualization algorithm proposed by Bishop and Tipping (1998) in order to design a
population-based PCA model (see Fig. 5.1).
5.2.1.1 Top-level PCA model
This step aimed to determine the most important modes that describe all the bladder
shapes and sizes observed in the training database, i.e. it was aimed to characterize the
bladder space as in Chapter 3. A data matrix S𝑠𝑛𝑎𝑝𝑠ℎ𝑜𝑡 was then obtained by stacking as
a column each vector shape represented in spherical harmonics. Denoting the observed
bladder shape of the i-th patient at the j-th CT parametrized as 𝑐𝑖𝑗 , the data matrix
S𝑠𝑛𝑎𝑝𝑠ℎ𝑜𝑡 was defined as follows:
S𝑠𝑛𝑎𝑝𝑠ℎ𝑜𝑡 =
[︀
𝑐10 𝑐11 · · · 𝑐1𝑗1 𝑐21 · · · 𝑐𝑛1 · · · 𝑐𝑛𝑗𝑛
]︀
= UΣV𝑇 (5.1)
where 𝑗𝑖 was the number of observations available for the i-th patient, Σ was the
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Figure 5.1: Workflow of the method used to train the hierarchical population-based
model. 1) prostate-based registration, 2) parameterization of bladder surface using
SPHARM coefficients, 3) hierarchical principal component analysis (PCA) followed by
mixed effects models, 4) leave-one-out cross validation.
90 Characterization of patient-specific modes from the population modes
respectively. The column vectors of matrix U defined the directions of variability of
the bladders called modes. Singular values of matrix Σ defined a significance ranking
for the data variability represented by each mode, attesting 𝑣𝑎𝑟(𝜙1) = 𝜎21 ≥ 𝑣𝑎𝑟(𝜙2) =
𝜎22 ≥ · · · ≥ 𝑣𝑎𝑟(𝜙𝑟) = 𝜎2𝑟 , where 𝑟 was the rank of the data matrix S𝑠𝑛𝑎𝑝𝑠ℎ𝑜𝑡 and 𝜙𝑖 was
the i-th left singular vector of matrix U.
5.2.1.2 Projection and clustering of bladder into latent space
This step sought to represent each shape vector 𝑐𝑖𝑗 as an linear combination of the first
three modes of the top-level model, as is described as follows:
𝑐𝑖𝑗 ≈ 𝑐𝑖𝑗 = 𝑤𝑖𝑗1 𝜙1 + 𝑤𝑖𝑗2 𝜙2 + 𝑤𝑖𝑗3 𝜙3 (5.2)
where 𝑤𝑖𝑗, 𝑘 = 𝑐𝑇𝑖𝑗 𝜙𝑘 for 𝑘 = 1, 2, 3. The first three modes 𝜙𝑘 defined a new coordi-
nate system, henceforth called top-latent space, where each bladder 𝑐𝑖𝑗 was represented
by the three new coordinates (𝑤𝑖𝑗1, 𝑤𝑖𝑗2, 𝑤𝑖𝑗3). We then sought to display the entire
structure of the longitudinal database revealing the presence of clusters of bladders with
similar shapes on the top-latent space using K-means algorithm. As in Chapter 3, we
used well-defined regions of bladders with similar shapes to define the number 𝒯 of
clusters. As a result, mean bladder shape of well-defined regions were used as initial
values for the K-means algorithm [114].
Let 𝑤 = (𝑤1, 𝑤2, 𝑤3) be the measure of geometric variation of an organ along a
mode in the top-latent space. Considering the patient as the unit of observation state
(subject), we used an index 𝑖, ranging from 1 to 𝑛, to differentiate among patients,
and an index 𝑗 to differentiate between observation times in a patient. The encoded
longitudinal data was thus defined as follows:
{𝑤11, . . . , 𝑤1𝑗1}, {𝑤21, . . . , 𝑤2𝑗2}, · · · , {𝑤𝑛1, . . . , 𝑤𝑛𝑗𝑛} (5.3)
Our goal was then to partition the data in 𝒯 clusters. So, we firstly introduced a set
of 3-dimensional vector 𝑚𝑡, where 𝑡 = 1, . . . , 𝒯 , in which 𝑚𝑡 was the mean associated
with the 𝑡−𝑡ℎ cluster (i.e. 𝑚𝑡 represented the cluster center). Let 𝜋𝑡𝑖𝑗 ∈ {0, 1} be also a
binary indicator that described which of the 𝒯 clusters the data point 𝑤𝑖𝑗 was assigned
to, i.e. if the data point 𝑤𝑖𝑗 was assigned to cluster 𝑡, then 𝜋𝑡𝑖𝑗 = 1 and 𝜋𝑖𝑗𝑏 = 0 for










This function was minimized following an iterative procedure, which is described
as follows: firstly a set of initial values for 𝑚𝑡 were proposed. Function 𝐽 was then
minimized with respect to 𝜋𝑡𝑖𝑗 , keeping 𝑚𝑡 fixed. Subsequently, function 𝐽 was mini-
mized with respect to 𝑚𝑡, keeping 𝜋𝑡𝑖𝑗 fixed [114]. This two-step optimization, known
as expectation-maximization (EM) algorithm, was then repeated until convergence.
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Now consider first the optimization 𝐽 with respect to 𝜋𝑡𝑖𝑗 , keeping 𝑚𝑡 fixed. The
objective function 𝐽 was a linear function of 𝜋𝑡𝑖𝑗 , where the terms of the function 𝐽
involving different 𝑖𝑗 were independent. As a result, each term 𝜋𝑡𝑖𝑗‖𝑤𝑖𝑗 − 𝑚𝑡‖2 was
optimized separately by choosing 𝜋𝑡𝑖𝑗 to be 1 for whichever value of 𝑡 that gave the
minimum value of ‖𝑤𝑖𝑗−𝑚𝑡‖2. In other words, we assigned the 𝑖𝑗-th data to the closest
cluster center. This can thus be expressed as follows:
𝜋𝑡𝑖𝑗 =
{︃





The equality between both arguments arg in Eq. 5.5 can be found in Appendix B.
Consider then the optimization 𝐽 with respect to 𝑚𝑡, keeping 𝜋𝑡𝑖𝑗 fixed. The objective
function 𝐽 was then a quadratic function of 𝑚𝑡, and it can be minimized by setting its






namely that 𝑚𝑡 was equal to the mean of the data points 𝑤𝑖𝑗 assigned to cluster 𝑡.
5.2.1.3 Second-level PCA
We subsequently selected the corresponding shape vectors 𝑐𝑡𝑖𝑗 = 𝑤𝑖𝑗1 𝜙1 + 𝑤𝑖𝑗2 𝜙2 +
𝑤𝑖𝑗3 𝜙3 such that 𝑤𝑖𝑗 = (𝑤𝑖𝑗1, 𝑤𝑖𝑗2, 𝑤𝑖𝑗3) ∈ Ω𝑡 with 𝑡 = 1, . . . , 𝒯 . For each cluster Ω𝑡, a


























where 𝑐𝑡𝑖 was the average bladder shape of the i-th Patient at the t-th cluster. 𝑛𝑡
and 𝑗𝑡𝑖 were the number of patients and patient’s observation in the t-th cluster, re-
spectively. The vector 𝑑𝑡𝑖𝑗 = 𝑐𝑡𝑖𝑗 − 𝑐𝑡𝑖 described the difference between the observed
bladder 𝑐𝑘𝑖𝑗 and patient mean bladder shape. Similarly, U𝑡 was a matrix composed of
eigenvectors 𝜓𝑡𝑘 of C𝑡, andD𝑡 was the diagonal matrix constructed from its correspond-
ing eigenvalues 𝜆𝑡𝑘, i.e, C𝑡𝜓𝑡𝑘 = 𝜆𝑡𝑘𝜓𝑡𝑘. Eigenvectors 𝜓𝑡𝑘 thus defined the directions
of geometric variability observed in the cluster Ω𝑡. The eigenvalues of matrix D also
defined a significance ranking for the data variability represented by each mode, at-
testing 𝑣𝑎𝑟(𝜓𝑡1) = 𝜆𝑡1 ≥ 𝑣𝑎𝑟(𝜓𝑡2) = 𝜆𝑡2 ≥ · · · ≥ 𝑣𝑎𝑟(𝜓𝑡𝑛𝑡) = 𝜆𝑡𝑟𝑡 , and showing that
data variability was dominated by the first 𝑞𝑡 modes with 𝑞𝑡 << 𝑟𝑡 = 𝑛𝑡 (𝑟𝑡 was the
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rank of the matrix C𝑡). As a result, each bladder shape of Ω𝑡 was expressed as a linear
combination of the first 𝑞𝑡 modes, as follows:
𝑐𝑡𝑖𝑗 = 𝑐𝑡𝑖 + 𝑧𝑡𝑖𝑗1 𝜓𝑡1 + · · ·+ 𝑧𝑡𝑖𝑗𝑞𝑡 𝜓𝑡𝑞𝑡 (5.8)
where 𝑧𝑡𝑖𝑗𝑘 = 𝑑𝑇𝑡𝑖𝑗 𝜓𝑡𝑘. According to theory of PCA, each coefficient 𝑧𝑡𝑖𝑗𝑘 obeyed a
Gaussian distribution with mean of zero and the corresponding eigenvalue as variance.





, 𝑞𝑡 = 1, . . . , 𝑟𝑡 (5.9)
The corresponding population-based hierarchical PCA model is thus described as
follows:
Hierarchical Local PCA model := 𝑐𝑖𝑗 =
𝒯∑︁
𝑡=1
𝜋𝑡𝛩𝑡, 𝜋𝑡 ∈ {0, 1} (5.10)
𝛩𝑡 = 𝑐𝑡𝑖 + 𝑧𝑡𝑖𝑗 1 𝜓𝑡1 + · · ·+ 𝑧𝑡𝑖𝑗 𝑞𝑡 𝜓𝑡𝑞𝑡
𝜋𝑡 =
{︃




In addition, we proposed an additional hierarchical model that used two second-level
PCA models, if the bladder 𝑐𝑖𝑗 was almost at the same distance to two cluster centers.
The corresponding population-based hierarchical PCA model is described as follows:


















where 𝛿 > 0 is threshold for ratio between two distance. As a result, the bladder
𝑐𝑖𝑗 can be assigned to the two nearest clusters. Observe that both hierarchical PCA
models shared the same top-level and second-level PCA models.
We evaluated the capability of the hierarchical PCA model to represent a typical
bladder using only a few dominating modes. So, we performed leave-one out cross
validation on the training database using a reconstruction error metric 𝑒. This means
that one patient and his images were used as validation set, and the remaining patients
were used to train the model. The error assessing the difference between the original
and reconstructed motion-deformation error was defined as follows:
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𝑒𝑖 =
‖ 𝑑𝑖 − 𝑑𝑖 ‖
‖ 𝑑𝑖 ‖
(5.12)
where 𝑑𝑖 and 𝑑𝑖 were the i-th bladder motion-deformation vector and its approx-
imation, respectively. If the reconstruction of 𝑐𝑖 was exact, then 𝑒𝑖 was equal to 0;
otherwise, the value of 𝑒𝑖 was between 0 and 1. The mean of the reconstruction error
𝑒𝑖 in all the motion-deformation vectors was also calculated, i.e.,ℳ = (1/𝑁) ·
∑︀𝑁
𝑖=1 𝑒𝑖,
where 𝑒𝑖 denoted the approximation error of an i-th motion-deformation vector 𝑑 and
𝑁 the number of the available images, either in the hierarchical PCA model or left-out
patients.
We also defined error metrics in order to measure the quality of the K-means classifier
in the left-out patients, as follows:















where 𝑔 denoted the classifier, 𝑐𝑖 was an observed bladder in the left-out patients, 𝑦𝑖
was respective class, and 𝑁 the number of images in the training database. In addition,
an conventional population PCA-based model was also used to compare the reconstruc-
tion performance of our proposed model. Such PCA model taken from Budiarto et al.
(2011) is described as follows:































𝑖𝑗 𝜑𝑘 = 𝜆𝑘 𝜑𝑘
where 𝑛 was the number of patients, 𝑗𝑖 was the number of observations available for
the i-th patient, and 𝑐𝑖 the average shape of the i-th patient.
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5.2.2 Linear mixed-effects models
As in fourth chapter, the longitudinal data was encoded in the second-level modes by
projecting the observed motion-deformation vectors of the training database over each
mode. A linear mixed-effects model was then fit to each mode aiming to characterize
patient-specific variance from population.
Denoting the measure of motion/deformation of an organ along the k-th mode of
the i-th Patient at the j-th observation and in the t-th cluster as 𝑧𝑡𝑖𝑗𝑘. The encoded
longitudinal data was thus defined as follows:
{𝑧𝑡11𝑘, . . . , 𝑧𝑡1𝑗1𝑘}, {𝑧𝑡21𝑘, . . . , 𝑧𝑡2𝑗2𝑘}, · · · , {𝑧𝑡𝑛1𝑘, . . . , 𝑧𝑡𝑛𝑗𝑛𝑘}, 𝑘 = 1, . . . , 𝑞𝑡 (5.15)
with the linear mixed-effects model proposed for each mode described as follows:
𝑧𝑡𝑖𝑗𝑘 = 𝜇𝑡𝑘 + 𝑏𝑡𝑖𝑘 + 𝜀𝑡𝑖𝑗 𝑘, 𝑖 = 1, . . . , 𝑛, 𝑗 = 1, . . . , 𝑗𝑖, (5.16)
𝑏𝑡𝑖𝑘 ∼ 𝒩 (0, 𝜎2𝑡𝑏𝑘), 𝜖𝑡𝑖𝑗𝑘 ∼ 𝒩 (0, 𝜎2𝑡𝑘),
where 𝜇𝑡𝑘 was the mean projection along the k-th mode for the whole population in
the t-th cluster. 𝑏𝑡𝑖𝑘 was also a random variable representing the deviation of the i-th
patient mean from the population mean, and 𝜀𝑡𝑖𝑗𝑘 was a random variable representing
the deviation for j-th projection of the i-th patient from the i-th patient mean in the t-th
cluster. In addition, variances 𝜎2𝑡𝑏𝑘 and 𝜎
2
𝑡𝑘 denote inter and intra-patient variability,
respectively. The second-level PCA models with mixed-effects were thus described as
follows:















𝑧𝑡1 · · · 𝑧𝑡𝑞
]︀
where 𝑐𝑡𝑖 was the patient mean shape, 𝑧𝑡𝑘 ∼ 𝒩 (𝜇𝑡𝑘, 𝜎2𝑡𝑏𝑘 + 𝜎2𝑡𝑘), for 𝑘 = 1, . . . , 𝑞𝑡.
5.2.3 Out-of-sample problem
We also sought to predict a likely motion-deformation region of the bladder for a new
patient 𝑃𝑙 using only his planning CT information. As shown in Fig. 5.2, the first step
was also to spatially normalize the out-of-sample patient 𝑃𝑙 to match the template pa-
tient; secondly, the SPHARM representation of his delineated bladder 𝑐𝑙,0 was obtained
and classified in the top-latent space; and thirdly, second-level Local-PCA models were
adapted to the new patient by estimating his patient-specific mean and variance ?̂?𝑡𝑙𝑘
and ?̂?𝑡𝑙𝑗𝑘.
Consider the adaptation of each second-level PCA models to the new patient 𝑃𝑙.
















Figure 5.2: Workflow to estimate new structures based on the planning CT for a new
patient for the hierarchical-based PCA model.
𝑧𝑡𝑙𝑗𝑘 = 𝜇𝑡𝑘 + 𝑏𝑡𝑙𝑘 + 𝜖𝑡𝑙𝑗𝑘 ∼ 𝒩 (?̂?𝑡𝑙𝑘, ?̂?2𝑡𝑙𝑘), 𝑗 = 1, . . . , 𝑗𝑡𝑙, 𝑘 = 1, . . . , 𝑞𝑡 (5.18)
A shrinkage estimator of ?̂?𝑡𝑙𝑘 = 𝜇𝑡𝑘 + 𝑏𝑡𝑙𝑘 was then given by:







, 𝑘 = 1, . . . , 𝑞𝑡 (5.19)
where 𝜇𝑡𝑙𝑘 was the mean of the l-th patient at the k-th mode, and 𝑗𝑡𝑙 was the number
of patient's observations. Term 𝜁𝑡𝑘 was known as the credibility factor. Similarly, the


























+ 𝜎2𝑡𝑘 + 𝜎
2
𝑡𝑏𝑘 (5.20)
In our study, 𝑐𝑡𝑙 = 𝑐𝑡𝑙,0, 𝜇𝑙 = 𝑊 𝑇𝑡 (𝑐𝑡𝑙 − 𝑐𝑡𝑙,0) = 𝑧𝑡𝑙 = 0 and 𝑗𝑡𝑙 = 1 due to we only
had the information obtained from the planning CT. In this way, probable structures
of the bladder during treatment were thus inferred after sampling 𝑆 times the Normal
distributed vector 𝑧𝑡. Subsequently, each sample of 𝑧𝑡 was mapped to a vector 𝑐 in the
spherical harmonic space using matrix 𝑊𝑡. Then, binary images representing probable
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bladder configurations were obtained from the parameterized surfaces that were coded in
vectors 𝑐. Following this, an estimation of the motion/deformation region was calculated
by the ratio between the number of times that a voxel was occupied by the bladder and
the 𝑆 generated samples.
5.2.4 Evaluation of prediction performance
The models’ prediction performance was also evaluated by following leave-one-out cross
validation in the training database and also using the independent database. We thus
estimated probability maps with each model and compared with the observed PM in
both databases. Seven PMs were thus calculated for each out-sample patient: one
PM obtained from the patient's observed available images, labeled 𝑃𝑀𝑜𝑏𝑠; one PM es-
timated by using the local PCA model, labeled 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴; one PM estimated by
means of the local PCA model with mixed-effects, labeled 𝑃𝑀𝐿𝑜𝑐𝑎𝑙 𝑃𝐶𝐴−𝑀𝐸 ; one PM
estimated by means of the Hierarchical-Local PCA model, labeled 𝑃𝑀𝐻𝑅𝑃𝐶𝐴; one PM
estimated by means of the Hierarchical-Local PCA model with mixed-effects models,
labeled 𝑃𝑀𝐻𝑅𝑃𝐶𝐴−𝑀𝐸 ; one PM estimated by means of the Hierarchical Mixed-Local
PCA model, labeled 𝑃𝑀𝐻𝑅−𝑀𝐿𝑃𝐶𝐴; and one PM estimated by means of the Hierarchi-
cal Mixed-Local PCA model with mixed-effects models, labeled 𝑃𝑀𝐻𝑅−𝑀𝐿𝑃𝐶𝐴−𝑀𝐸 .
Estimated PMs were derived for each model and patient, as follows: firstly, 40
bladder structures were generated using the bladder observed at the planning CT (i.e.
𝑆 = 40, see Fig. 5.2); and secondly, a distribution of 15 PMs were derived from the
40 estimated structures, where each PM was obtained from a sub-set of estimated
bladders (without replacement) whose cardinality was equal to the number of available
CT/CBCTs. We also used the mutual information-based metric to assess the similarity
between two PMs 𝑋 and 𝑌 (see Eq. 4.14).
5.3 Results
5.3.1 Hierarchical PCA representation
The number of columns of the data matrix S𝑠𝑛𝑎𝑝𝑠ℎ𝑜𝑡 varied from 151 to 154. The first,
second and third mode contributed, on average, 52.91%, 4.75%, and 3.34% of the vari-
ability, respectively. Fig. 5.6 presents sagittal views of the first three modes of the top-
level PCA model over the population mean bladder. The first mode was also associated
with bladder volume, i.e it describes the direction of maximum volume variability ob-
served in the database. Meanwhile, the second and third mode describe directions that
dilate and shrink regions in the bladder. For example, the second mode indicated dila-
tion/contraction in the upper-ventral and medial-dorsal regions of the bladder whereas
the third mode indicated dilation/contraction in the inferior and medial-ventral regions.
Fig. 5.4a depicts the projection of all the bladder instances in the space spanned by
the first two and three modes. In this reduced space, it can be observed several well-
defined regions or clusters of bladder shapes. For example, oval-like bladders are found

































Figure 5.3: 3D sagittal views of the first three top-level modes applied on the population
mean bladder (center column). The left and right columns correspond to geometric
variations along the respective mode 𝜙𝑖, defined as population mean bladder ± 2𝜎𝑖𝜙𝑖,
where 𝜎2𝑖 is the mode variance. The prostate (red color) and rectum (green color) of
the template patient were also included as spatial reference).
be also observed that each patient had a motion/deformation region (see Patient 6 and
7). As the first mode had the largest variance contribution, we used this mode to define
the number of clusters and the groups of patients to initialize the cluster centers for the
K-means algorithm. We then proposed two and three clusters in the top-latent space
defining two hierarchical models, as follows: a first clustering made by those patients
with 𝑐𝑇𝑖𝑗 𝜙𝑘 < −100 and 𝑐𝑇𝑖𝑗 𝜙𝑘 ≥ −100; and a second clustering made by those patients
with 𝑐𝑇𝑖𝑗 𝜙𝑘 < −120, −120 ≤ 𝑐𝑇𝑖𝑗 𝜙𝑘 < −80, and 𝑐𝑇𝑖𝑗 𝜙𝑘 ≥ −80. Figs. 5.4b and 5.4c
show the K-means clustering results in the top-latent space. Figs. 5.4d and 5.4e also
depict the accumulated variability of the eigenvalues for these second-level Local PCA
models. Fixing a threshold of 0.95%, we obtained a conventional Local PCA model
with 16 modes, on average. Similarly, we obtained 8 and 17 modes for the hierarchical
PCA model with Local PCA model in the second-level, and 7, 13 and 15 modes for the
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(c) Top latent-space partitioned in two clusters






































(d) 𝑃𝑞𝑡 for two PCA models in the second-level





































(e) 𝑃𝑞𝑡 for three PCA models in the second-level
Figure 5.4: a) Scatterplot of the patients projected in the space spanned by the first
two and three modes (Black points). b)-c) Color circles and squares correspond to the
vectors of two individuals. b) Top-latent space partitioned in two and three clusters
using k-means algorithm. Cluster centers are marked using larger + symbol. d)-e)
Accumulated mode variance 𝑃𝑞𝑡 using PCA in each cluster of the second-level.
hierarchical PCA model with three Local PCA model in the second-level.




































Figure 5.5: 3D sagittal views of the first three motion/deformation modes for the first
cluster applied on the mean bladder (center column), when the top-latent space is
divided into two clusters. The left and right columns correspond to geometric variations
along the respective mode 𝜓1𝑖, defined as cluster mean bladder ± 2𝜎1𝑖𝜓1𝑖 is the mode
variance. The prostate (red color) and rectum (green color) of the template patient
were also included as spatial reference.
mean bladder of each cluster for the hierarchical model with two Local PCA models in
the second-level. As in previous results, the first mode also describes the direction of
maximum volume variability. Meanwhile, the second and third mode also describe di-
rections that dilate and shrink regions in the bladder. For example, the second and third
mode in the first cluster indicated dilation/contraction in the medial-ventral and lateral
regions of the bladder whereas in the second cluster indicated dilation/contraction in
the medial-anterior and lateral regions. Fig. 5.7 presents the mean approximation error
ℳ in both the training and left-out patients for the three PCA models. Table 5.1 also
presents the error metrics of the classifier for both hierarchical models. The precision
metric was 0.025 and 0.0313 for the hierarchical model with two and three second-level
clusters, respectively.



































Figure 5.6: 3D sagittal views of the first three motion/deformation modes for the first
cluster applied on the mean bladder (center column), when the top-latent space is
divided into two clusters. The left and right columns correspond to geometric variations
along the respective mode 𝜓2𝑖, defined as cluster mean bladder ± 2𝜎2𝑖𝜓2𝑖 is the mode
variance. The prostate (red color) and rectum (green color) of the template patient





































































Figure 5.7: Mean approximation errorℳ of the Hierarchical PCA models compared to
the conventional Local PCA model in the training and left-out patients
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Table 5.1: Error metrics of the classifier for both hierarchical models
Cluster
Hierarchical model Hierarchical model
Two clusters Three clusters
Sensitivity(g) Specificity(g) Sensitivity(g) Specificity(g)
Cluster 1 0.95 0.99 0.94 1
Cluster 2 0.99 0.95 0.95 1



















































(c) Local models vs Hierarchical models
Figure 5.8: Average 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 values of observed and estimated PMs for patients in
the training database using Hierarchical PCA models.
5.3.2 Evaluation of performance prediction with groundwork models
Defining a threshold 𝛿 = 0.95, Fig. 5.8 and Fig. 5.9 depict the averages of the metric
𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 for patients in both databases. On average, the Local PCA model obtained
the highest measures of dissimilarity in both databases while the hierarchical model
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obtained the lowest measures. Similarly, Figs. 5.10 and 5.11 also show the averages
of the metric Accuracy for patients in both databases. On average, the Local PCA
model also obtained the lowest accuracy in both databases while the hierarchical models
obtained the highest. In both metrics, we obtained that the HR-ML PCA-ME models
with two and three clusters obtained the best performances. For each patient and
metric, a significant test was also made between the HR-ML PCA-ME and Local PCA
models using the Wilcoxon rank sum test for all 15 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 and Accuracy values.
Table 5.2 shows the number of patients that had significant difference in both databases.
We also obtained three variance distributions by deriving the variance of the 15 values
for each metric and patient in both databases. Table 5.3 presents the p-values of the
significant tests that were made between these variance distributions of the Local PCA





















































(c) Local models vs Hierarchical models
Figure 5.9: Average 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 values of observed and estimated PMs for patients in





























































(c) Local models vs Hierarchical models
Figure 5.10: Average 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 values of observed and estimated PMs for patients in
the training database using Hierarchical PCA models.
5.4 Discussion
We have hereby proposed a new methodology for predicting uncertainties produced by
inter-fraction shape variations of the bladder in prostate cancer radiotherapy via pop-
ulation analysis. We firstly used a visualization algorithm to obtain hierarchical modes
that enables us to reveal the latent structure of a longitudinal database of bladders.
The idea was then to properly characterize the patient-specific modes from the popula-
tion. We secondly fit a ME model along each mode to the longitudinal data defined by
the projections of the motion/deformation vectors observed in the training database.
In addition, bladder shapes and motion/deformation regions were characterized in the
top-latent space while bladders with similar shape were then characterized in the lower-
level subspaces. We proposed reconstruction error metrics to assess the capability of the
modes to represent a typical bladder following leave-one-cross validation. Bladder mo-
tion and deformation regions were also computed using solely the planning CT scan, and


















































(c) Local models vs Hierarchical models
Figure 5.11: Average Accuracy values of observed and estimated PMs for patients in
the validation databases using Hierarchical PCA models.
we used leave-one-cross validation on the training database and an external database
to validate the model. We used a conventional population PCA model in order to com-
pare the performance of the hierarchical models. Motion/deformation regions were also
characterized by means of PMs and metrics were used to measure similarities between
observed and estimated PMs.
From the algorithm proposed by Bishop et al [106], we have obtained a set of fun-
damental modes that were hierarchical nested to separate intra- and inter-patient di-
rections of geometric variability observed in the database. As in Fig. 3.3 and 4.5, the
first modes also described the directions of maximum volume variability that were ob-
served in each level and cluster. Meanwhile, further modes also described directions of
geometric variability that dilated or shrunk certain regions of the bladders. From Figs.
4.5, 5.5 and 5.6, it can be observed that the number of geometrical directions described
by the first modes in the hierarchical models has been increased compared to the Local
PCA model. We therefore conclude that hierarchically nesting PCA models enable us
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Table 5.2: Number of patients exhibiting significance difference using the Wilcoxon rank
sum test in both databases between the Local PCA and HR-ML PCA-ME models.
Local PCA model Local PCA model
vs vs




Table 5.3: p-values of the Wilcoxon rank sum tests for the variance distributions between
PCA models in both databases the Local PCA and HR-ML PCA-ME models.
Local PCA model Local PCA model
vs vs
2C-HR-ML PCA-ME 3C-HR-ML PCA-ME
Database 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦/Accuracy 𝑑𝑖𝑠𝑡𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦/Accuracy
Training 0.19/0.13 0.0239/6 · 10−4
Validation 0.99/0.017 0.75/5 · 10−4
to increase the degree of freedom of the overall motion-deformation model. However,
we consider that hierarchical PCA models introduce a higher number of parameters,
increasing the model complexity. For instance, the hierarchical models required more
modes than the conventional model to describe the same threshold of accumulated
variability.
As in Chapter 2, we characterized bladder shapes and patients’ motion/deformation
regions in the top-latent space. Although a voxel-based representation was used in
Chapter 2, we obtained that the distribution of the patients and bladders with similar
shapes was preserved in both latent spaces. We thereby conclude that the character-
ization of the bladder space remains invariant from orthogonal basis (modes). We in
turn conclude that SPHARM reduces the number of variables required to represent the
bladder surface while preserving shape information. From Fig. 5.4a, we also consider
that the motion/deformation region of a patient in the latent space is mainly described
by the bladder volume. We have thus proposed to use the first mode to define groups
of patients that were used as initial centers for the clusters.
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From Fig. 5.7, we obtained that the mean reconstruction error of the Local PCA
model was higher than the hierarchical models in the training database. Meanwhile,
the hierarchical model with two clusters only outperformed the reconstruction error
in the validation database. As opposed in Rios et al in [115], we consider that this
outcome was produced as some patients with a single observation in a cluster could not
be considered to derive the empirical covariance matrix to train the Local PCA models
in the second-level (see Eq. 5.2). As a result, this resulted in a loss of information that
reflected in a lower description for bladders not included in the training set compared to
the conventional model. As a future work, for those patients with a single observation,
it could be used a prior patient-specific covariance matrix. For instance, an estimation
of the patient’s mean bladder shape can be obtained either using observations from
all the patients or only those patients that are closer. It is worth mentioning that
in hierarchical models with Global PCA models hierarchically nested as derived in
Rios et al in [115], all the bladder observations of a cluster were used to derive the
covariance matrix. Concerning the clustering method, we have used a conventional
algorithm like K-means as our main gaol in this study was to prove that the hierarchical
methodology outperformed conventional PCA models to predict motion/deformation
regions. However, we also used used Gaussian mixture models, and we obtained similar
results of classification. Future studies could then focus on testing different clustering
methods (e.g Fuzzy C-means) in the top-level latent space in order to study the effect of
the clustering algorithm in the reconstruction error. Concerning this issue, we consider
that the reconstruction error may also be reduced by adding a constraint that avoids
that observations of the patients were divided into two clusters, i.e, by achieving a
longitudinal classification of the patients.
As it was previously established, PCA-based shape models achieve a good perfor-
mance for organs whose shape variations can be captured by a reasonable number of
modes [108]. From Fig. 5.9 to 5.11, we consider that conventional PCA models are
not be suitable to properly capture the latent structure of longitudinal databases with
highly varying soft-tissue as they require a large number of modes. For instance, in our
study we required 8 modes to describe 90% of the cumulative variance while 40 modes to
generate an population PCA model. As consequence, we conclude that the first 8 modes
of the conventional model did not accomplish to properly describe the main modes for
all the patients. Instead the proposed hierarchical methodology has enabled us to bet-
ter describe the patient-specific modes by increasing the number of geometric directions
observed in the first modes compared to conventional model. As observed in 5.9 to 5.11,
the best predictions were achieved by those models designed with hierarchical modes
and mixed-effects models, accomplishing to reduce the uncertainties in the estimation
of the probable motion/deformation region. For example, comparing the performance
of the hierarchical models with mixed-effects and Local PCA model, we obtained more
patients with significance differences in both metrics and databases; moreover, we ac-
complished to significantly reduce the variance of the estimated motion/deformation
region regarding the Local PCA model in the training and validation databases (see
Table 5.3). Finally, we consider that this methodology enables us to increase the de-
grees of freedom outperforming the characterization of organ shape variations in a wide
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range of applications including segmentation [60, 108], modeling of organ motion and
deformation [53–55, 57], margin evaluation [51, 55], delivered dose estimation [50], and
the design of robust treatment plans [43,50,52,116], among others.
5.5 Conclusion
We proposed hierarchical population-based PCA model to characterize and predict
shape variations of the bladder between fractions in prostate cancer radiotherapy. This
hierarchical structure enables us to increase the degree of freedom of the model and
to better reveal the latent structure of the longitudinal database than the conventional
PCA model. In comparison with previous studies, our proposed hierarchical model with
mixed-effects accomplished to significantly reduce the uncertainties in the estimation
of the region where the bladder will likely moves and deforms. We also demonstrated
that using hierarchically nesting modes, it was possible to separate the patient-specific
directions of geometric variability from the population reducing uncertainties in the
estimation of the motion/deformation region. The potential applications of this model
include organ segmentation, margin evaluation, delivered dose estimation, toxicity pre-
diction, and the design of robust treatment plans, among others. Future studies should
be focused to study the relationship among bladder motion and deformation, delivered
dose and urinary symptoms in prostate cancer radiotherapy.
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Quantification of dose uncertainties
for the bladder in prostate cancer
radiotherapy based on PCA-based
models
The radiotherapy goal is to deliver a dose distribution that enables a high dose to the
tumor and preserves at most neighboring healthy organs. This dose distribution is
usually obtained based on the organ delineations made in the planning CT. However,
organs move and deform between treatment fractions leading to geometries that are not
exactly to those delineated in the planning CT. As a result, non-trivial deviations may
arise between the planning and delivered dose to the tumor and OARs, reducing the
treatment quality. For example, such deviations may lead to highly irradiated OARs and
increase the patient’s probability of developing side-effects. Although new technologies
such as IGRT have enabled us to determine the actual position and shape of organs,
the acquisition of patient-specific data during treatment is time-intensive, costly and
thereby not always feasible in clinical practice. Methods that enable us to simulate
or monitor the actual delivered dose are therefore vital to assess or replan treatments
during treatment course.
PCA has been used as virtual tool to evaluate dosimetric uncertainties produced by
organ motion and deformation [50, 116]. In this context, PCA was used to calculate
mean and variance of the accumulated dose via Monte Carlo simulations or integration
over the probability distribution. However, some questions have not been addressed
yet: firstly, how many modes are required for dosimetric treatment course simulations?;
secondly, how many modes are required for an adequate estimation of patient-specific
dosimetric uncertainties?. As accumulated dose only varies at the points that move in
or out of the beams [111], it is expected that a limited number of modes would have a
significant effect on dosimetric uncertainties produced by organ motion and deformation
between fractions.
This chapter presents PCA models as a tool to estimate dosimetric uncertainties
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for the bladder produced by inter-fraction motion and deformation. We used three pa-
tients treated for prostate cancer radiotherapy that underwent a planning CT as well
as 35-39 on-treatment CBCTs for each. For each patient, we trained an individual PCA
models using the bladder samples available from the on-treatment CT/CBCTs. Our
objective was to determine the number of modes required for an adequate estimation of
the patient-specific dosimetric variability. We then obtained three accumulated doses:
one reference accumulated dose that was calculated via deformable image registration
(DIR); one accumulated dose that was computed by sampling the multivariate Gaussian
distribution of the PCA model followed by a Monte Carlo approach; and a accumulated
dose computed by integrating the planning dose over the Gaussian probability distri-
bution of the PCA model. We finally compared the three accumulated doses using
iterative procedure to determine our objective.
The chapter is organized as follows. Section 6.1 describes the database used in this
study. Section 6.2 presents the methodology used to quantify dose uncertainties via
Monte Carlo simulation and integration over the probability distribution. Section 6.3
subsequently presents the results and comparison to groundwork methods. Lastly, sec-
tion 6.4 discusses the experimental findings, with a conclusion in section 6.5 in addition
to final considerations and future work.
6.1 Data
We used the three patients having a planning CT and on-treatment CBCTs of the
validation database described in Chapter 2. The resolution of the CT scans were 512×
512× 80, with a voxel size of 1𝑚𝑚× 1 𝑚𝑚× 3 𝑚𝑚.
6.2 Methods
Fig. 6.1 describes the methodology performed to quantify dose uncertainties of the blad-
der using PCA models. Firstly, we derived an individual PCA model for each patient
in the database using the observations obtained from the on-treatment CT/CBCTS;
secondly, we calculated a reference accumulated dose using the patient’s on-treatment
CBCTs via DIR; thirdly, we estimated an accumulated dose by integrating the plan-
ning dose over the Gaussian probability distribution of the PCA model; fourthly, we
estimated an accumulated dose by simulating treatment courses via a Monte Carlo ap-
proach. Finally, we compared the planning dose with the three accumulated doses,
and we calculated average voxel doses, local dose variability and dose-volume histogram
uncertainties.
6.2.1 Principal component analysis
This step was aimed to derive an individual PCA model for each patient from the on-
treatment CT/CBCTS, following the same work of Shön et al. [57]. For each patient, an



























Figure 6.1: Workflow of the method used to quantify dose uncertainties of the bladder.
1) principal component analysis (PCA) reduction, 2) reference accumulated dose via
deformable image registration (DIR), 3) accumulated dose via dose integration, 4) ac-
cumulated dose via Monte Carlo simulation (MC), 5) comparison of the planning dose
and the three accumulated doses.
to calculate the directions of maximum variability by using matrix diagonalization.
Here, a motion-deformation vector defined the difference between the observed bladder
and patient mean bladder. Thus, denoting the observed bladder at the j-th CT as 𝑐𝑗 ,
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where 𝑑𝑗 = 𝑐𝑗 − 𝑐, 𝑁 was the number of observations available for the patient, and
𝑐 the average shape of the patient. Similarly, U was a matrix composed of eigenvectors
𝜙𝑘 of C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙, and D was the diagonal matrix constructed from its corresponding
eigenvalues 𝜆𝑘, i.e, C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙𝜙𝑘 = 𝜆𝑘𝜙𝑘. Eigenvectors 𝜙𝑘 defined the directions of
geometric variability of the bladder, called modes. As a result, each bladder in the
spherical harmonic space was expressed as a linear combination of the modes, as follows:
𝑐𝑗 = 𝑐+ 𝑧𝑗 1 𝜙1 + · · ·+ 𝑧𝑗 𝑟 𝜙𝑟 (6.2)
where 𝑟 was the rank of covariance matrix C𝑒𝑚𝑝𝑖𝑟𝑖𝑐𝑎𝑙, and equal to the number of
available images for the patient. Each coefficient 𝑧𝑗𝑘 = 𝑑𝑇𝑗 𝜙𝑘 denoted a geometric
variation of the bladder 𝑐𝑗 along the mode 𝜙𝑘. Modes {𝜙𝑘}𝑘 defined a new coordinate
system, where each vector 𝑑𝑖𝑗 was represented by new 𝑟 coordinates 𝑧𝑗 1, . . . , 𝑧𝑗 𝑟. The
eigenvalues of matrix D defined a significance ranking for the data variability represented
by each mode, attesting 𝑣𝑎𝑟(𝜙1) = 𝜆1 ≥ 𝑣𝑎𝑟(𝜙2) = 𝜆2 ≥ · · · ≥ 𝑣𝑎𝑟(𝜙𝑟) = 𝜆𝑟, and
showing that data variability was dominated by the first 𝑞 modes with 𝑞 << 𝑟. The





, 𝑞 = 1, . . . , 𝑟 (6.3)
According to theory of PCA, each coefficient 𝑧𝑘 obeyed a Gaussian distribution
with mean of zero and the corresponding eigenvalue 𝜆𝑘 as variance. The corresponding
patient-specific PCA model is thus described as follows:
Patient-specific PCA model := 𝑐 = 𝑐+ 𝑧𝑗 1 𝜙1 + · · ·+ 𝑧𝑗 𝑞 𝜙𝑞 (6.4a)











where 𝑓𝑧 was a multivariate Gaussian probability density function. Bladder contours
with their probability of occurrence can be generated byâ sampling vector z. â
As in Chapter 4, we also described regions of motion/deformation in terms of 3D
probability maps (PM) that express the probability of a voxel being occupied by the
bladder during treatment. Estimated PMs were derived for each patient by generating
𝑆 bladder structures from Eq. 6.4. Two PMs were thus calculated for each patient: one
PM estimated by means of the Patient-specific PCA model, labeled 𝑃𝑀𝑖𝑛𝑑𝑃𝐶𝐴; and
one PM obtained from the patient's available images, labeled 𝑃𝑀𝑜𝑏𝑠.
6.2.2 Estimation of the reference accumulated dose distribution
As in [117,118], we computed for each patient an accumulated dose distribution, called
the reference accumulated dose 𝑑𝑐𝑢𝑚,𝑟𝑒𝑓 , using four steps: firstly, the dose at fraction
was computed; secondly, a geometrical transformation 𝑈 was computed between the
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planning CT scan and each CBCT scan using DIR; thirdly, the fraction dose was de-
formed using the deformation field 𝑈 ; and fourthly, the deformed doses were summed to
obtain the accumulated dose 𝑑𝑐𝑢𝑚,𝑟𝑒𝑓 . The fractional dose distribution 𝐷𝑠 was assessed
for each CBCT by translating the planned dose distribution 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑 according to the
transformation 𝑇 resulting from the alignment of the prostate barycenters, since we
assumed invariant dose distributions between the planning and fractions. Meanwhile,
the DIR was not applied to the original grayscale images but to images resulting from
the manual delineations of the bladder on the CT and CBCT images. For this pur-
pose, for both the CT and CBCT images, distance maps were computed, representing
for each voxel the signed squared Euclidean distance from the organ surface. Distance
maps obtained from CT and CBCT delineations were then registered with a variant of
Demons algorithm providing the estimated deformation field 𝑈 , further details can be
found in [117, 118]. The fraction dose 𝐷𝑠 was finally deformed using the deformation
field 𝑈 and resampled in the planning CT with a trilinear interpolation. As a result,










where 𝐷𝑠 ≈ 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑/𝑁𝑓𝑟𝑎𝑐, 𝑥𝑠,𝑜𝑏𝑠 was the delineated bladder observed at the s-
th CBCT scan (i.e. at the s-th dose fraction), and 𝑁𝑓𝑟𝑎𝑐 was the number of treatment
fractions. For each patient, the 𝐷𝑐𝑢𝑚,𝑟𝑒𝑓 was calculated from the available on-treatment
CBCTs. As a result, 𝑁𝑓𝑟𝑎𝑐 was equal to the number of patient’s CBCTs. We denoted
𝐷𝑉𝐻𝑐𝑢𝑚,𝑟𝑒𝑓 as the DVH obtained from the reference accumulated dose, and 𝐷𝑉𝐻𝑜𝑏𝑠,𝑠
as the DVH of the dose fraction 𝐷𝑠 applied to the observed bladder structure 𝑥𝑠,𝑜𝑏𝑠.
6.2.3 Mean and variance accumulated dose via integration
According to Eqs. 6.4, the delivered dose is as well a random variable as the bladder
randomly moves and deforms following a Gaussian probability distribution. As in [116],
the density function of the dose 𝐷 can then be estimated by integrating the planning
dose over the motion and deformation probability density function 𝑓𝑧 (see Eq. 6.4b).
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𝐷2(𝑥(𝑧))𝑓𝑧(𝑧)𝑑𝑧 − 𝜇2𝑐𝑢𝑚,𝑖𝑛𝑡 (6.7b)
where 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡 and 𝜎𝑐𝑢𝑚,𝑖𝑛𝑡 denoted the mean and variance of the accumulated
dose, respectively. Defining 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑘 and 𝜎𝑐𝑢𝑚,𝑖𝑛𝑡,𝑘 as the mean and variance of the
accumulated dose restricted to the first 𝑘 modes, respectively, we proposed the following
iterative procedure to determine the number of modes required to quantify patient-
specific dose uncertainties:
Step 1 To calculate 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1 and 𝜎𝑐𝑢𝑚,𝑖𝑛𝑡,1
Step 2 To calculate 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,2 and 𝜎𝑐𝑢𝑚,𝑖𝑛𝑡,2
Step 3 To calculate 𝑑𝑖𝑠𝑡𝑖𝑛𝑡,2(𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,2, 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1) =
‖𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,2−𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1‖
‖𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,2‖
Step 4 To repeat step 2 and 3 for 𝑘 = 3, . . . , 𝑞, if 𝑑𝑖𝑠𝑡𝑖𝑛𝑡,𝑘 > 𝜀
where 𝜀 defined a tolerance value. For each value of 𝑘, the integrals of Eqs. 6.6 and
6.7 were solved numerically using the composite Simpson’s Rule to calculate 𝜇𝑐𝑢𝑚,𝑀𝐶,𝑘
and 𝜎𝑐𝑢𝑚,𝑀𝐶,𝑘. Fig. 6.2 illustrates a Pareto curve that shows the quantification of
dose uncertainties as a function of the number of modes in the PCA model. It is
worth mentioning that computational complexity of the numerical solution increases as
function of the number of modes. Appendix C provides numerical details for solving
these multi-dimensional integrals. We denoted the DVH of the mean accumulated dose
distribution 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑘 as 𝐷𝑉𝐻𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑘 . In addition, we denoted 𝐷𝑉𝐻𝑖𝑛𝑡,𝑘,𝑠 as the
DVH of the s-th dose fraction applied to the s-th estimated bladder structure 𝑥𝑖𝑛𝑡,𝑘,𝑠 in
the numerical solution of 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑘.
6.2.4 Mean and variance accumulated dose via Monte Carlo simula-
tion
As in [50], single treatment courses can be simulated by drawing random vectors from
the probability function 𝑓𝑧 (Eqs. 6.4), and their corresponding accumulated dose ob-
tained using DIR. As a result, we also propose to use a Monte Carlo approach to estimate
the first two moments of the dose density probability function. Monte Carlo approach
is described as follows.
Let 𝑥𝑠 = {𝑣𝑖1,𝑖2,𝑖3}𝑖1,𝑖2,𝑖3 ∈ R𝑑1×𝑑2×𝑑3 and
𝐷𝑠(𝑥𝑠) = (𝐷𝑠(𝑣1,1,1), 𝐷𝑠(𝑣1,1,2), . . . , 𝐷𝑠(𝑣𝑑1,𝑑2,𝑑3)) ∈ R𝑑1×𝑑2×𝑑3 (6.8)
be the bladder obtained by shape regularization from the parameterized bladder 𝑐𝑠,










Figure 6.2: Pareto curve used to determine the number of modes required to properly
estimate the patient-specific dose uncertainties.
then represented the dose at the voxel 𝑣𝑖1,𝑖2,𝑖3 of the bladder structure 𝑥𝑠. Similarly,
𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑(𝑥𝑝𝑙𝑎𝑛𝑛𝑒𝑑) denoted the dose associated to the bladder contour 𝑥𝑝𝑙𝑎𝑛𝑛𝑒𝑑 at the
treatment planning CT.
Generating 𝑁𝑓𝑟𝑎𝑐 random bladder structures {𝑥𝑠,𝑒𝑠𝑡}
𝑁𝑓𝑟𝑎𝑐
𝑠=1 from Eq. 6.4, a treatment











where 𝐷𝑠 ≈ 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑/𝑁𝑓𝑟𝑎𝑐 was the dose fraction applied to the estimated bladder
structure 𝑥𝑠,𝑒𝑠𝑡. Considering 𝑑𝑐𝑢𝑚,𝑀𝐶 as a random variable, a Monte Carlo approach was
performed for each patient in order to obtain realizations of single-treatment courses,
as follows: firstly, we drew 𝑆 random vectors of the PCA scores in Matlab from Eq.
6.4b; secondly, we mapped these vectors to SPHARM coordinates using the orthogonal
transformation obtained from Eq. 6.4a; thirdly, a set of 𝑆 binary images represent-
ing probable bladder contours were obtained from the parameterized surfaces that were
coded in SPHARM vectors (this set was denoted as ∆ = {𝑥𝑠,𝑒𝑠𝑡}𝑆𝑠=1); finally, a distribu-
tion of 𝒩 accumulated doses {𝑑𝑐𝑢𝑚,𝑀𝐶,𝑚}𝒩𝑚=1 were derived using Eq. 6.9 by simulating
treatment courses with 𝑁𝑓𝑟𝑎𝑐 bladder structures taken (without replacement) from the
∆ set. Each accumulated dose 𝑑𝑐𝑢𝑚,𝑀𝐶,𝑚 was calculated by applying the DIR process
to 𝑥𝑝𝑙𝑎𝑛𝑛𝑒𝑑 and 𝑥𝑠,𝑒𝑠𝑡 contours. Distance maps were also computed, and they were then
registered with a variant of Demons algorithm providing the estimated deformation
fields.
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From the distribution of accumulated doses {𝑑𝑐𝑢𝑚,𝑀𝐶,𝑚}𝒩𝑚=1, we obtained the mean












(𝑑𝑐𝑢𝑚,𝑀𝐶,𝑚 − 𝜇𝑐𝑢𝑚,𝑀𝐶)2 (6.10b)
We also computed the DVH of the expected mean accumulated dose distribution
𝜇𝑐𝑢𝑚,𝑀𝐶 , denoted as 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶 ; as well as, the DVH of each simulated accumulated
dose 𝑑𝑐𝑢𝑚,𝑀𝐶,𝑚, denoted as 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶,𝑚. We also denoted 𝐷𝑉𝐻𝑀𝐶,𝑠 as the DVH
of the dose fraction 𝐷𝑠 applied to the estimated bladder structure 𝑥𝑠,𝑒𝑠𝑡.
6.2.4.1 Dose confidence region for single fractions
From the probability density function 𝑓𝑧 in Eq. 6.4b, it was possible to obtain contours
of bladder structures with equal probability mass. Contours are useful as they provide
confidence regions that are analogous to the confidence intervals for the univariate
distribution [119]. Contours were defined for those vectors 𝑧 such that:
(𝑧 − 𝜇)𝑇D−1(𝑧 − 𝜇) = 𝜃2 = 𝜒2𝑞(𝛼) (6.11)
where 𝜇 was the mean of 𝑧, D = diag(𝜆1, . . . , 𝜆𝑞) was the diagonal matrix made
from eigenvalues of the covariance matrix, and 𝜃 was derived from the Chi-Squared
distribution 𝜒2𝑞 with 𝑞 degrees of freedom. The value of 𝛼 provided the confidence
region (CR) containing 1−𝛼 of the probability mass of the probability density function
𝑓𝑧. These contours defined hyper-ellipsoids in the latent space spanned by the first k
modes, whose axes were in the direction of the eigenvectors 𝜙𝑘 while the lengths of the
axes were proportional to the square root of the eigenvalues 𝜃
√
𝜆𝑘, as it is described as
follows:
(𝑧 − 𝜇)𝑇D−1(𝑧 − 𝜇) = 𝜃2 = 𝜒2𝑞(𝛼) (6.12)
(𝛽1𝑒1 + · · ·+ 𝛽𝑞𝑒𝑞)𝑇 diag(𝜆−11 , . . . , 𝜆
−1
𝑞 )(𝛽1𝑒1 + · · ·+ 𝛽𝑞𝑒𝑞) = 𝜃2 = 𝜒2𝑞(𝛼)
𝛽21
𝜆1
+ · · ·+
𝛽2𝑞
𝜆𝑞
= 𝜃2 = 𝜒2𝑞(𝛼)
where 𝑧 − 𝜇 =
∑︀𝑞
𝑘=1 𝛽𝑘𝑒𝑘, and the vectors 𝑒𝑘 were the canonical basis of the latent
space. The coefficients 𝛽𝑘 thus represented the coordinates of 𝑧−𝜇 in the latent space.
Bladders structures with 95% of probability to fall can thereby be parameterized




















Figure 6.3: Visualization of the dose confidence region for single fractions in the space
spanned by first two modes.
































Figure 6.4: Relative mode variances obtained for the three patients (relative values:
sum of all eigenvalues normalized to 100%).
confidence region then provided the uncertainty region of the fraction doses with 95% of
probability to be delivered on accounting for geometric variations of the bladder during
treatment. We hereby denoted 𝐷𝐵𝑜𝑢𝑛𝑑𝑎𝑟𝑦,𝑞 = 𝐷(𝑥(𝑧𝐵𝑜𝑢𝑛𝑑𝑎𝑟𝑦,𝑞)) as the dose vector
associated to the bladder structure obtained by the vector 𝑧𝐵𝑜𝑢𝑛𝑑𝑎𝑟𝑦,𝑞 =
∑︀𝑞
𝑘=1 𝛽𝑘𝑒𝑘 and
coefficients 𝛽1, . . . , 𝛽𝑞 holding Eq. 6.11. We also denoted 𝐷𝑉𝐻𝐵𝑜𝑢𝑛𝑑𝑎𝑟𝑦,𝑞,𝑠 as the DVH
of the boundary dose 𝐷𝐵𝑜𝑢𝑛𝑑𝑎𝑟𝑦,𝑞,𝑠.
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Planning and some weekly 
prostates
Mean bladder 
Figure 6.5: Intra-patient analysis for patients with on-treatment CBCTs. Left column
depicts 3D sagittal views of the segmented prostate (white) at the planning CT with
two observations (color contours) during treatment. Right columns shows 3D sagittal
views of geometric variations (blue and cyan) along the first mode applied on the mean
bladder (white), where 𝜎21 is the mode variance. The prostate (red) and rectum (green)
of the patient were also included as spatial reference.
6.3 Results
Fig. 6.4 provides the eigenvalue spectrum for all the three patients. For Patient 1
and 2 having 𝑁𝑓𝑟𝑎𝑐 = 36 and 𝑁𝑓𝑟𝑎𝑐 = 35, the first mode contributed 0.56% of the
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Table 6.1: Mean and standard deviation of the Dice Scores (DS) obtained following
DIR for each bladder and estimated bladder structure.
Patient
Obs. bladders Est. bladders Est.bladders Est. bladders
in the CBCTs for MC simulation for dose integration for CR
Patient 1 0.97± 0.0064 0.96± 0.0031 0.96± 0.0011 0.96± 0.0037
Patient 2 0.97± 0.0001 0.97± 0.0016 0.97± 0.0030 0.97± 0.0021
Patient 3 0.98± 0.0001 0.98± 0.0011 0.97± 0.0052 0.98± 0.0022
variability while the first eight and 11 modes described 95% of the cumulative variance,
respectively. Meanwhile, for Patient 3 having 𝑁𝑓𝑟𝑎𝑐 = 39, the first mode contributed
0.71% of the variability while the first seven modes described 95% of the cumulative
variance. Fig. 6.5 provides 3D sagittal views of the first mode for each patient, where
Patient 1 is denoted as P6, Patient 2 as P18 and Patient 3 as P28. As is observed from
Fig. 6.5, the first mode describes the direction of maximum volume variability observed
in the patient images.
For each patient, we calculated the reference accumulated dose together with its
respective 𝐷𝑉𝐻𝑐𝑢𝑚, 𝑟𝑒𝑓 . Figs. 6.7a to 6.9a show the reference accumulated DVHs.
Table 6.1 provides the mean and standard deviation of the Dice Scores (DS) obtained
following DIR for each delineated bladder in the CBCTs. Similarly, we generated 𝑆 = 80
bladder structures based on the above PCA models with 𝑃𝑞 = 95%. According to Eq.
6.4, the coefficients 𝑧𝑞 were sampled from the multivariate Gaussian distribution aiming
to estimate probable bladder geometries during treatment. Fig. 6.6 shows the observed
and estimated PMs that were obtained for each patient. Table 6.1 also provides the
mean and standard deviation of the Dice Scores (DS) obtained following DIR for each
estimated bladder structure. We then simulated 𝒩 = 100 treatment courses using Eq.
6.8, where 𝑁𝑓𝑟𝑎𝑐 estimated bladder structures were taken without replacement from the
bladder set ∆. Fig. 6.7a, 6.8a and 6.9a show the accumulated DVHs of 100 simulated
treatment courses together with the average of these DVHs (𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶).
Fig. 6.10 provides 3D sagittal views of the variance dose 𝜎𝑐𝑢𝑚,𝑀𝐶 for each patient.
Fig. 6.7b, 6.8b and 6.9b also show the DVH uncertainties resulting from MC simulation.
These figures depict the variability of the dose fractions delivered to each delineated
bladder on the patient’s CBCTs as well as to each estimated bladder from the MC
simulation (i.e. the set of bladder ∆). Dose fractions were rescaled to the total dose for
easier visual comparison.
We also sought to determine the number of modes that are required to quantify
patient-specific dose uncertainties. For each patient we calculated the mean and variance
dose via integration of the planned dose over the Gaussian distribution of the first mode,
the first two modes and the first three modes (see numerical details in Appendix C). We
then used 10 subintervals along the 𝑧1-axis to calculate 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1 while 8 subintervals
along the 𝑧1-, 𝑧2- and 𝑧3-axes to calculate 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,2 and 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,3. As a result, a mesh of
11, 81 and 729 bladder geometries were generated to calculate 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1, 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,2 and
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(a) PM𝑜𝑏𝑠 for Patient 1 (b) PM𝑖𝑛𝑑−𝑃𝐶𝐴 for Patient 1
(c) PM𝑜𝑏𝑠 for Patient 2 (d) PM𝑖𝑛𝑑−𝑃𝐶𝐴 for Patient 2
(e) PM𝑜𝑏𝑠 for Patient 3 (f) PM𝑖𝑛𝑑−𝑃𝐶𝐴 for Patient 3
Figure 6.6: 3D sagittal views of PMs obtained for each patient. Segmented prostate
(blue), bladder (purple) and rectum (green) at the planning CT scan are overlaid.
Patient’s mean bladder (cyan) is also depicted.
𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,3, respectively. Table 6.2, 6.3 and 6.4 provide the values of the metric 𝑑𝑖𝑠𝑡𝑖𝑛𝑡,𝑘
for each integral for all the three patients. Besides, Fig. 6.7c, 6.8c and 6.9c provide
the single-fraction DVHs of each bladder geometry generated from the mesh used to
calculate 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,3. These figures also depict DVHs for some bladder structures from
the CR (ellipsoid) generated with the first three modes. This ellipsoid corresponded to
the contour of 95% of probability to fall defined by 𝜒23(0.05) = 7.92.
Fig. 6.11a shows the DVH differences between the reference and accumulated doses
obtained via DIR and MC simulation. Meanwhile, Fig. 6.11b show the DVH differences
between the accumulated 𝐷𝑉𝐻𝑐𝑢𝑚,𝑖𝑛𝑡.3 obtained with dose integration over the first
three modes and the mean accumulated 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶 obtained via MC simulation.
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(a) 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶,𝑚 and 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶
































(b) DVH uncertainties resulting from MC simulation


































(c) DVH uncertainties resulting from dose integration
Figure 6.7: Visualization of DVH uncertainties for Patient 1. (a) Mean (green) and
accumulated DVHs (red) resulting from Monte Carlo (MC) simulation are depicted.
Planned DVH (blue) and DVH (cyan) obtained from the patient’s mean bladder shape
are also illustrated. (b) DVH uncertainties resulting from observed and estimated blad-
der structures (rescaled to the total dose) in the MC simulation. (c) DVH uncertainties
resulting from observed and estimated bladder structures (rescaled to the total dose) in
the dose integration and confidence region (CR).
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(a) 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶,𝑚 and 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶
































(b) DVH uncertainties resulting from MC simulation


































(c) DVH uncertainties resulting from dose integration
Figure 6.8: Visualization of DVH uncertainties for Patient 2. (a) Mean (green) and
accumulated DVHs (red) resulting from Monte Carlo (MC) simulation are depicted.
Planned DVH (blue) and DVH (cyan) obtained from the patient’s mean bladder shape
are also illustrated. (b) DVH uncertainties resulting from observed and estimated blad-
der structures (rescaled to the total dose) in the MC simulation. (c) DVH uncertainties
resulting from observed and estimated bladder structures (rescaled to the total dose) in
the dose integration and confidence region (CR).
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(a) 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶,𝑚 and 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶
































(b) DVH uncertainties resulting from MC simulation


































(c) DVH uncertainties resulting from dose integration
Figure 6.9: Visualization of DVH uncertainties for Patient 3. (a) Mean (green) and
accumulated DVHs (red) resulting from Monte Carlo (MC) simulation are depicted.
Planned DVH (blue) and DVH (cyan) obtained from the patient’s mean bladder shape
are also illustrated. (b) DVH uncertainties resulting from observed and estimated blad-
der structures (rescaled to the total dose) in the MC simulation. (c) DVH uncertainties
resulting from observed and estimated bladder structures (rescaled to the total dose) in
the dose integration and confidence region (CR).
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(a) 𝜎𝑐𝑢𝑚,𝑀𝐶 for Patient 1 (b) 𝜎𝑐𝑢𝑚,𝑀𝐶 for Patient 2
(c) 𝜎𝑐𝑢𝑚,𝑀𝐶 for Patient 3
Figure 6.10: 3D sagittal views of 𝜎𝑐𝑢𝑚,𝑀𝐶 for each patient. Segmented prostate (cyan),
bladder (purple) and rectum (red) at the planning CT scan are overlaid.
6.4 Discussion
We have quantified dosimetric uncertainties produced by geometric variations of the
bladder between fractions using PCA models. For each patient in the study we trained
an individual PCA model using the available bladder samples from the on-treatment
CT/CBCTs. We also calculated three accumulated doses: a reference accumulated
dose obtained from the available CT/CBCTs via DIR; an accumulated dose derived via
Monte Carlo simulation of treatment courses; and an accumulated dose computed via
dose integration. We sought to determine the number of modes required to properly
estimate patient-specific dose uncertainties using an iterative procedure. We subse-
quently compared the three accumulated doses, and we calculated average voxel doses,
local dose variability and dose-volume histogram uncertainties.
Concerning to patient-specific models, we obtained that at least 𝑞 ∼ 8 − 11 modes
were required to describe most of the geometric variability observed in the on-treatment
CBCTs. Although, Shön et al (2005) studied a composite of prostate/bladder/ rectum
for individual patients, results from eigenvalue spectrum showed that the same range
of mode number was required to describe the same level of accumulated variability for
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Table 6.2: Relative errors from the metric 𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒 for the mean and variance accumu-
lated dose via integration for Patient 1.
Modes
𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒 𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒 𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒
(𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞, 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞−1) (𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞, 𝜇𝑐𝑢𝑚,𝑀𝐶) (𝜎𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞, 𝜎𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞−1)
1 – 3% –
1 and 2 2.5% 1.8% 72%
1,2 and 3 0.8% 1.6% 17%
Table 6.3: Relative errors from the metric 𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒 for the mean and variance accumu-
lated dose via integration for Patient 2.
Modes
𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒 𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒 𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒
(𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞, 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞−1) (𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞, 𝜇𝑐𝑢𝑚,𝑀𝐶) (𝜎𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞, 𝜎𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞−1)
1 – 2.5% –
1 and 2 1.4% 1.5% 45%
1,2 and 3 0.45% 1.4% 8.4%
Table 6.4: Relative errors from the metric 𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒 for the mean and variance accumu-
lated dose via integration for Patient 3.
Modes
𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒 𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒 𝑑𝑖𝑠𝑡𝑑𝑜𝑠𝑒
(𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞, 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞−1) (𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞, 𝜇𝑐𝑢𝑚,𝑀𝐶) (𝜎𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞, 𝜎𝑐𝑢𝑚,𝑖𝑛𝑡,𝑞−1)
1 – 3.2% –
1 and 2 2% 2% 20%
1,2 and 3 1% 1.7% 9%
the studied patients. As a result, we consider that at least an input sample of 𝑁 = 12
on treatment CT/CBCTs would be necessary to obtain a patient-specific PCA model.
From Fig. 6.6, it can be observed that PCA may be sensible to outlier observations. For
Patient 3, for instance, few large volume variations were observed in the upper-ventral
region of the bladder while most of its geometric variations were in the central and
lower region. Nevertheless, these outlier observations led to include this direction in the
modes obtained by the PCA and to estimate geometric variations along this mode (see
Fig. 6.6f). As a result, we consider that motion-deformation models based on PCA are
mainly affected by outlier observations in two aspects: in overestimating directions of
geometric variability and in misestimating the average bladder shape. It can also be
observed that PCA models estimated a motion/deformation region that looks like an
ellipsoid around the patient’s average bladder. This result can be explained as PCA
models estimate bladder geometries by linearly deforming the average bladder shape
along the dominating modes following a normal distribution. From Fig. 6.6e and 6.6f,
we consider that PCA models may have limitations to properly describe geometric
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Figure 6.11: DVH differences between the reference and estimated accumulated doses
for all the three patients. (a) DVH differences between the reference accumulated
𝐷𝑉𝐻𝑐𝑢𝑚,𝑟𝑒𝑓 and the mean accumulated 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶 via MC simulation. (b) DVH
differences between the accumulated DVH 𝐷𝑉𝐻𝑐𝑢𝑚,𝑖𝑛𝑡.3 obtained with dose integra-
tion over the first three modes and the mean accumulated 𝐷𝑉𝐻𝑐𝑢𝑚,𝑀𝐶 obtained via
MC simulation.
variations of highly varying tissue like the bladder as contours of equal probability in
the observed PMs did not follow an elliptical behavior.
From Fig. 6.7b and 6.9b, we think that the average bladder shape may not be
feasible to estimate the accumulated dose as geometric variations of the bladder were
not symmetrically distributed around the patient’s average bladder shape. For Patient
1 and 3, it can be observed that single-fraction DVHs from observed bladder geometries
(𝐷𝑉𝐻𝑜𝑏𝑠,𝑠) were highly distributed above the DVH obtained from the average bladder
shape (𝐷𝑉𝐻mean bladder). As a result, this may also indicate that geometric variations
of the bladder may not follow a Gaussian distribution along the limited set of orthogonal
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modes. A possible solution may thus consider a non-Gaussian parametric probability
density function (PDF) to represent the distribution of PCA scores related to intra-
subject organ motion. However, as it may be reasonable to assume that an organ moves
and deforms following a Gaussian distribution along a set of dominating directions,
future works can be focused to apply Kernel PCA in order to determine non-orthogonal
directions that better describe geometric variations of the bladder. Previously, Kernel
PCA has been used to develop 4D motion models for the lung [67].
From Fig. 6.7c, 6.8c and 6.9c, it is observed that the CR of 95% of probability
described by the first three modes included most of the bladder geometries estimated in
the MC simulation. We thereby consider that it is possible to estimate the uncertainty
region of bladder motion and deformation by using solely the joint distribution of the
first three modes. This CR thus enable us to infer those dose fractions that are more
probable of being delivered during treatment for a patient. However, relative dose errors
in Tables 6.2, 6.3 and 6.4 established that the mean accumulated dose was mainly
described by the first mode. These relative errors indicated that the first mode enable
us to obtain a good approximation of the estimated accumulated dose with errors less
than 5%, and also that including a second mode would reduce at most a 2% of the
estimation error. As a result, we conclude that the first mode is enough to obtain
good estimation of the accumulated dose during treatment. It is important to highlight
that results in this study have established that the first mode described the direction
of maximum volume variability, and we therefore think that the accumulated dose is
mainly described by those volume changes that takes places along this direction.
Concerning dosimetric uncertainties, relative dose errors in Tables 6.2, 6.3 and 6.4
indicated that the estimation of the dose variance converged as the number of modes was
increased. Nevertheless, at least four modes would be required to reduce the converge
error to a value lower than 10%. As in [50,111], it is observed from Fig. 6.10 that those
voxels with highest dose variations were obtained in the center region of the bladder,
i.e., the region of the bladder that is not directly connected to the prostate. We consider
that this can be understood as dose varies only on tissue elements that move in or out of
the beams and not at the border region to the prostate. Future studies should now be
conducted to determine the number of modes to fully determine dosimetric uncertainties
for the bladder.
6.5 Conclusion
We have hereby presented PCA models as a tool to quantify and predict dosimetric
uncertainties produced by inter-fraction geometric variations of the bladder. We have
provided the number of modes required to determine motion/deformation regions as
well as to estimate the accumulated dose of the bladder. We also showed some limi-
tations of PCA models to describe bladder motion and deformation between fractions.
Future studies should now be conducted to validate the number of modes required to es-
timate the accumulated dose by means of a large cohort of patients who have undergone
prostate cancer radiotherapy. Future studies could also be focused on the relationship
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between inter-fraction bladder motion/deformation, delivered dose, and late GU toxicity





This final chapter contains general remarks on the main results presented in this dis-
sertation. Perspectives are made to further extend the research presented in this work
in several directions.
Concluding remarks
In this thesis we have presented a methodology to characterize and predict bladder mo-
tion and deformation between fractions using solely the planning CT scan for prostate
cancer radiotherapy. In this study we have followed a population approach as in clinical
practice only the planning CT scan is available for a typical patient, while on-treatment
CT/CBCT scans are seldom available. In this study we have considered that bladder
motion and deformation between fractions is not a chaotic process and neither a de-
terministic. We have instead considered that the bladder randomly moves and deforms
along a limited number of geometric directions in a relatively stable overall shape. As
previous work these directions were also determined using PCA based on the assump-
tion that principal directions of geometric variations are similar in all patients, despite
the potential variations in organ size and shape across the population.
This dissertation considered three main research subjects. Firstly, it focused on the
characterization of shapes and motion/deformation regions of the bladder for a database
of patients using PCA; secondly, it proposed to use a longitudinal approach to predict
patient-specific bladder motion and deformation for an unseen patient by learning from
a longitudinal training database; thirdly, this thesis presented PCA models as virtual
tool to evaluate dosimetric uncertainties produced by bladder motion and deformation
between fractions. Concerning the first research subject, we have the following conclud-
ing remarks:
 A normalization method was proposed to anatomically align the pelvic structures
(prostate and bladder) for all the patients in the same spatial referential. This
method was a prostate-based rigid registration that enabled bladder motion and
deformations to be quantified with respect to the prostate barycenter of a template
patient. However, this spatial normalization introduces inter-patient geometric
variations in the lower posterior part of the bladder – the region that presented
the geometric variations produced by the barycenter alignment– that may be
captured by higher modes. Although in our study, these geometric variations
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were not captured by the most significant modes, higher modes describing these
geometric variations may lead to estimate unrealistic deformations in the most
stable part of the bladder. Nevertheless, such modes may have a low impact in
the estimation of motion-deformation regions and cumulated doses.
 Surface parametrization by means of SPHARM offered the advantage of signifi-
cantly reducing the number of variables required to represent the bladder surface
without resulting in a loss of information. This parametrization thus enabled
us to reduce computation time, numerical errors by affording finite arithmetic
operations, and data storage.
 As in previously-proposed population-based models, the main directions of ge-
ometric variability were determined using PCA. These directions enabled us to
characterize shapes and motion/deformation regions of the bladder; and subse-
quently, to visualize and quantify the heterogeneous variability observed in the
database.
Concerning the second research subject, our aim was to characterize intra and inter-
patient variability of the bladder observed in a population database to subsequently
infer a probable region of bladder motion and deformation. We have the subsequent
concluding remarks:
 We firstly sought to characterize patient-specific variance from the population
using mixed-effects models. This technique enables us to consider the inherent
correlation of intra-individual observations, while reducing observed population
variance by grouping repeated observations per patient by means of a “patient
factor”. However, in population databases of highly varying soft-tissue like the
bladder, a large number of modes may be required to properly capture the complex
shape variations observed in the training database. We consider that the large
number of modes makes the inference and analysis of the ME models’ parameters
difficult.
 We secondly sought to characterize patient-specific modes from the population
using hierarchical PCA. This methodology increased the degree of freedom of the
motion/deformation model as the number of geometrical directions described by
the first modes in the hierarchical models has been increased compared to the
groundwork PCA models. Nevertheless, hierarchical PCA models introduced a
higher number of parameters, increasing the model complexity.
From both remarks, we conclude that both techniques enabled us to reduce the
uncertainties in the estimation of the probable motion/deformation region. Finally, we
have the subsequent concluding remarks concerning the third research subject of this
dissertation:
 Patient-specific PCA models were presented as tools to quantify and predict dosi-
metric uncertainties produced by inter-fraction geometric variations of the blad-
der. Our main contributions were the number of modes required to determine
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motion/deformation regions as well as to estimate the cumulated dose of the
bladder.
 The delivered dose only varies on tissue elements that move in or out of the beams
and not at the border region to the prostate. We have showed that only the first
mode had a significant impact on the cumulated dose estimation as it described
the most significant changes in volume outside the beams.
It is worth mentioning that in this study we have defined several covariance matrices
in order to determine modes of bladder geometrical variability. Physical interpretations
of such modes were provided as a qualitative validation along this study. The first
mode, for instance, always described the main direction where changes in volume were
observed. This direction enabled us to describe the shape and motion/deformation
region of the bladder for a typical patient in longitudinal analysis, and the probable
cumulated dose for intra-patient analysis.
Finally, we consider that PCA models have two main limitations to model organ
motion and deformation between fractions. The first limitation is related the organ
mean shape used to estimate geometrical uncertainties. PCA models deform the organ
mean shape along the modes with their corresponding variances to estimate new organ
structures. However, several images should be required to obtain a good estimation
of the true mean shape, and the organ shape delineated in the planning CT scan may
only capture a momentary shape during treatment. In our study, the estimated mean
shape had strong impact in the estimation of both the motion/deformation region and
cumulated dose. Nevertheless, this limitation can be overcome whenever more CT
scans are available during treatment in an adaptive radiotherapy scheme. The second
limitation is related to assuming that bladder moves and deforms between fractions
following a Gaussian distribution. For some patients, we have observed that geometric
variations of the bladder did not distributed like a bell-curve around the mean shape.
As PCA models assume that geometric variations obey a Gaussian distribution along a
limited number of modes, we consider orthogonal directions may not properly describe
the geometric variations of the bladder between fractions. A result, future work may
be extended to determine non-orthogonal directions of geometric variability that better
describe bladder motion and deformation.
Perspectives
The research presented in this work can be further extended in several directions.
 We have used SPHARM to model bladder shape obtaining a significant reduc-
tion on the variables required to represent the surface. However, we consider
that surface shape modeling should be improved as not all the bladder shapes
were properly parameterized using the radial sampling in spherical coordinates.
A first option is to extend the SPHARM methodology to model a much larger
class of simply connected closed shapes using an area-preserving, distortion mini-
mizing spherical mapping as expressed in [73,80]. A second option is also to use a
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different computational technique called isogeometric analysis, which generalizes
and improves on the standard finite element method [84,85]. In population data,
this technique offers the advantage of obtaining a surface parameterization with
corresponding points in all organ instances without requiring a mesh relaxation
procedure. This methodology defines a transformation to a canonical domain,
where it is made the parametrization and extrapolated to any organ instance.
 In this study, we have observed that outlier observations may lead to incorrect
the model’s parameters ( like patient-specific variance and modes, and average
bladder shape). As a result, a future research topic to be explored is to analyze
the robustness of the methodology for handling outlier patients using robust PCA
either in population or individual motion/deformation models.
 Future work can also be focused to determine general forms of covariates that may
correlate with the modes. We consider that there may be some covariates that
underlie the motion/deformation region for an arbitrary patient. For example,
the bladder size or volume could be considered as fixed-effects that may deter-
mine the volume changes and directions of geometric variations. In an adaptive
radiotherapy scheme, it can also be added a time covariate, as a random or fixed
variable, that describes the daily volume changes of the bladder.
 Future studies should also be focused on studying the impact of dosimetric uncer-
tainties produced by inter-fraction variations of the bladder on the prediction of
late GU toxicity in prostate cancer radiotherapy [35,69,111]. A recurrent criticism
to DVH-based toxicity models is that they reduce 3D dose distributions to a set of
dose-volume parameters [e.g. the fraction of the organ volume receiving at least
𝑋 Gy (𝑉 𝑋), or equivalent uniform dose (EUD)] in order to provide a probability
for a patient of developing side effects after radiation [69,120–123]. Although this
reduction enables us to study, under the same framework, patients undergoing
the same treatment, crucial information may be disregarded that may help to dis-
criminate between high-risk and low-risk treatments. For example, two patients
could have the same dose-volume parameters but different dose distributions. It
may therefore be important to introduce new information like inter-fraction geo-
metric variations of organs to overcome limitations of DVH-based toxicity mod-
els [124–126].
 From a clinical point of view, the proposed methodology can be applied to tailor
treatment plans to specific needs of patient. For example, it has potential ap-
plications for margin evaluation, estimation of delivered dose, on-treatment dose
adaptation and the design of robust treatment plans, among others. In an adap-
tive radiotherapy scheme, population-based models can be used to estimate prob-
able single dose fractions and motion-including doses for a typical patient while
on-treatment CT/CBCT scans are acquired to subsequently fit a patient-specific
PCA model ( Söhn et al. [50] has been established 5 scans as the minimum num-
ber of observations for intra-patient models). Estimated motion-including doses
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can then be used to adapt the dose during treatment. Besides of dose estimation,
this methodology can also be used to adapt margins during fractions to further
personalise treatment plans. As in [55], the most probable bladder contours can
be generated from the population or patient-specific models in order to estimate
the percentage of bladder volume inside the PTV and CTV volumes. As a result,
motion-inclusive margins can be determined in order to ensure an adequate dose
coverage.
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Appendix A
Supplementary material for
characterization of bladder motion
and deformation
In this appendix, we provide supplementary material for the prostate-based rigid regis-
tration performed to normalize the patients in the training database.
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a) Average prostate volume in the training database 
b) Template prostate (white) vs observed prostates of patients
 outside from rst and third quartiles 
Figure A.1: (a) Boxplot of average prostate volume in the training database. Green
line shows the average volume of the template prostate. (b) Overlays of some observed
prostates (green and red) of patients outside from first and third quartiles vs template
prostate (white).
Appendix B
Cluster center that minimizes the
distance to data point in K-means
clustering
In this appendix, we outline the mathematical details that prove the equality between
both arguments arg in Eq. 5.5.
Corollary
Let 𝑚1,𝑚2, . . . ,𝑚𝒯 and 𝑤 be vectors in R𝑛. We thus aim to prove that:
𝑡 = arg min
𝑏






For an arbitrary 𝑚𝑏, it holds that
‖𝑤 −𝑚𝑏‖2 = ⟨𝑤 −𝑚𝑏, 𝑤 −𝑚𝑏⟩ (B.2)










Because 𝑚𝑏 was arbitrary and 𝑤 fixed, it then means that
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𝑡 = arg min
𝑏



















This establishes the equality.
Appendix C
Elements of numerical analysis for
solving mean and variance dose
integrals
In this appendix we describe the numerical details used to solve the multidimensional
integrals involved in the computation of the mean and variance cumulated dose (see
Eqs. 6.6). We describe algorithms to calculate both integrals restricted to the first
three modes. The generalization to further modes can be done following an inductive
procedure. Further elements about numerical integration can be found in [127].
The mean and variance cumulated dose restricted to the first mode
Let’s firstly solve the integral of the cumulative distribution function (CDF) of the




























𝜆1. As for the normal distribution, the values less than three standard
deviations away from the mean account for 99.73% of the set, the improper integral
in Eq. C.1 can then be approximated by a definite integral defined in the interval
[−3.5𝜎1, 3.5𝜎1]. The interval [−3.5𝜎1, 3.5𝜎1] is split up into a even number 𝑛1 of subin-
tervals and evenly spaced mesh points 𝑧1,0, . . . , 𝑧1,𝑛 to apply the Composite Simpson’s
rule. The improper integral can then be approximated as follows:
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0
Figure C.1: Visualization of the Gaussian distribution of the first mode for a patient
in the interval [−3.5𝜎1, 3.5𝜎1]. The interval was split up into a even number 𝑛1 of
















where ℎ1 = 7𝜎1/𝑛1 is the size of the subintervals. For 𝑛1 = 10, the relative error
of the integral is lower than 0.05%. Defining 𝐹𝑧(𝑧1) = 𝐷(𝑧1)𝑓𝑧(𝑧1), the mean dose can





𝐹𝑧(−3.5𝜎1) + 𝐹𝑧(3.5𝜎1) + 4
𝑛1/2∑︁
𝑖=1






where 𝐷 = 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑. The dose 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑(𝑧1,𝑖) was deformed using the deformation
field 𝑈 obtained from the DIR process between the two images resulting from the
bladder contours 𝑥𝑝𝑙𝑎𝑛𝑛𝑒𝑑 and 𝑥(𝑧1,𝑖). For this purpose, for both the 𝑥𝑝𝑙𝑎𝑛𝑛𝑒𝑑 and 𝑥(𝑧1,𝑖)
contours, distance maps were computed, representing for each voxel the signed squared
Euclidean distance from the organ surface. Distance maps were then registered with a
variant of Demons algorithm providing the estimated deformation fields. Fig.C.1 shows
the Gaussian distribution of the first mode for a patient in the interval [−3.5𝜎1, 3.5𝜎1].






𝐹𝑧(−3.5𝜎1) + 𝐹𝑧(3.5𝜎1) + 4
𝑛1/2∑︁
𝑖=1






where 𝐹𝑧(𝑧1,𝑖) = (𝐷(𝑧1,𝑖) − 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1)2𝑓𝑧(𝑧1,𝑖). We did not use the expression
𝐷2(𝑧1,𝑖)𝑓𝑧(𝑧1,𝑖) because the rounding errors produced by finite-digit calculation were
higher, i.e., digits of significance were lost on account of the multiplications of numbers
with large magnitude (𝐷2(𝑧1,𝑖)) and subtraction of nearly equal numbers (
∫︀
𝐷2𝑓𝑧𝑑𝑧 −
𝜇2) (see Chapter 1 in [127]). Besides, it is worth highlighting that the dose was a vector
where 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑(𝑧1,𝑖) ∈ R𝑑1×𝑑2×𝑑3 . As a result, the numerical solutions of the integrals
in Eqs. C.3 and C.4 could challenge the CPU’s storage capacity and computation time,
if we decided to load the 𝑛+ 1 doses at the same time. We then proposed an algorithm
that can feasibly be implemented in an i7-4510U CPU @2.00GHz with 8G RAM. This
algorithm is described in Algorithm 1 for the integral of Eq. C.3 (while for the integral
of Eq. C.4 is straightforward by changing 𝑠 = (𝐷(𝑧1,𝑖)− 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1)2𝑓𝑧(𝑧1,𝑖) + 𝑠 ).
Input: values of 𝜎1; even positive integer 𝑛1; function of density probability
𝑓𝑧(𝑧)
Output: approximation 𝑠 to integral
set ℎ1 = 7𝜎1/𝑛1;
set 𝑠 = 0;
for 𝑖 = 0 : 𝑛1 do
load 𝐷(𝑧1,𝑖);
if 𝑖 𝑖𝑠 0 then
𝑠 = 𝐷(𝑧1,𝑖)𝑓(𝑧1,𝑖) + 𝑠;
else if 𝑖 𝑖𝑠 𝑛1 then
𝑠 = 𝐷(𝑧1,𝑖)𝑓(𝑧1,𝑖) + 𝑠;
else if 𝑖 𝑖𝑠 𝑒𝑣𝑒𝑛 then
𝑠 = 2𝐷(𝑧1,𝑖)𝑓(𝑧1,𝑖) + 𝑠;
else
𝑠 = 4𝐷(𝑧1,𝑖)𝑓(𝑧1,𝑖) + 𝑠;
end
end
𝑠 = ℎ13 𝑠
Algorithm 1: Numerical algorithm to approximate the integral mean cumulated dose
restricted to the first mode.
The mean and variance cumulated dose restricted to the first two
modes
Let’s consider the integral of the cumulative distribution function (CDF) of the Gaussian
distribution for the first two modes using the Composite Simpson’s rule, as follows:
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𝜆1 and 𝜎2 =
√
𝜆2. To apply the Composite Simpson’s rule, both
intervals [−3.5𝜎1, 3.5𝜎1] and [−3.5𝜎2, 3.5𝜎2] are also divided into a even number of
subintervals of equal size. To simplify the notation, we use even integers 𝑛1 and 𝑛2 and
partitions with the evenly spaced mesh points 𝑧1,0, . . . , 𝑧1,𝑛 and 𝑧2,0, . . . , 𝑧2,𝑛 for the
intervals [−3.5𝜎1, 3.5𝜎1] and [−3.5𝜎2, 3.5𝜎2], respectively. The improper integral can

































The constants ℎ1 = 7𝜎1/𝑛1 and ℎ2 = 7𝜎2/𝑛2 are the size of the subintervals. For
𝑛1 = 𝑛2 = 8, the relative error of the integral is lower than 0.33%. Defining 𝐹𝑧(𝑧1, 𝑧2) =






















Figure C.2: Visualization of the multivariate Gaussian distribution of the first two
mode for a patient in the square region 𝑅 = {(𝑧1, 𝑧2)| − 3.5𝜎1 ≤ 𝑧1 ≤ 3.5𝜎2,−3.5𝜎2 ≤
𝑧2 ≤ 3.5𝜎2}. The square region was divided into a mesh of points (𝑧1,𝑖, 𝑧2,𝑗) with















The dose 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑(𝑧1,𝑗 , 𝑧2,𝑗) was also deformed using the deformation field 𝑈 ob-
tained from the DIR process between the two images resulting from the bladder 𝑥𝑝𝑙𝑎𝑛𝑛𝑒𝑑
and 𝑥(𝑧1,𝑖, 𝑧2,𝑗). The dose 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑(𝑧1,𝑗 , 𝑧2,𝑗) was subsequently resampled in the plan-
ning CT with a trilinear interpolation. Fig.C.2 shows the multivariate Gaussian dis-
tribution of the first two mode for a patient in the region 𝑅 = {(𝑧1, 𝑧2)| − 3.5𝜎1 ≤
𝑧1 ≤ 3.5𝜎2,−3.5𝜎2 ≤ 𝑧2 ≤ 3.5𝜎2}. The integral for the variance dose can also be
approximated as follows:
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where 𝐹𝑧(𝑧𝑖, 𝑧𝑗) = (𝐷(𝑧1,𝑖, 𝑧2,𝑗) − 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1−2)2𝑓𝑧(𝑧1,𝑖, 𝑧2,𝑗). Algorithm 2 describes
the steps required to calculate the mean dose 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1−2 while for the variance dose
is straightforward. Because of the dose vectors 𝐷(𝑧1,𝑖, 𝑧2,𝑗) ∈ R𝑑1×𝑑2×𝑑3 , this algorithm
enables us to iteratively load each deformed dose.
Input: values of 𝜎1 and 𝜎2; even positive integer 𝑛1 and 𝑛2; function of density
probability 𝑓𝑧(𝑧)
Output: approximation 𝑠 to integral
set ℎ1 = 7𝜎1/𝑛1;
set 𝑠1 = 0 and 𝑠2 = 0;
for 𝑖 = 0 : 𝑛1 do
𝑠2 ← Algorithm 1(𝜎2,𝑛2, 𝑓𝑧(𝑧1,𝑖, :));
if 𝑖 𝑖𝑠 0 then
𝑠1 = 𝑠2 + 𝑠1;
else if 𝑖 𝑖𝑠 𝑛1 then
𝑠1 = 𝑠2 + 𝑠1;
else if 𝑖 𝑖𝑠 𝑒𝑣𝑒𝑛 then
𝑠1 = 𝑠2 + 𝑠1;
else
𝑠1 = 𝑠2 + 𝑠1;
end
end
𝑠 = ℎ13 𝑠1
Algorithm 2: Numerical algorithm to approximate the integral mean cumulated dose
restricted to the first two modes.
The mean and variance cumulated dose restricted to the first three
modes
Let’s consider the integral of the cumulative distribution function (CDF) of the Gaussian































𝜆2 and 𝜎3 =
√
𝜆3. To apply the Composite Simpson’s rule,
the intervals [−3.5𝜎1, 3.5𝜎1], [−3.5𝜎2, 3.5𝜎2] and [−3.5𝜎3, 3.5𝜎3] are also divided into a
even number of subintervals of equal size. To simplify the notation, we use even inte-
gers 𝑛1, 𝑛3 and 𝑛2 and partitions with the evenly spaced mesh points 𝑧1,0, . . . , 𝑧1,𝑛,
𝑧2,0, . . . , 𝑧2,𝑛 and 𝑧3,0, . . . , 𝑧3,𝑛 for the intervals [−3.5𝜎1, 3.5𝜎1], [−3.5𝜎2, 3.5𝜎2] and












































𝑓𝑧(𝑧1,𝑖, 𝑧2,2𝑗−1, 𝑧3,𝑟) + 2
𝑛2/2∑︁
𝑗=1
𝑓𝑧(𝑧1,𝑖, 𝑧2,2𝑗 , 𝑧3,2𝑟)
)︁
(C.14)
The constants ℎ1 = 7𝜎1/𝑛1, ℎ2 = 7𝜎2/𝑛2 and ℎ3 = 7𝜎3/𝑛3 are the size of the
subintervals. For 𝑛1 = 𝑛2 = 𝑛3 = 8, the relative error of the integral is lower than
0.5%. Defining 𝐹𝑧(𝑧) = 𝐷(𝑧1, 𝑧3, 𝑧3)𝑓𝑧(𝑧1, 𝑧2, 𝑧3) and 𝐷 = 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑, the mean dose can
thus be calculated as follows:
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𝐹𝑧(𝑧1,𝑖, 𝑧2,2𝑗−1, 𝑧3,𝑟) + 2
𝑛2/2∑︁
𝑗=1
𝐹𝑧(𝑧1,𝑖, 𝑧2,2𝑗 , 𝑧3,2𝑟)
)︁
(C.16)
The dose𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑(𝑧1,𝑗 , 𝑧2,𝑗 , 𝑧3,𝑟) was also deformed using the deformation field 𝑈 ob-
tained from the DIR process between the two images resulting from the bladder 𝑥𝑝𝑙𝑎𝑛𝑛𝑒𝑑
and 𝑥(𝑧1,𝑖, 𝑧2,𝑗 , 𝑧3,𝑟). The dose 𝐷𝑝𝑙𝑎𝑛𝑛𝑒𝑑(𝑧1,𝑗 , 𝑧2,𝑗 , 𝑧3,𝑟) was subsequently resampled in
the planning CT with a trilinear interpolation. The integral for the variance dose can




















where 𝐹𝑧(𝑧) = (𝐷(𝑧)−𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1−3)2𝑓𝑧(𝑧). Algorithm 3 describes the steps required
to calculate the mean dose 𝜇𝑐𝑢𝑚,𝑖𝑛𝑡,1−3 while for the variance dose is also straightfor-
ward. Because of the dose vectors 𝐷(𝑧) ∈ R𝑑1×𝑑2×𝑑3 , this algorithm also enables us to
iteratively load each deformed dose.
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Data: value of 𝜎1, 𝜎2 and 𝜎3; even positive integer 𝑛1, 𝑛2 and 𝑛3; function of
density probability 𝑓(𝑧)
Result: approximation 𝑠 to integral
set ℎ3 = 7𝜎3/𝑛3;
set 𝑠1 = 0 and 𝑠2 = 0;
for 𝑟 = 0 : 𝑛3 do
𝑠2 ← Algorithm 2(𝜎1,𝜎2,𝑛1,𝑛2, 𝑓𝑧(:, :, 𝑧3,𝑟));
if 𝑟 𝑖𝑠 0 then
𝑠1 = 𝑠2 + 𝑠1;
else if 𝑟 𝑖𝑠 𝑛3 then
𝑠1 = 𝑠2 + 𝑠1;
else if 𝑟 𝑖𝑠 𝑒𝑣𝑒𝑛 then
𝑠1 = 𝑠2 + 𝑠1;
else
𝑠1 = 𝑠2 + 𝑠1;
end
end
𝑠 = ℎ33 𝑠1
Algorithm 3: Numerical algorithm to approximate the integral mean cumulated dose
restricted to the first three modes.
156
Appendix C. Elements of numerical analysis for solving mean and variance dose
integrals
Bibliography
[1] B. W. Sterwart and C. P. Wild, “World cancer report 2014,” World Health Orga-
nization, Tech. Rep., 2014.
[2] INCa, “Les cancers en france en 2014,” Institut National du Cancer (INCa),
Boulogne-Billancourt„ Tech. Rep., octobre 2011.
[3] INC, “Guia de atencion integral para la deteccion temprana, diagnostico,
tratamiento, seguimiento y rehabilitacion del cancer de prostata,” Instituo Na-
cional de Cancerlogia, Ministerio de Salud y Proteccion Social, Colciencias„ Tech.
Rep., 2013.
[4] “Cancer country profiles 2014,” World Health Organization, Tech. Rep., 2014.
[5] A. Stangelberger, M. Waldert, and B. Djavan, “Prostate Cancer in Elderly Men,”
Rev. Urol., vol. 10, no. 2, pp. 111–119, 2008.
[6] H. Scher, J. Isaacs, and M. J. Zelefsky, Prostate cancer, 2nd ed. Abeloff MD,
Armitage JO, Lichter AS, et al., editors. Clinical Oncology. New York, NY :
Churchill Livingstone, pages 1823 -1884., 2000.
[7] A. Heidenreich, P. J. Bastian, J. Bellmunt, M. Bolla, S. Joniau, T. van der Kwast,
M. Mason, V. Matveev, T. Wiegel, F. Zattoni, and N. Mottet, “EAU Guidelines
on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with
Curative Intent-Update 2013,” European Urology, vol. 65, no. 1, pp. 124–137,
Jan. 2014.
[8] A. Heidenreich, G. Aus, M. Bolla, S. Joniau, V. B. Matveev, H. P. Schmid, and
F. Zattoni, “EAU Guidelines on Prostate Cancer,” European Urology, vol. 53,
no. 1, pp. 68–80, Jan. 2008.
[9] L. Lemaitre, A. Villers, D. Mouton, and P. Puech, “Echographie et biopsies de
prostate,” J. Radiol., vol. 87, no. 2, pp. 201–209, Feb. 2006.
[10] M. Ghei, S. Pericleous, A. Kumar, R. Miller, S. Nathan, and B. H. Maraj,
“Finger-guided transrectal biopsy of the prostate: a modified, safer technique.”
Ann. R. Coll. Surg. Engl., vol. 87, no. 5, pp. 386–387, Sep. 2005.
157
158 Bibliography
[11] J. I. Epstein, W. C. Allsbrook, M. B. Amin, L. L. Egevad, and ISUP Grad-
ing Committee, “The 2005 International Society of Urological Pathology (ISUP)
Consensus Conference on Gleason Grading of Prostatic Carcinoma,” Am. J. Surg.
Pathol., vol. 29, no. 9, pp. 1228–1242, Sep. 2005.
[12] J. I. Epstein, L. Egevad, M. B. Amin, B. Delahunt, J. R. Srigley, P. A. Humphrey,
and Grading Committee, “The 2014 International Society of Urological Pathol-
ogy (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma:
Definition of Grading Patterns and Proposal for a New Grading System,” Am. J.
Surg. Pathol., vol. 40, no. 2, pp. 244–252, Feb. 2016.
[13] M. J. Barry, “Clinical practice. Prostate-specific-antigen testing for early diagnosis
of prostate cancer,” N. Engl. J. Med., vol. 344, no. 18, pp. 1373–1377, May 2001.
[14] M. Peyromaure, P. Beuzeboc, L. Salomon, P. Richaud, P. Coloby, B. Malavaud,
X. Rebillard, P. Rischmann, A. Villers, and M. Soulie, “Le dépistage du cancer
de la prostate en 2009: mise au point du comité de cancérologie de l’association
francaise d’urologie,” Progrés en Urologie, vol. 20, no. 1, pp. 17–23, Jan. 2010.
[15] S. Natarajan, L. S. Marks, D. J. A. Margolis, J. Huang, M. L. Macairan, P. Lieu,
and A. Fenster, “Clinical application of a 3d ultrasound-guided prostate biopsy
system,” Urologic Oncology: Seminars and Original Investigations, vol. 29, no. 3,
pp. 334–342, May 2011.
[16] D. Bonekamp, M. A. Jacobs, R. El-Khouli, D. Stoianovici, and K. J. Macura,
“Advancements in MR Imaging of the Prostate: From Diagnosis to Interventions,”
RadioGraphics, vol. 31, no. 3, pp. 677–703, May 2011.
[17] S. Edge, D. Byrd, C. Compton, A. Fritz, F. Greene, and A. Trotti, Eds., AJCC:
Cancer Staging Manual. Springer, 2010.
[18] A. Barrett, J. Dobbs, S. Morris, and T. Roques, Practical Radiotherapy Planning,
4th ed. Hodder Education, an Hachette UK Company, London, UK, 2009.
[19] A. Magheli and A. L. Burnett, “Erectile dysfunction following prostatectomy:
prevention and treatment,” Nat Rev Urol, vol. 6, no. 8, pp. 415–427, Aug. 2009.
[20] B. Hardemark, A. Liander, H. Rehbinder, and J. Löf, “Direct machine parameter
optimization with raymachine® in pinnacle3® ” RaySearch White Paper. Stock-
holm, Sweden: RaySearch Laboratories AB, 2003.
[21] D. Verellen, M. De Ridder, N. Linthout, K. Tournel, G. Soete, and G. Storme,
“Innovations in image-guided radiotherapy,” Nat. Rev. Cancer, vol. 7, no. 12, pp.
949–960, Dec. 2007.
[22] H. Shirato, S. Shimizu, K. Kitamura, and R. Onimaru, “Organ motion in
image-guided radiotherapy: lessons from real-time tumor-tracking radiotherapy,”
Int. J. Clin. Oncol., vol. 12, no. 1, pp. 8–16, Feb. 2007.
Bibliography 159
[23] International Commission on Radiation Units and Measurements, “Prescribing,
recording, and reporting photon-beam intensity-modulated radiation therapy-
IMRT: ICRU report 83,” ICRU, Bethesda, Maryland, USA., Tech. Rep., 2010.
[24] M. Krengli, S. Gaiano, E. Mones, A. Ballarè, D. Beldì, C. Bolchini, and G. Loi,
“Reproducibility of patient setup by surface image registration system in confor-
mal radiotherapy of prostate cancer,” Radiat. Oncol., vol. 4, p. 9, 2009.
[25] J. C. Stroom, H. C. J. de Boer, H. Huizenga, and A. G. Visser, “Inclusion
of geometrical uncertainties in radiotherapy treatment planning by means of
coverage probability,” Int. J. Radiat. Oncol. Biol. Phys., vol. 43, no. 4, pp.
905–919, Mar. 1999.
[26] J. C. Roeske, J. D. Forman, C. F. Mesina, T. He, C. A. Pelizzari, E. Fontenla,
S. Vijayakumar, and G. T. Y. Chen, “Evaluation of changes in the size and location
of the prostate, seminal vesicles, bladder, and rectum during a course of external
beam radiation therapy,” Int. J. Radiat. Oncol. Biol. Phys., vol. 33, no. 5, pp.
1321–1329, Dec. 1995.
[27] G. S. Mageras, G. J. Kutcher, S. A. Leibel, M. J. Zelefsky, E. Melian, R. Mohan,
and Z. Fuks, “A method of incorporating organ motion uncertainties into three-
dimensional conformal treatment plans,” Int. J. Radiat. Oncol. Biol. Phys., vol. 35,
no. 2, pp. 333–342, May 1996.
[28] J. M. Crook, Y. Raymond, D. Salhani, H. Yang, and B. Esche, “Prostate motion
during standard radiotherapy as assessed by fiducial markers,” Radiother. Oncol.,
vol. 37, no. 1, pp. 35–42, Oct. 1995.
[29] M. van Herk, A. Bruce, A. P. Guus Kroes, T. Shouman, A. Touw, and J. V.
Lebesque, “Quantification of organ motion during conformal radiotherapy of the
prostate by three dimensional image registration,” Int. J. Radiat. Oncol. Biol.
Phys., vol. 33, no. 5, pp. 1311–1320, Dec. 1995.
[30] E. Melian, G. S. Mageras, Z. Fuks, S. A. Leibel, A. Niehaus, H. Lorant, M. Zelef-
sky, B. Baldwin, and G. J. Kutcher, “Variation in prostate position quantitation
and implications for three-dimensional conformal treatment planning,” Int. J. Ra-
diat. Oncol. Biol. Phys., vol. 38, no. 1, pp. 73–81, Apr. 1997.
[31] S. L. Turner, R. Swindell, N. Bowl, J. Marrs, B. Brookes, G. Read, and R. A.
Cowan, “Bladder movement during radiation therapy for bladder cancer: impli-
cations for treatment planning,” Int. J. Radiat. Oncol. Biol. Phys., vol. 39, no. 2,
pp. 355–360, Sep. 1997.
[32] L. P. Muren, R. Smaaland, and O. Dahl, “Organ motion, set-up variation and
treatment margins in radical radiotherapy of urinary bladder cancer,” Radiother.
Oncol., vol. 69, no. 3, pp. 291–304, Dec. 2003.
160 Bibliography
[33] A. N. Viswanathan, E. D. Yorke, L. B. Marks, P. J. Eifel, and W. U. Shipley,
“Radiation dose-volume effects of the urinary bladder,” Int. J. Radiat. Oncol.
Biol. Phys., vol. 76, no. 3, pp. S116–122, 2010.
[34] T. Rosewall, C. Catton, G. Currie, A. Bayley, P. Chung, J. Wheat, and
M. Milosevic, “The relationship between external beam radiotherapy dose and
chronic urinary dysfunction â a methodological critique,” Radiother. Oncol.,
vol. 97, no. 1, pp. 40–47, 2010.
[35] M. Thor, L. Bentzen, L. B. Hysing, C. Ekanger, S.-I. Helle, A. Karlsdóttir, and
L. P. Muren, “Prediction of rectum and bladder morbidity following radiother-
apy of prostate cancer based on motion-inclusive dose distributions,” Radiother.
Oncol., vol. 107, no. 2, pp. 147–152, May 2013.
[36] R. K. Ten Haken, J. D. Forman, D. K. Heimburger, A. Gerhardsson, D. L. Mc-
Shan, C. Perez-Tamayo, S. L. Schoeppel, and A. S. Lichter, “Treatment planning
issues related to prostate movement in response to differential filling of the rectum
and bladder,” Int. J. Radiat. Oncol. Biol. Phys., vol. 20, no. 6, pp. 1317–1324,
Jun. 1991.
[37] J. M. Balter, H. M. Sandler, K. Lam, R. L. Bree, A. S. Lichter, and R. K.
Ten Haken, “Measurement of prostate movement over the course of routine ra-
diotherapy using implanted markers,” Int. J. Radiat. Oncol. Biol. Phys., vol. 31,
no. 1, pp. 113–118, Jan. 1995.
[38] G. S. Mageras, Z. Fuks, S. A. Leibel, C. C. Ling, M. J. Zelefsky, H. M. Kooy,
M. van Herk, and G. J. Kutcher, “Computerized design of target margins for
treatment uncertainties in conformal radiotherapy,” Int. J. Radiat. Oncol. Biol.
Phys., vol. 43, no. 2, pp. 437–445, Jan. 1999.
[39] M. Thor, M. Vaeth, A. Karlsdottir, and L. P. Muren, “Rectum motion and mor-
bidity prediction: Improving correlation between late morbidity and DVH param-
eters through use of rectum planning organ at risk volumes,” Acta Oncol, vol. 49,
no. 7, pp. 1061–1068, Oct. 2010.
[40] J. H. Killoran, H. M. Kooy, D. J. Gladstone, F. J. Welte, and C. J. Beard, “A
numerical simulation of organ motion and daily setup uncertainties: Implications
for radiation therapy,” Int. J. Radiat. Oncol. Biol. Phys., vol. 37, no. 1, pp. 213–
221, Jan. 1997.
[41] T. Craig, J. Battista, V. Moiseenko, and J. Van Dyk, “Considerations for the
implementation of target volume protocols in radiation therapy,” Int. J. Radiat.
Oncol. Biol. Phys., vol. 49, no. 1, pp. 241–250, Jan. 2001.
[42] T. F. Mutanga, H. C. J. de Boer, G. J. van der Wielen, M. S. Hoogeman, L. In-
crocci, and B. J. M. Heijmen, “Margin evaluation in the presence of deformation,
rotation, and translation in prostate and entire seminal vesicle irradiation with
Bibliography 161
daily marker-based setup corrections,” Int. J. Radiat. Oncol. Biol. Phys., vol. 81,
no. 4, pp. 1160–1167, Nov. 2011.
[43] M. Thor, A. Apte, J. O. Deasy, and L. P. Muren, “Statistical simulations to esti-
mate motion-inclusive dose-volume histograms for prediction of rectal morbidity
following radiotherapy,” Acta Oncol., vol. 52, no. 3, pp. 666–675, Apr. 2013.
[44] M. S. Hoogeman, M. van Herk, D. Yan, L. J. Boersma, P. C. M. Koper, and J. V.
Lebesque, “A model to simulate day-to-day variations in rectum shape,” Int. J.
Radiat. Oncol. Biol. Phys., vol. 54, no. 2, pp. 615–625, Oct. 2002.
[45] L. M. Pavel-Mititean, C. G. Rowbottom, C. L. Hector, M. Partridge, T. Bortfeld,
and W. Schlegel, “A geometric model for evaluating the effects of inter-fraction
rectal motion during prostate radiotherapy,” Phys. Med. Biol., vol. 49, no. 12, p.
2613, Jun. 2004.
[46] D. Yan, D. Jaffray, and J. Wong, “A model to accumulate fractionated dose in a
deforming organ,” Int J Radiat Oncol Biol Phys, vol. 44, no. 3, pp. 665–675, Jun.
1999.
[47] M. B. Boubaker, M. Haboussi, J.-F. Ganghoffer, and P. Aletti, “Finite element
simulation of interactions between pelvic organs: Predictive model of the prostate
motion in the context of radiotherapy,” J. Biomech., vol. 42, no. 12, pp. 1862–1868,
Aug. 2009.
[48] E. Fontenla, C. A. Pelizzari, J. C. Roeske, and G. T. Y. Chen, “Numerical analysis
of a model of organ motion using serial imaging measurements from prostate
radiotherapy,” Phys. Med. Biol., vol. 46, no. 9, p. 2337, Sep. 2001.
[49] ——, “Using serial imaging data to model variabilities in organ position and shape
during radiotherapy,” Phys. Med. Biol., vol. 46, no. 9, p. 2317, Sep. 2001.
[50] M. Söhn, B. Sobotta, and M. Alber, “Dosimetric treatment course simulation
based on a statistical model of deformable organ motion,” Phys. Med. Biol.,
vol. 57, no. 12, pp. 3693–3709, Jun. 2012.
[51] S. Thörnqvist, L. B. Hysing, A. G. Zolnay, M. Söhn, M. S. Hoogeman, L. P. Muren,
L. Bentzen, and B. J. M. Heijmen, “Treatment simulations with a statistical
deformable motion model to evaluate margins for multiple targets in radiotherapy
for high-risk prostate cancer,” Radiother. Oncol., vol. 109, no. 3, pp. 344–349, Dec.
2013.
[52] Q. Zhang, A. Pevsner, A. Hertanto, Y.-C. Hu, K. E. Rosenzweig, C. C. Ling,
and G. S. Mageras, “A patient-specific respiratory model of anatomical motion
for radiation treatment planning,” Med Phys, vol. 34, no. 12, pp. 4772–4781, Dec.
2007.
162 Bibliography
[53] A. M. Badawi, E. Weiss, W. C. Sleeman, C. Yan, and G. D. Hugo, “Optimizing
principal component models for representing interfraction variation in lung cancer
radiotherapy,” Med. Phys., vol. 37, no. 9, pp. 5080–5091, Sep. 2010.
[54] E. Budiarto, M. Keijzer, P. R. Storchi, M. S. Hoogeman, L. Bondar, T. F. Mu-
tanga, H. C. J. de Boer, and A. W. Heemink, “A population-based model to
describe geometrical uncertainties in radiotherapy: applied to prostate cases,”
Phys. Med. Biol., vol. 56, no. 4, pp. 1045–1061, Feb. 2011.
[55] L. Bondar, M. Intven, J. P. M. Burbach, E. Budiarto, J. P. Kleijnen, M. Philip-
pens, B. van Asselen, E. Seravalli, O. Reerink, and B. Raaymakers, “Statistical
modeling of ctv motion and deformation for imrt of early-stage rectalÂ cancer,”
Int. J. Radiat. Oncol. Biol. Phys., vol. 90, no. 3, pp. 664–672, November 2014.
[56] R. Rios, J. D. Ospina, C. Lafond, O. Acosta, J. Espinosa, and R. de Crevoisier,
“Characterization of Bladder Motion and Deformation in Prostate Cancer Radio-
therapy,” IRBM, vol. 37, no. 5–6, pp. 276–283, Nov. 2016.
[57] M. Söhn, M. Birkner, D. Yan, and M. Alber, “Modelling individual geometric
variation based on dominant eigenmodes of organ deformation: implementation
and evaluation,” Phys. Med. Biol., vol. 50, no. 24, pp. 5893–5908, Dec. 2005.
[58] T. F. Cootes, C. J. Taylor, D. H. Cooper, and J. Graham, “Active Shape Models-
Their Training and Application,” Computer Vision and Image Understanding,
vol. 61, no. 1, pp. 38–59, Jan. 1995.
[59] Y. Jeong, R. J. Radke, and D. M. Lovelock, “Bilinear models for inter- and intra-
patient variation of the prostate,” Phys. Med. Biol., vol. 55, no. 13, pp. 3725–3739,
Jul. 2010.
[60] A. H. Foruzan, Y.-W. Chen, M. Hori, Y. Sato, and N. Tomiyama, “Capturing
large shape variations of liver using population-based statistical shape models,”
Int J Comput Assist Radiol Surg, Apr. 2014.
[61] R. Rios, J. D. Ospina, F. Commandeur, C. Lafond, O. Acosta, J. Espinosa, and
R. de Crovoiser, “Prediction of geometrical variations of the bladder in image
guided radiotherapy for prostate cancer.” in ICART Workshoop MICCAI 9th
Octuber, Munich, Germany, 2015.
[62] R. Rios, R. De Crevoisier, J. D. Ospina, F. Commandeur, C. Lafond, A. Simon,
P. Haigron, J. Espinosa, and O. Acosta, “Population model of bladder motion and
deformation based on dominant eigenmodes and mixed-effects models in prostate
cancer radiotherapy,” Med. Image Anal., vol. 38, pp. 133–149, May 2017.
[63] J. R. McClelland, D. J. Hawkes, T. Schaeffter, and A. P. King, “Respiratory
motion models: A review,” Med. Image Anal., vol. 17, no. 1, pp. 19–42, Jan.
2013.
Bibliography 163
[64] S. Durrleman, X. Pennec, A. Trouvé, J. Braga, G. Gerig, and N. Ayache, “To-
ward a comprehensive framework for the spatiotemporal statistical analysis of
longitudinal shape data,” Int J Comput Vis, vol. 103, no. 1, pp. 22–59, May 2013.
[65] J. Pinheiro and D. Bates, Mixed-Effects Models in S and S-PLUS, 1st ed.
Springer.
[66] Y. Hu, E. Gibson, H. U. Ahmed, C. M. Moore, M. Emberton, and D. C. Barratt,
“Population-based prediction of subject-specific prostate deformation for MR-to-
ultrasound image registration,” Med. Image Anal., vol. 26, no. 1, pp. 332–344,
Dec. 2015.
[67] T. He, Z. Xue, W. Xie, and S. T. C. Wong, “Online 4-D CT Estimation for
Patient-Specific Respiratory Motion Based on Real-Time Breathing Signals,” in
Medical Image Computing and Computer-Assisted Intervention â MICCAI 2010.
Springer, Berlin, Heidelberg, Sep. 2010, pp. 392–399.
[68] F. Preiswerk, V. De Luca, P. Arnold, Z. Celicanin, L. Petrusca, C. Tanner,
O. Bieri, R. Salomir, and P. C. Cattin, “Model-guided respiratory organ motion
prediction of the liver from 2d ultrasound,” Med. Image Anal., vol. 18, no. 5, pp.
740–751, Jul. 2014.
[69] C. Fiorino, R. Valdagni, T. Rancati, and G. Sanguineti, “Dose volume effects for
normal tissues in external radiotherapy: Pelvis,” Radiother. Oncol., vol. 93, no. 2,
pp. 153–167, Nov. 2009.
[70] V. Beckendorf, S. Guérif, E. L. Prisé, J. M. Cosset, O. Lefloch, B. Chauvet,
N. Salem, O. Chapet, S. Bourdin, J. M. Bachaud, P. Maingon, J.-L. Lagrange,
L. Malissard, J.-M. Simon, P. Pommier, M. H. Hay, B. Dubray, E. Luporsi, and
P. Bey, “The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate
cancer: Feasibility and acute toxicity,” Int. J. Radiat. Oncol. Biol. Phys., vol. 60,
no. 4, pp. 1056–1065, Nov. 2004.
[71] C. Lorenz and N. Krahnstöver, “Generation of point-based 3d statistical shape
models for anatomical objects,” Computer Vision and Image Understanding,
vol. 77, no. 2, pp. 175–191, 2000.
[72] D. H. Ballard and C. M. Brown, Computer Vision, first edition ed. Englewood
Cliffs, N.J: Prentice Hall, May 1982.
[73] C. Brechbühler, G. Gerig, and O. Kübler, “Parametrization of Closed Surfaces
for 3-D Shape Description,” Computer Vision and Image Understanding, vol. 61,
no. 2, pp. 154–170, Mar. 1995.
[74] G. Székely, A. Kelemen, C. Brechbühler, and G. Gerig, “Segmentation of 2-D
and 3-D objects from MRI volume data using constrained elastic deformations of
flexible Fourier contour and surface models,” Med. Image Anal., vol. 1, no. 1, pp.
19–34, Mar. 1996.
164 Bibliography
[75] A. Kelemen, G. Szekely, and G. Gerig, “Elastic model-based segmentation of 3-
D neuroradiological data sets,” IEEE Transactions on Medical Imaging, vol. 18,
no. 10, pp. 828–839, Oct. 1999.
[76] L. Shen, J. Ford, F. Makedon, and A. Saykin, “A surface-based approach for
classification of 3d neuroanatomical structures,” Intelligent Data Analysis, vol. 8,
no. 6, pp. pp.519–542, 2004.
[77] M. Styner, J. A. Lieberman, D. Pantazis, and G. Gerig, “Boundary and medial
shape analysis of the hippocampus in schizophrenia,” Med. Image Anal., vol. 8,
no. 3, pp. 197–203, Sep. 2004.
[78] M. Styner, I. Oguz, S. Xu, C. Brechbühler, D. Pantazis, J. J. Levitt, M. E.
Shenton, and G. Gerig, “Framework for the Statistical Shape Analysis of Brain
Structures using SPHARM-PDM,” Insight J, no. 1071, pp. 242–250, 2006.
[79] L. Shen, S. Kim, and A. J. Saykin, “Fourier method for large scale surface modeling
and registration,” Comput. Graph., vol. 33, no. 3, pp. 299–311, Jun. 2009.
[80] L. Shen, H. Farid, and M. A. McPeek, “Modeling three-dimensional morphological
structures using spherical harmonics,” Evolution, vol. 63, no. 4, pp. 1003–1016,
Apr. 2009.
[81] J.-L. Dillenseger, H. Guillaume, and J.-J. Patard, “Spherical harmonics based
intrasubject 3-D kidney modeling/registration technique applied on partial infor-
mation,” IEEE Trans Biomed Eng, vol. 53, no. 11, pp. 2185–2193, Nov. 2006.
[82] G. Gerig, M. Styner, D. Jones, D. Weinberger, and J. Lieberman, “Shape analysis
of brain ventricles using SPHARM,” in IEEEWorkshop on Mathematical Methods
in Biomedical Image Analysis, 2001. MMBIA 2001, 2001, pp. 171–178.
[83] T. Tateyama, M. Okegawa, M. Uetani, H. Tanaka, S. Kohara, X. Han,
S. Kanasaki, S. Sato, M. Wakamiya, A. Furukawa, H. Jiang, and Y. W. Chen,
“Efficient shape representation and statistical shape modeling of the liver using
spherical harmonic functions (SPHARM),” in 2012 Joint 6th International Con-
ference on Soft Computing and Intelligent Systems (SCIS) and 13th International
Symposium on Advanced Intelligent Systems (ISIS), Nov. 2012, pp. 428–431.
[84] Y. Zhang, Y. Bazilevs, S. Goswami, C. L. Bajaj, and T. J. R. Hughes, “Patient-
specific vascular NURBS modeling for isogeometric analysis of blood flow,” Com-
puter Methods in Applied Mechanics and Engineering, vol. 196, no. 29, pp. 2943–
2959, May 2007.
[85] V. P. Nguyen, C. Anitescu, S. P. A. Bordas, and T. Rabczuk, “Isogeometric analy-
sis: An overview and computer implementation aspects,” Mathematics and Com-
puters in Simulation, vol. 117, pp. 89–116, November 2015.
Bibliography 165
[86] N. M. Laird and J. H. Ware, “Random-effects models for longitudinal data,” Bio-
metrics, vol. 38, no. 4, pp. 963–974, Dec. 1982.
[87] R. D. G. Donald Hedeker, Longitudinal Data Analysis. John Wiley & Sons, Inc.,
Hoboken, New Jersey, USA, 2006.
[88] G. Fitzmaurice, N. Laird, and J. Ware, Applied Longitudinal Analysis, ser. Wiley
Series in Probability and Statistics. John Wiley & Sons, Inc., Hoboken, New
Jersey, USA, 2011.
[89] E. W. Frees, Longitudinal and Panel Data: Analysis and Applications in the
Social Sciences, 1st ed. New York: Cambridge University Press, 2004.
[90] R. S. Prabhu, M. Won, E. G. Shaw, C. Hu, D. G. Brachman, J. C. Buckner, K. J.
Stelzer, G. R. Barger, P. D. Brown, M. R. Gilbert, and M. P. Mehta, “Effect of the
addition of chemotherapy to radiotherapy on cognitive function in patients with
low-grade glioma: Secondary analysis of RTOG 98-02,” J. Clin. Oncol., vol. 32,
no. 6, pp. 535–541, 2014.
[91] A. L. Hanlon, D. F. Moore, and G. E. Hanks, “Modeling postradiation prostate
specific antigen level kinetics,” Cancer, vol. 83, no. 1, pp. 130–134, Jul. 1998.
[92] T. Bastogne, A. Samson, P. Vallois, S. Wantz-Mézières, S. Pinel, D. Bechet, and
M. Barberi-Heyob, “Phenomenological modeling of tumor diameter growth based
on a mixed effects model,” J. Theor. Biol., vol. 262, no. 3, pp. 544–552, 2010.
[93] J. L. Bernal-Rusiel, M. Reuter, D. N. Greve, B. Fischl, and M. R. Sabuncu,
“Spatiotemporal linear mixed effects modeling for the mass-univariate analysis of
longitudinal neuroimage data,” Neuroimage, vol. 81, pp. 358–370, November 2013.
[94] G. Ziegler, W. D. Penny, G. R. Ridgway, S. Ourselin, and K. J. Friston, “Estimat-
ing anatomical trajectories with Bayesian mixed-effects modeling,” Neuroimage,
vol. 121, pp. 51–68, Nov. 2015.
[95] X. Liu, “Chapter 3 - linear mixed-effects models,” in Methods and Applications
of Longitudinal Data Analysis, X. Liu, Ed. Oxford: Academic Press, 2016, pp.
61 – 94.
[96] K.-Y. Liang and S. L. Zeger, “Longitudinal data analysis using generalized linear
models,” Biometrika, vol. 73, no. 1, pp. 13–22, Apr. 1986.
[97] W. Guo, “Functional Mixed Effects Models,” Biometrics, vol. 58, no. 1, pp. 121–
128, 2002.
[98] J. S. Morris and R. J. Carroll, “Wavelet-based functional mixed models,” J R Stat
Soc Series B Stat Methodol, vol. 68, no. 2, pp. 179–199, Apr. 2006.
[99] H. Wu and J.-T. Zhang, “Local Polynomial Mixed-Effects Models for Longitudinal
Data,” J. Am. Stat. Assoc., vol. 97, no. 459, pp. 883–897, 2002.
166 Bibliography
[100] J. A. D. Aston, J.-M. Chiou, and J. P. Evans, “Linguistic pitch analysis using
functional principal component mixed effect models,” Journal of the Royal Sta-
tistical Society: Series C (Applied Statistics), vol. 59, no. 2, pp. 297–317, Mar.
2010.
[101] A. Kraskov and P. Grassberger, “MIC: Mutual information based hierarchical
clustering,” in Information Theory and Statistical Learning, F. Emmert-Streib
and M. Dehmer, Eds. Springer US, 2009, pp. 101–123.
[102] D. B. Russakoff, C. Tomasi, T. Rohlfing, and C. R. M. Jr, “Image similarity using
mutual information of regions,” in Computer Vision - ECCV 2004, ser. Lecture
Notes in Computer Science. Springer Berlin Heidelberg, 2004, vol. 3023, pp.
596–607.
[103] F. Maes, A. Collignon, D. Vandermeulen, G. Marchal, and P. Suetens, “Multi-
modality image registration by maximization of mutual information,” IEEE Trans
Med Imaging, vol. 16, no. 2, pp. 187–198, 1997.
[104] J. C. Pinheiro and D. M. Bates, “Unconstrained parametrizations for variance-
covariance matrices,” Statistics and Computing, vol. 6, no. 3, pp. 289–296,
1996.
[105] S. Gill, K. Dang, C. Fox, M. Bressel, T. Kron, N. Bergen, N. Ferris, R. Owen,
S. Chander, K. H. Tai, and F. Foroudi, “Seminal vesicle intrafraction motion
analysed with cinematic magnetic resonance imaging,” Radiat. Oncol., vol. 9,
Aug. 2014.
[106] C. Bishop and M. Tipping, “A hierarchical latent variable model for data visu-
alization,” IEEE Trans. Pattern Anal. Mach. Intell., vol. 20, no. 3, pp. 281–293,
Mar. 1998.
[107] G. J. Price and C. J. Moore, “A method to calculate coverage probability from
uncertainties in radiotherapy via a statistical shape model,” Phys. Med. Biol.,
vol. 52, no. 7, pp. 1947–1965, Apr. 2007.
[108] T. Heimann and H.-P. Meinzer, “Statistical shape models for 3d medical image
segmentation: A review,” Med. Image Anal., vol. 13, no. 4, pp. 543–563, Aug.
2009.
[109] H. Hotelling, “Analysis of a complex of statistical variables into principal compo-
nents.” J. Educ. Psychol., vol. 24, no. 6, pp. 417–441, 1933.
[110] I. T. Jolliffe, Principal Component Analysis. Springer, Oct. 2002.
[111] F. Palorini, A. Botti, V. Carillo, S. Gianolini, I. Improta, C. Iotti, T. Rancati,
C. Cozzarini, and C. Fiorino, “Bladder dose–surface maps and urinary toxicity:
Robustness with respect to motion in assessing local dose effects,” Physica Medica,
vol. 32, no. 3, pp. 506–511, Mar. 2016.
Bibliography 167
[112] C.-Z. Di, C. M. Crainiceanu, B. S. Caffo, and N. M. Punjabi, “Multilevel functional
principal component analysis,” The Annals of Applied Statistics, vol. 3, no. 1, pp.
458–488, 2009.
[113] S. Greven, C. Crainiceanu, B. Caffo, and D. Reich, “Longitudinal functional prin-
cipal component analysis,” Electron J Stat, vol. 4, pp. 1022–1054, 2010.
[114] C. M. Bishop, Pattern Recognition and Machine Learning. 1st edition, Springer,
Cambridge, U.K, 2006.
[115] R. Rios, F. Commandeur, O. Acosta, C. Lafond, J. Espinosa, and R. De Crevoisier,
“Hierarchical eigenmodes to characterize bladder motion and deformation in
prostate cancer radiotherapy,” in Proc. SPIE 10160, 12th International Sym-
posium on Medical Information Processing and Analysis, vol. 10160, 2017, pp.
101 601E–101 601E–13. http://dx.doi.org/10.1117/12.2 256 916.
[116] E. Budiarto, M. Keijzer, P. R. M. Storchi, A. W. Heemink, S. Breedveld, and
B. J. M. Heijmen, “Computation of mean and variance of the radiotherapy dose
for PCA-modeled random shape and position variations of the target,” Phys. Med.
Biol., vol. 59, no. 2, pp. 289–310, Jan. 2014.
[117] G. Cazoulat, A. Simon, A. Dumenil, K. Gnep, R. de Crevoisier, O. Acosta,
and P. Haigron, “Surface-constrained nonrigid registration for dose monitoring
in prostate cancer radiotherapy,” IEEE Trans Med Imaging, vol. 33, no. 7, pp.
1464–1474, Jul. 2014.
[118] M. Nassef, A. Simon, G. Cazoulat, A. Duménil, C. Blay, C. Lafond, O. Acosta,
J. Balosso, P. Haigron, and R. de Crevoisier, “Quantification of dose uncertain-
ties in cumulated dose estimation compared to planned dose in prostate IMRT,”
Radiother. Oncol., vol. 119, no. 1, pp. 129–136, Apr. 2016.
[119] R. A. Johnson and D. W. Wicherm, Applied Multivariate Statistical Analysis,
6th ed. Pearson, USA, 2008.
[120] G. J. Kutcher, C. Burman, L. Brewster, M. Goitein, and R. Mohan, “Histogram
reduction method for calculating complication probabilities for three-dimensional
treatment planning evaluations,” Int. J. Radiat. Oncol. Biol. Phys., vol. 21, no. 1,
pp. 137–146, May 1991.
[121] T. E. Schultheiss, C. G. Orton, and R. A. Peck, “Models in radiotherapy: volume
effects,” Med. Phys., vol. 10, no. 4, pp. 410–415, Aug. 1983.
[122] P. Källman, A. Agren, and A. Brahme, “Tumour and normal tissue responses to
fractionated non-uniform dose delivery,” Int. J. Radiat. Biol., vol. 62, no. 2, pp.
249–262, Aug. 1992.
[123] L. A. Dawson, M. Biersack, G. Lockwood, A. Eisbruch, T. S. Lawrence, and
R. K. Ten Haken, “Use of principal component analysis to evaluate the partial
168 Bibliography
organ tolerance of normal tissues to radiation,” Int. J. Radiat. Oncol. Biol. Phys.,
vol. 62, no. 3, pp. 829–837, Jul. 2005.
[124] F. Buettner, S. L. Gulliford, S. Webb, M. R. Sydes, D. P. Dearnaley, and M. Par-
tridge, “Assessing correlations between the spatial distribution of the dose to the
rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data
from the MRC RT01 trial (ISRCTN 47772397),” Phys. Med. Biol., vol. 54, no. 21,
pp. 6535–6548, Nov. 2009.
[125] O. Acosta, G. Drean, J. D. Ospina, A. Simon, P. Haigron, C. Lafond, and R. d.
Crevoisier, “Voxel-based population analysis for correlating local dose and rectal
toxicity in prostate cancer radiotherapy,” Phys Med Biol, vol. 58, no. 8, p. 2581,
Apr. 2013.
[126] J. D. Ospina, J. Zhu, C. Chira, A. Bossi, J. B. Delobel, V. Beckendorf, B. Dubray,
J.-L. Lagrange, J. C. Correa, A. Simon, O. Acosta, and R. de Crevoisier, “Random
forests to predict rectal toxicity following prostate cancer radiation therapy,” Int.
J. Radiat. Oncol. Biol. Phys., vol. 89, no. 5, pp. 1024–1031, Aug. 2014.
[127] R. L. Burden and J. D. Faires, Numerical Analysis, 9th ed. CENGAGE Learning,
Boston, USA, 2010.

